

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 22, 2005, 06:30:09 ; Search time 57 Seconds
(without alignments)
89.838 Million cell updates/sec

Title: US-10-009-809-2
Perfect score: 57
Sequence: 1 KNNLKDCGLF 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot_03:.*
1: uniprot_sprot:.*
2: uniprot_trembl:.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	57	100.0	53	2	Q92Y26 mus musculus
2	57	100.0	132	2	Q8J2T4 mus musculus
3	57	100.0	157	2	Q6LCB5 homo sapien
4	57	100.0	301	2	Q9Y206 hydra wagni
5	57	100.0	339	2	Q8I271 homo sapien
6	57	100.0	347	2	Q7ZW15 brachydanio
7	57	100.0	353	1	GBI1_BOVIN
8	57	100.0	353	1	GBI1_CAVPO
9	57	100.0	353	1	GBI1_CHICK
10	57	100.0	353	1	GBI1_HUMAN
11	57	100.0	353	1	GBI1_ORYLA
12	57	100.0	353	1	GBI1_RAT
13	57	100.0	353	1	GBI1_XENLA
14	57	100.0	353	1	GBI1_ASTPE
15	57	100.0	353	1	GBI1_HELTI
16	57	100.0	353	1	GBI1_LYMT
17	57	100.0	354	1	GBI2_CANFA
18	57	100.0	354	1	GBI2_CAVPO
19	57	100.0	354	1	GBI2_CHICK
20	57	100.0	354	1	GBI2_HUMAN
21	57	100.0	354	1	GBI2_MOUSE
22	57	100.0	354	1	GBI2_ORYLA
23	57	100.0	354	1	GBI2_RAT
24	57	100.0	354	1	GBI2_HOMAM
25	57	100.0	354	2	Q8TAN5
26	57	100.0	354	2	Q9UGA4
27	57	100.0	354	2	Q8WP45
28	57	100.0	354	2	Q8WSS1
29	57	100.0	354	2	Q8WSS2
30	57	100.0	354	2	Q6QM16
31	57	100.0	354	2	Q6QM17 strongyloce

RESULT 1

Q922Y6	PRELIMINARY;	PRT;	53 AA.
AC	Q922Y6;		
DT	01-DEC-2001 (Tremblrel. 19, Created)		
DT	01-OCT-2003 (Tremblrel. 19, Last sequence update)		
DE	Gnai2 protein (Fragment).		
GN	Names=Gnai2;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
OX	NCBI_TaxID=10090;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=FVB/N; TISSUE=Mammary tumor;		
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;		
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,		
RA	Klauser R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,		
RA	Altschul S.P., Zeeberg B., Buetow K.H., Schaefer C.P., Bhat N.K.,		
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,		
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,		
RA	Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,		
RA	Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,		
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,		
RA	Richards S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,		
RA	Villalon D.K., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,		
RA	Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,		
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,		
RA	Rodriguez A.C., Grumman J., Schmutz J., Myers R.M., Butterfield Y.S.,		
RA	Krzywinski M.I., Skaleka U., Smailus D.E., Schnerch A., Schein J.E.,		
RT	Generation and initial analysis of more than 15,000 full-length human		
RL	and mouse cDNA sequences."		
RN	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=FVB/N; TISSUE=Mammary tumor;		
RA	Strausberg R.;		
RL	Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.		
DR	EMBL; BC006695; AA06695.1; -		
DR	HSSP; P10824; 1GDD.		
DR	MGD; MGI:95772; Gnai2.		
DR	GO; GO:0003924; F:GTPase activity; TAS.		
DR	GO; GO:0005515; F:protein binding; IPI.		
DR	GO; GO:0007213; P:acetylcholine receptor signaling, muscarini. . . ; IMP.		
DR	GO; GO:0007193; P:G-protein signaling, adenylyate cyclase inh. . . ; IMP.		
DR	GO; GO:0008016; P:regulation of heart rate; IMP.		
DR	Pfam; PF00503; G-alpha; 1.		
FT	NON_TER 1		
SEQUENCE	53 AA; 6220 MW; 6574BE1F71B8B4E4 CRC64;		

ALIGNMENTS

```

Query Match          100.0%; Score 57; DB 2; Length 53;
Best Local Similarity 100.0%; Pred. No. 0.0039;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 44 KNNLKDCGLF 53

RESULT 2
Q8JZT4 PRELIMINARY; PRT; 132 AA.
AC Q8JZT4;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Gna12 protein.
GN Name=Gna12;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Salivary gland;
RX MEDLINE=22388257; PubMed=1247732; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T.J., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalka U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Salivary gland;
RA Strausberg R.;
RL Submitted (AUG-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC037130; AAH37130.1; -.
DR HSSP; P10824; IAGR.
DR MGD; MGI:95772; Gna12.
DR GO; GO:0003924; F:GTPase activity; TAS.
DR GO; GO:0005515; F:protein binding; IPI.
DR GO; GO:0007213; P:acetylcholine receptor signaling, muscarini. . .; IMP.
DR GO; GO:0007193; P:G-protein signaling, adenylyate cyclase inh. . .; IMP.
DR GO; GO:0008016; P:regulation of heart rate; IMP.
DR InterPro; IPR001019; G-protein_alpha.
DR InterPro; IPR001408; G-protein_alphaI.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00441; GPROTEINAI.
DR SMART; SM00275; G_alpha; 1.
SQ SEQUENCE 132 AA; 15289 MW; 064DCD1E011C3C4C CRC64;

Query Match          100.0%; Score 57; DB 2; Length 132;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 123 KNNLKDCGLF 132

RESULT 3
Q6LCB5 PRELIMINARY; PRT; 157 AA.
AC Q6LCB5;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE WUGSC:H_LUCA15.1 protein (Fragment).
GN Name=WUGSC:H_LUCA15.1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RA Waterston R.;
RL Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; U73166; AAD12230.1; -.
DR HSSP; P10824; 1AS3.
DR GO; GO:0004871; F:signal transducer activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro; IPR001019; G-protein_alpha.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR SMART; SM00275; G_alpha; 1.
FT NON_TER 1
SQ SEQUENCE 157 AA; 18241 MW; E420341B2294B81C CRC64;

Query Match          100.0%; Score 57; DB 2; Length 157;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 148 KNNLKDCGLF 157

RESULT 4
Q9Y206 PRELIMINARY; PRT; 301 AA.
AC Q9Y206;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE G protein a subunit 4 (Fragment).
OS Hydra magnipapillata (Hydra).
OC Eukaryota; Metazoa; Cnidaria; Hydrozoa; Hydroidea; Anthomedusae;
OC Hydridae; Hydra.
OX NCBI_TaxID=6085;
RN [1]
SEQUENCE FROM N.A.
RP MEDLINE=99246375; PubMed=10229568;
RA Suga H., Koyanagi M., Hoshiyama D., Ono K., Iwabe N., Kuma K.,
RA Miyata T.;
RT "Extensive gene duplication in the early evolution of animals before
RT the parazoan-eumetazoan split demonstrated by G proteins and protein
RT tyrosine kinases from sponge and hydra.";
RJ Vol. Evol. 48:646-653(1999).
DR EMBL; AB008542; BAA81696.1; -.
DR HSSP; P10824; IBOF.
DR GO; GO:0005525; F:GTP binding; IEA.
DR GO; GO:0004871; F:signal transducer activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro; IPR001019; G-protein_alpha.
DR InterPro; IPR001408; G-protein_alphaI.
DR InterPro; IPR011025; Transducin_insert.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR PRINTS; PR00441; GPROTEINAI.
DR SMART; SM00275; G_alpha; 1.
FT NON_TER 1

```

SQ SEQUENCE 301 AA; 34701 MW; DEE4681C554F2E3E CRC64;

Query Match 100.0%; Score 57; DB 2; Length 301;
 Best Local Similarity 100.0%; Pred. No. 0.024;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||

DB 292 KNNLKDCGLF 301

RESULT 5

Q81Z71 PRELIMINARY; PRT; 339 AA.

AC Q81Z71; DT 01-MAR-2003 (TEMBLrel. 23, Last sequence update)
 DT 01-MAR-2003 (TEMBLrel. 23, Last sequence update)
 DT 01-JUN-2003 (TEMBLrel. 24, Last annotation update)
 DE GNA12 protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Breast;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bosak S.A., McWan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Breast;
 RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC016995; AAH16995.1; -;
 DR HSSP; P10824; IAS3.
 DR GO; GO:0005525; F:GTP binding; IEA.
 DR GO; GO:0004871; F:signal transducer activity; IEA.
 DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. .; IEA.
 DR InterPro; IPR001019; G-protein_alpha.
 DR InterPro; IPR001048; Gprotein_alpha.
 DR Pfam; PF00503; G-alpha; 1.
 DR PRINTS; PR00318; GPROTEINA.
 DR ProDom; PD000281; Gprotein_alpha; 1.
 DR SMART; SM00275; G_alpha; 1.
 SQ SEQUENCE 339 AA; 38472 MW; F14AB73488153C5 CRC64;

Query Match 100.0%; Score 57; DB 2; Length 339;
 Best Local Similarity 100.0%; Pred. No. 0.027;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||

DB 330 KNNLKDCGLF 339

RESULT 6

Q7ZW15 PRELIMINARY; PRT; 347 AA.

AC Q7ZW15; DT 01-JUN-2003 (TEMBLrel. 24, Created)
 DT 01-JUN-2003 (TEMBLrel. 24, Last sequence update)
 DT 01-MAR-2004 (TEMBLrel. 26, Last annotation update)
 DE Guanine nucleotide-binding protein Gi2 alpha-subunit.
 GN Name=gna12;
 OS Brachydanio rerio (Zebrafish) (Danio rerio).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
 OC Cyprinidae; Danio.
 OX NCBI_TaxID=7955;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Whole body;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bosak S.A., McWan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Whole body;
 RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC049343; AAH49343.1; -;
 DR HSSP; P10824; IAS3.
 DR ZFIN; ZDB-GENE-030131-5861; gna12.
 DR GO; GO:0005525; F:GTP binding; IEA.
 DR GO; GO:0004871; F:signal transducer activity; IEA.
 DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. .; IEA.
 DR InterPro; IPR001019; Gprotein_alpha.
 DR InterPro; IPR001048; Gprotein_alpha.
 DR Pfam; PF00503; G-alpha; 1.
 DR PRINTS; PR00318; GPROTEINA.
 DR PRINTS; PR00441; GPROTEINAI.
 DR ProDom; PD000281; Gprotein_alpha; 1.
 DR SMART; SM00275; G_alpha; 1.
 SQ SEQUENCE 347 AA; 39596 MW; A04C87DBC919348C CRC64;

Query Match 100.0%; Score 57; DB 2; Length 347;
 Best Local Similarity 100.0%; Pred. No. 0.027;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||

DB 338 KNNLKDCGLF 347

RESULT 7

GB11_BOVIN

SO	SEQUENCE	353 AA; 40230 MW; B456C4E189530A6D CRC64;
Query Match	100.0%; Score 57; DB 1; Length 353;	
Best Local Similarity	100.0%; Pred. NO. 0.028; Mismatches 0; Indels 0; Gaps 0;	
Matches	10; Conservative 0;	
QY	1 KNNLKDCGLF 10 	
Dd	344 KNNLKDCGLF 353 	
RESULT 8		
GB1L_CAVPO		
ID_-GB1L_CAVPO	STANDARD; PRT; 353 AA.	
AC	P38401;	
DT	01-OCT-1994 (Rel. 30, Created)	
DT	01-OCT-1996 (Rel. 34, Last sequence update)	
DT	05-JUL-2004 (Rel. 44, Last annotation update)	
DE	Guanine nucleotide-binding protein G(i), alpha-1 subunit (Adenylate cyclase-inhibiting G alpha protein).	
DE	cyclase-inhibiting G alpha protein).	
GN	Name=GNAIL;	
OS	Cavia porcellus (Guinea pig).	
OC	Eukaryota; Metazoa; Chordata;	
OC	Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.	
OX	NBI_TaxID=10141;	
CC	[1]	
RN	SEQUENCE FROM N A.	
RP	STRAIN=Hartley; TISSUE=Lung;	
RX	MEDLINE=93129640; PubMed=1482697; DOI=10.1016/0167-4889(92)90009-Z;	
RA	Sakanaka C., Izumi T., Nakamura M., Honda Z.-I., Watanabe T., Minami M., Mutoh H., Bito H., Seyama Y., Ui M., Shimizu T.;	
RA	"Three types of Gi alpha protein of the guinea-pig lung: cDNA cloning and analysis of their tissue distribution.";	
RT	Biochim. Biophys. Acta 1175:61-66(1992).	
RL	Biochim. Biophys. Acta 1175:61-66(1992).	
CC	-!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. The G(i) proteins are involved in hormonal regulation of adenylate cyclase; they inhibit the cyclase in response to beta-adrenergic stimuli.	
CC	-!- SUBUNIT: G proteins are composed of 3 units; alpha, beta and gamma. The alpha chain contains the guanine nucleotide binding site.	
CC	-!- TISSUE SPECIFICITY: Mainly expressed in the brain, lung and kidney.	
CC	-!- SIMILARITY: Belongs to the G-alpha family. Subfamily 1 (Gi/o/t/z)).	
CC	(Gi/o/t/z)).	
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announcement/ or send an email to license@isb-sib.ch).	
CC	or send an email to license@isb-sib.ch).	
DR	EMBL; D21232; BAA04764.1; --	
DR	HSSP; P10824; IAS3.	
DR	InterPro; IPRO01019; Gprotein alpha.	
DR	InterPro; IPRO01408; Gprotein alpai.	
DR	InterPro; IPRO11025; Transducn_insert.	
DR	Pfam; PF00503; G-alpha; 1.	
DR	PRINTS; PR00318; GPROTEINA.	
DR	PRINTS; PR00441; GPROTEINAL.	
DR	ProDom; PD000281; Gprotein alpha; 1.	
KW	ADP-ribosylation; GTP-binding; Lipoprotein; Multigene family; Myristate; Palmitate; Transducer.	
FT	INIT MET 0 By similarity.	
FT	LIPID 1 1 N-myristoyl glycine (By similarity).	
FT	LIPID 2 2 S-palmitoyl cysteine (By similarity).	
FT	NP_BIND 39 46 GTP (By similarity).	
FT	NP_BIND 199 203 GTP (By similarity).	
FT	NP_BIND 268 271 GTP (By similarity).	
FT	MOD_RES 177 177 ADP-ribosylarginine (by cholera toxin).	


```
FT MOD_RES 350 350 ADP-ribosylcysteine (by pertussis toxin).
SQ SEQUENCE 353 AA; 40250 MW; 04E8C5DFB92D979 CRC64;

Query Match 100.0%; Score 57; DB 1; Length 353;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
   |||||
Db 344 KNNLKDCGLF 353

RESULT 9
GB11_CHICK STANDARD; PRT; 353 AA.
ID GB11_CHICK
AC P50146;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Guanine nucleotide-binding protein G(i), alpha-1 subunit (Adenylate
DE cyclase-inhibiting G alpha protein).
GN Name=GNAIL;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95121926; PubMed=7821803; DOI=10.1016/0378-1119(94)90449-9;
RA Kilbourne E.J., Galper J.B.;
RT "Cloning of cDNAs coding for the G alpha i1 and G alpha i2 G-proteins
RT from chick brain."
RL Gene 150:341-344(1994).
CC -I- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC involved as modulators or transducers in various transmembrane
CC signaling systems. The G(i) proteins are involved in hormonal
CC regulation of adenylate cyclase; they inhibit the cyclase in
CC response to beta-adrenergic stimuli.
CC -I- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
CC gamma. The alpha chain contains the guanine nucleotide binding
CC site.
CC -I- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
CC (G(i/o/t/z)).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC ENBL; L24548; AAA65066.1; --
CC PIR; I50237; I50237.
CC HSSP; P10824; IAS3.
CC InterPro; IPR001019; Gprotein_alpha.
CC InterPro; IPR001408; Gprotein_alpha.
CC InterPro; IPR011025; Transduct_insert.
CC Pfam; PF00503; G-alpha; 1.
CC PRINTS; PR00318; GPROTEINAI.
CC PRODOM; PD000281; Gprotein_alpha; 1.
CC KMW; ADP-ribosylation; GTP-binding; Lipoprotein; Multigene family;
KW Myristate; Palmitate; Transducer.
FT INIT_MET 0 0 By similarity.
FT LIPID 1 1 N-myristoyl glycine (By similarity).
FT LIPID 2 2 S-palmitoyl glycine (By similarity).
FT NP_BIND 39 46 GTP (By similarity).
FT NP_BIND 199 203 GTP (By similarity).
FT NP_BIND 268 271 GTP (By similarity).
FT MOD_RES 177 177 ADP-ribosylarginine (by cholera toxin).
FT MOD_RES 350 350 ADP-ribosylcysteine (by pertussis toxin).
```

```
SQ SEQUENCE 353 AA; 40247 MW; E1DD0C848140137C CRC64;

Query Match 100.0%; Score 57; DB 1; Length 353;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
   |||||
Db 344 KNNLKDCGLF 353

RESULT 10
GB11_HUMAN STANDARD; PRT; 353 AA.
ID GB11_HUMAN
AC P63096; P04898; P11015; P31871;
DT 13-AUG-1987 (Rel. 05, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Guanine nucleotide-binding protein G(i), alpha-1 subunit (Adenylate
DE cyclase-inhibiting G alpha protein).
GN Name=GNAIL;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE OF 1-100 FROM N.A.
RX MEDLINE=88198230; PubMed=2834384;
RA Ttoh H., Toyama R., Kozasa T., Tsukamoto T., Matsuoka M., Kaziro Y.;
RT "Presence of three distinct molecular species of G protein alpha
RT subunit. Structure of rat cDNAs and human genomic DNAs."
RL J. Biol. Chem. 263:6656-6664(1988).
RN [2]
RP SEQUENCE OF 5-353 FROM N.A.
RX MEDLINE=87260939; PubMed=3110783;
RA Bray P., Carter A., Guo V., Puckett C., Kamholz J., Spiegel A.,
RA Nirenberg M.;
RT "Human cDNA clones for an alpha subunit of G protein-transduction
RT protein."
RL Proc. Natl. Acad. Sci. U.S.A. 84:5115-5119(1987).
RN [3]
RP SEQUENCE FROM N.A.
RX TISSUE=Brain;
RA Yu W., Gibbs R.A.;
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RA Fuhr H.L. III, Ikeda S.R., Aronstam R.S.;
RT "cDNA clones of human proteins involved in signal transduction
RT sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
RN [5]
RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 30-348 IN COMPLEX WITH RGS14.
RX MEDLINE=21973246; PubMed=11976690; DOI=10.1038/416878a;
RA Kimple R.J., Kimple M.E., Betts L., Sondek J., Siderovski D.P.;
RT "Structural determinants for G-protein-induced inhibition of nucleotide
RT release by Galpha subunits."
RL Nature 416:878-881(2002).
CC -I- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC involved as modulators or transducers in various transmembrane
CC signaling systems. The G(i) proteins are involved in hormonal
CC regulation of adenylate cyclase; they inhibit the cyclase in
CC response to beta-adrenergic stimuli.
CC -I- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
CC gamma. The alpha chain contains the guanine nucleotide binding
CC site.
CC -I- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
CC (G(i/o/t/z)).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
```



```

FT HELIX 158 161
FT TURN 162
FT TURN 164
FT TURN 165
FT HELIX 170 174
FT TURN 175
FT TURN 175
FT STRAND 183 190
FT TURN 191 192
FT STRAND 193 200
FT STRAND 204 213
FT TURN 215 216
FT STRAND 219 225
FT STRAND 226 230
FT STRAND 232 233
FT TURN 234 235
FT STRAND 236 240
FT HELIX 241 253
FT TURN 254 254
FT HELIX 256 258
FT TURN 259 260
FT STRAND 262 268
FT HELIX 270 277
FT TURN 278 279
FT HELIX 282 284
FT TURN 285 285
FT TURN 287 288
FT HELIX 295 307
FT TURN 308 309
FT TURN 313 315
FT STRAND 318 322
FT TURN 325 326
FT TURN 328 345
SQ SEQUENCE 353 AA; 40214 MW; B23724E187E90A6D CRC64;

Query Match 100.0%; Score 57; DB 1; Length 353;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 344 KNNLKDCGLF 353
|||||

RESULT 13
GB11_XENLA
ID GB11_XENLA STANDARD; PRT; 353 AA.
AC F27044;
DT 01-AUG-1992 (Rel. 23, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Guanine nucleotide-binding protein G(i), alpha-1 subunit (Adenylate
DE cyclase-inhibiting G alpha protein).
GN Names=GNAIL;
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;
OC Xenopodinae; Xenopus.
OC NCBI_TaxID=8355;
OX [1]
RN SEQUENCE FROM N.A.
RP TISSUE=Oocyte;
RX MEDLINE=90346157; PubMed=2116977; DOI=10.1016/0014-5793(90)80964-K;
RA Olate J., Martinez S., Purcell P., Jorquera H., Codina J.,
RA Birnbaumer L., Allende J.E.;
RT "Molecular cloning and sequence determination of four different cDNA
RT species coding for alpha-subunits of G proteins from Xenopus laevis
RT oocytes."
RL PNAS Lett. 268:27-31(1990).
CC -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC involved as modulators or transducers in various transmembrane
CC signaling systems. The G(i) proteins are involved in hormonal
CC regulation of adenylate cyclase; they inhibit the cyclase in
CC response to beta-adrenergic stimuli.
CC -!- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
gamma. The alpha chain contains the guanine nucleotide binding

```


CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; Z15095; CAA78807.1; -.
DR PIR; S27013; S27013.
DR HSSP; P10824; 1GDD.
DR InterPro; IPR001019; Gprotein_alpha.
DR InterPro; IPR001408; Gprotein_alphai.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINAI.
DR PRINTS; PR00441; GPROTEINAI.
DR ProDom; PD000281; Gprotein_alpha; 1.
KW ADP-ribosylation; GTP-binding; Lipoprotein; Multigene family;
KW Myristate; Transducer.
FT INIT MET 0 By similarity.
FT LIPID 1 1 N-myristoyl glycine (By similarity).
FT NP_BIND 39 46 GTP (By similarity).
FT NP_BIND 199 203 GTP (By similarity).
FT NP_BIND 268 271 GTP (By similarity).
FT MOD_RES 177 177 ADP-ribosylarginine (by cholera toxin)
FT (By similarity).
FT MOD_RES 350 350 ADP-ribosylcysteine (by pertussis toxin)
FT (By similarity).
SQ SEQUENCE 353 AA; 40355 MW; 42277D2C0958EE1F CRC64;

Query Match 100.0%; Score 57; DB 1; Length 353;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 344 KNNLKDCGLF 353
|||||

RESULT 17
GBI2_CANFA
ID_GBI2_CANFA STANDARD; PRT; 354 AA.
AC P38400;
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Guanine nucleotide-binding protein G(i), alpha-2 subunit (Adenylate
DE cyclase-inhibiting G alpha protein).
GN Names:GNAI2;
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX NCBI_TaxID=9615;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=90003652; PubMed=2477170;
RA Holmer S.R., Stevens S., Homcy C.J.;
RT "Tissue- and species-specific expression of inhibitory guanine
RT nucleotide-binding proteins. Cloning of a full-length complementary
RT DNA from canine heart";
RL Circ. Res. 65:1136-1140(1989).
CC -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC involved as modulators or transducers in various transmembrane
CC signaling systems. The G(i) proteins are involved in hormonal
CC regulation of adenylate cyclase; they inhibit the cyclase in
CC response to beta-adrenergic stimuli.
CC -!- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
CC gamma. The alpha chain contains the guanine nucleotide binding
CC site. Interacts with UNC5B (By similarity).
CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Most abundant in the
CC lung and in the spleen.
CC -!- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
CC (G(i)/o/t/z)).

DR PIR; A61031; A61031.
DR HSSP; P10824; 1AS3.
DR InterPro; IPR001019; Gprotein_alpha.
DR InterPro; IPR001408; Gprotein_alphai.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINAI.
DR PRINTS; PR00441; GPROTEINAI.
DR ProDom; PD000281; Gprotein_alpha; 1.
KW ADP-ribosylation; GTP-binding; Lipoprotein; Multigene family;
KW Myristate; Palmitate; Transducer.
FT INIT MET 0 By similarity.
FT LIPID 1 1 N-myristoyl glycine (By similarity).
FT LIPID 2 2 S-palmitoyl cysteine (By similarity).
FT NP_BIND 39 46 GTP (By similarity).
FT NP_BIND 200 204 GTP (By similarity).
FT NP_BIND 269 272 GTP (By similarity).
FT MOD_RES 178 178 ADP-ribosylarginine (by cholera toxin).
FT MOD_RES 351 351 ADP-ribosylcysteine (by pertussis toxin).
SQ SEQUENCE 354 AA; 40414 MW; 93A01B69AA9DBDE7 CRC64;

Query Match 100.0%; Score 57; DB 1; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 345 KNNLKDCGLF 354
|||||

RESULT 18
GBI2_CAVPO
ID_GBI2_CAVPO STANDARD; PRT; 354 AA.
AC P38402;
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Guanine nucleotide-binding protein G(i), alpha-2 subunit (Adenylate
DE cyclase-inhibiting G alpha protein).
GN Name:GNAI2;
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.
OX NCBI_TaxID=10141;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=Hartley; TISSUE=Lung;
RX MEDLINE=93129640; PubMed=1482697; DOI=10.1016/0167-4898(92)90009-Z;
RA Sakanaka C., Izumi T., Nakamura M., Honda Z.-I., Watanabe T.,
RA Minami M., Mutoh H., Bito H., Seyama Y., Ui M., Shimizu T.;
RT "Three types of G i alpha protein of the guinea-pig lung: cDNA cloning
RT and analysis of their tissue distribution.";
RL Biochim. Biophys. Acta 1175:61-66(1992).
CC -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC involved as modulators or transducers in various transmembrane
CC signaling systems. The G(i) proteins are involved in hormonal
CC regulation of adenylate cyclase; they inhibit the cyclase in
CC response to beta-adrenergic stimuli.
CC -!- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
CC gamma. The alpha chain contains the guanine nucleotide binding
CC site. Interacts with UNC5B (By similarity).
CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Most abundant in the
CC lung and in the spleen.
CC -!- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
CC (G(i)/o/t/z)).
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC

DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . . ; TAS.
DR GO; GO:0007194; P:negative regulation of adenylate cyclase ac. . . ; TAS.
DR GO; GO:0007584; P:response to nutrients; TAS.
DR GO; GO:0007165; P:signal transduction; TAS.
DR InterPro; IPR001019; G-protein alpha.
DR InterPro; IPR001408; G-protein alpha.
DR InterPro; IPR011025; Transducin_insert.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR PRINTS; PR00441; GPROTEINAI.
DR ProDom; PD000281; G-protein alpha; 1.
DR ADP-ribosylation; GTP-binding; Lipoprotein; Multigene family;
KW Myristate; Palmitate; Transducer.
FT INIT MET 0 0 By similarity.
FT LIPID 1 1 N-myristoyl glycine (By similarity).
FT LIPID 2 2 S-palmitoyl cysteine (By similarity).
FT NP_BIND 39 46 GTP (By similarity).
FT NP_BIND 200 204 GTP (By similarity).
FT NP_BIND 269 272 GTP (By similarity).
FT MOD_RES 178 178 ADP-ribosylarginine (by cholera toxin).
FT MOD_RES 351 351 ADP-ribosylcysteine (by pertussis toxin).
FT MOD_RES 354 354 ADP-ribosylcysteine (by pertussis toxin).
SQ SEQUENCE 354 AA; 40319 MW; 6566B102DA0088EB CRC64;
Query Match 100.0%; Score 57; DB 1; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KNKLKDCGLF 10
DB 345 KNKLKDCGLF 354
RESULT 21
GBI2_MOUSE STANDARD; PRT; 354 AA.
ID GBI2_MOUSE
AC P08752;
DT 01-NOV-1988 (Rel. 09, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Guanine nucleotide-binding protein G(i), alpha-2 subunit (Adenylate
cyclase-inhibiting G alpha protein).
GN Name=Gnai2; Synonyms=Gnai-2;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_TaxID=10090;
ID 1
SEQUENCE FROM N.A.
MEDLINE=86313643; PubMed=3092218;
Sullivan K.A., Liao Y.-C., Alborzi A., Beiderman B., Chang F.-H.,
Masters S.B., Levinson A.D., Bourne H.R.;
"Inhibitory and stimulatory G proteins of adenylate cyclase: cDNA and
amino acid sequences of the alpha chains";
Proc. Natl. Acad. Sci. U.S.A. 83:6687-6691(1986).
[2]
SEQUENCE OF 22-354 FROM N.A.
RX MEDLINE=94224112; PubMed=8170357; DOI=10.1016/0169-328X(94)90267-4;
Tachibana M., Asano T., Wilcox E., Yokotani N., Rivolta M.N., Fex J.;
"G protein Gi2 alpha in the cochlea: cloning and selective occurrence
in receptor cells";
Brain Res. Mol. Brain Res. 21:355-358(1994).
-1- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
involved as modulators or transducers in various transmembrane
signaling systems. The G(i) proteins are involved in hormonal
regulation of adenylate cyclase: they inhibit the cyclase in
response to beta-adrenergic stimuli.
-1- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
gamma. The alpha chain contains the guanine nucleotide binding
site. Interacts with UNC5B (By similarity). Subfamily 1
-1- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
(G(i)/o/t/z)).

This SWISS-PROT entry is copyright. It is produced through a collaboration
GO; GO:0003927; F:heterotrimeric G-protein GTPase activity; TAS.

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC -----
 CC EMBL; M13963; AAA37692.1; -;
 CC EMBL; S71213; AAB30632.2; -;
 CC PIR; B25889; RGM512.
 CC HSSP; P10824; IAS3.
 CC MGD; MGI.95772; Gna12.
 CC GO; GO:0007213; P:acetyl choline receptor signaling, muscarin. . .; IMP.
 CC GO; GO:0007193; P:G-protein signaling, adenylyate cyclase inh. . .; IMP.
 CC InterPro; IPR001019; Gprotein_alpha.
 CC InterPro; IPR001408; Gprotein_alpha.
 CC InterPro; IPR011025; Transducn_insert.
 CC Pfam; PF00503; G-alpha; 1.
 CC PRINTS; PR00318; GPROTEINAI.
 CC ProDom; PD000281; GTP-binding; Lipoprotein; Multigene family;
 CC Myristate; Palmitate; Transducer.
 CC INIT_MET 0 0 By similarity.
 CC FT LIPID 1 1 N-myristoyl glycine (By similarity).
 CC FT LIPID 2 2 S-palmitoyl cysteine (By similarity).
 CC FT NP_BIND 39 46 GTP (By similarity).
 CC FT NP_BIND 200 204 GTP (By similarity).
 CC FT MOD_RES 178 178 ADP-ribosylarginine (by cholera toxin).
 CC FT MOD_RES 351 351 ADP-ribosylcysteine (by pertussis toxin).
 CC FT CONFLICT 81 81 L -> I (in Ref. 2).
 CC FT CONFLICT 86 86 A -> R (in Ref. 1).
 CC SQ SEQUENCE 354 AA; 40339 MW; 40A7CA30EDDC3778 CRC64;

Query Match 100.0%; Score 57; DB 1; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.028;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 |||||
 Db 345 KNNLKDCGLF 354

RESULT 22
 ID_GB12_ORYLA STANDARD; PRT; 354 AA.
 AC O13055;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Guanine nucleotide-binding protein G(i), alpha-2 subunit (Adenylyate
 DE cyclase-inhibiting G alpha protein) (Gi2 alpha subunit) (Gi alpha c).
 GN Name=GNAI2;
 OS Oryzias latipes (Medaka fish) (Japanese ricefish).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;
 OC Belontiiformes; Adrianichthyidae; Oryziatidae; Oryzias.
 OC NCBI_TaxID=8090;
 RN [1]
 RN TISSUE=Ovary;
 RC SEQUENCE FROM N.A.
 RX MEDLINE=98055713; PubMed=9395335;
 RA Oba Y., Yoshikuni M., Tanaka M., Mita M., Nagahama Y.;
 RT "Inhibitory guanine-nucleotide-binding-regulatory protein alpha
 RT subunits in medaka (Oryzias latipes) oocytes -- cDNA cloning and
 RT decreased expression of proteins during oocyte maturation.";
 RL Eur. J. Biochem. 249:846-853(1997).
 CC -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
 CC involved as modulators or transducers in various transmembrane
 CC signaling systems. The G(i) proteins are involved in hormonal
 CC regulation of adenylyate cyclase: they inhibit the cyclase in

CC response to beta-adrenergic stimuli.
 CC -!- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
 CC gamma. The alpha chain contains the guanine nucleotide binding
 CC site.
 CC -!- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
 CC (G1/o/t/z1).

CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC EMBL; AB001742; BAA20073.1; -;
 CC HSSP; P10824; IGDD.
 CC InterPro; IPR001019; Gprotein_alpha.
 CC InterPro; IPR001408; Gprotein_alpha.
 CC InterPro; IPR011025; Transducn_insert.
 CC Pfam; PF00503; G-alpha; 1.
 CC PRINTS; PR00318; GPROTEINAI.
 CC ProDom; PD000281; GTP-binding; Lipoprotein; Multigene family;
 CC Myristate; Palmitate; Transducer.
 CC INIT_MET 0 0 By similarity.
 CC FT LIPID 1 1 N-myristoyl glycine (By similarity).
 CC FT LIPID 2 2 S-palmitoyl cysteine (By similarity).
 CC FT NP_BIND 39 46 GTP (By similarity).
 CC FT NP_BIND 200 204 GTP (By similarity).
 CC FT NP_BIND 269 272 GTP (By similarity).
 CC FT MOD_RES 178 178 ADP-ribosylarginine (by cholera toxin)
 CC FT MOD_RES 351 351 ADP-ribosylcysteine (by pertussis toxin)
 CC FT CONFLICT 81 81 L -> I (in Ref. 2).
 CC FT CONFLICT 86 86 A -> R (in Ref. 1).
 CC SQ SEQUENCE 354 AA; 40861 MW; C5D64B0970E3BDD3 CRC64;

Query Match 100.0%; Score 57; DB 1; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.028;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 |||||
 Db 345 KNNLKDCGLF 354

RESULT 23

ID_GB12_RAT STANDARD; PRT; 354 AA.
 AC P04857;
 DT 13-AUG-1987 (Rel. 05, Created)
 DT 01-OCT-1994 (Rel. 30, Last sequence update)
 DT 25-JAN-2005 (Rel. 46, Last annotation update)
 DE Guanine nucleotide-binding protein G(i), alpha-2 subunit (Adenylyate
 DE cyclase-inhibiting G alpha protein).
 GN Name=Gnai2; Synonyms=Gnai-2;
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OC NCBI_TaxID=10116;
 RN [1]
 RN SEQUENCE FROM N.A.
 RX MEDLINE=86233317; PubMed=3086867;
 RA Itoh H., Kozasa T., Nagata S., Nakamura S., Katada T., Ui M., Iwai S.,
 RA "Molecular cloning and sequence determination of cDNAs for alpha
 RT subunits of the guanine nucleotide-binding proteins Gs, Gi, and Go
 RT from rat brain.";
 RL Proc. Natl. Acad. Sci. U.S.A. 83:3776-3780(1986).
 RN [2]
 RN SEQUENCE FROM N.A.

RX MEDLINE=88007678; PubMed=2820999;
 RA Jones D.T., Reed R.R.;
 RT "Molecular cloning of five GTP-binding protein cDNA species from rat
 RT olfactory neuroepithelium."
 RL J. Biol. Chem. 262:14241-14249 (1987).
 RN [3]
 RP SEQUENCE OF 11-125.
 RA PubMed=2159473;
 RX Linder M.E., Ewald D.A., Miller R.J., Gilman A.G.;
 RT "Purification and characterization of G_o alpha and three types of G_i
 RT alpha after expression in *Escherichia coli*."
 RL J. Biol. Chem. 265:8243-8251 (1990).
 CC -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
 CC involved as modulators or transducers in various transmembrane
 CC signaling systems. The G_i proteins are involved in hormonal
 CC regulation of adenylate cyclase: they inhibit the cyclase in
 CC response to beta-adrenergic stimuli.
 CC -!- SUBUNIT: G proteins are composed of 3 units: alpha, beta and
 CC gamma. The alpha chain contains the guanine nucleotide binding
 CC site. Interacts with UNC5B (By similarity).
 CC -!- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
 CC (G(i)/o(t/z)).
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; M12672; AAA41260.1; -;
 CC EMBL; M17528; AAA40824.1; -;
 CC PIR; D27423; RGRT12.
 CC HSP; P10824; IAS3.
 CC RGD; 620243; Gna12.
 CC InterPro; IPR001019; Gprotein_alpha.
 CC InterPro; IPR001408; Gprotein_alphai.
 CC InterPro; IPR011025; Transducn_insert.
 CC Pfam; PF00503; G-alpha; 1.
 CC PRINTS; PR00318; GPROTEINAI.
 CC PRINTS; PR00441; GPROTEINAI.
 CC ProDom; PD000281; Gprotein_alpha; 1.
 CC ADP-ribosylation; Direct protein sequencing; GTP-binding; Lipoprotein;
 CC Multigene family; Myristate; Palmitate; Transducer.
 CC INIT_MET 0 By similarity.
 CC LIPID 1 1 N-myristoyl glycine (By similarity).
 CC FT NP_BIND 2 46 S-palmitoyl cysteine (By similarity).
 CC FT NP_BIND 39 46 GTP (By similarity).
 CC FT NP_BIND 200 204 GTP (By similarity).
 CC FT NP_BIND 269 272 GTP (By similarity).
 CC FT MOD_RES 178 178 ADP-ribosylarginine (by cholera toxin).
 CC FT MOD_RES 351 351 ADP-ribosylcysteine (by pertussis toxin).
 CC FT MOD_RES 165 166 SD -> PN (in tryptic peptides).
 CC SEQUENCE 354 AA; 40367 MW; 436B75599113FC19 CRC64;
 CC
 CC Query Match 100.0%; Score 57; DB 1; Length 354;
 CC Best Local Similarity 100.0%; Pred. No. 0.028;
 CC Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 1 KNNLKDCGLF 10
 CC |||||
 CC Db 345 KNNLKDCGLF 354
 CC
 CC RESULT 24
 CC GBI_HOMAM STANDARD; PRT; 354 AA.
 CC AC P4176;
 CC DT 01-NOV-1995 (Rel. 32, Created)
 CC DT 01-NOV-1995 (Rel. 32, Last sequence update)
 CC DT 05-JUL-2004 (Rel. 44, Last annotation update)
 CC DE Guanine nucleotide-binding protein G(i), alpha subunit (Adenylate

DE cyclase-inhibiting G alpha protein).
 OS Homarus americanus (American lobster).
 CC Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;
 CC Eumalacostraca; Eucarida; Decapoda; Pleocyemata; Astacidea;
 CC Nephropoidea; Nephropidae; Homarus.
 CC NCBI_TaxID=6706;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA TISSUE=Olfactory organ;
 RX MEDLINE=93061797; PubMed=1279345; DOI=10.1016/0169-328X(92)90183-C;
 RA McClintock T.S., Byrnes A.P., Lerner M.R.;
 RT "Molecular cloning of a G-protein alpha i subunit from the lobster
 RT olfactory organ."
 RL Brain Res. Mol. Brain Res. 14:273-276 (1992).
 CC -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
 CC involved as modulators or transducers in various transmembrane
 CC signaling systems.
 CC -!- SUBUNIT: G proteins are composed of 3 units: alpha, beta and
 CC gamma. The alpha chain contains the guanine nucleotide binding
 CC site.
 CC -!- SIMILARITY: Belongs to the G-alpha family. Subfamily 1
 CC (G(i)/o(t/z)).
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; S47614; AAB24072.2; ALT_SEQ.
 CC PIR; A48976; A48976.
 CC HSP; P10824; IAS3.
 CC InterPro; IPR001019; Gprotein_alpha.
 CC InterPro; IPR001408; Gprotein_alphai.
 CC InterPro; IPR011025; Transducn_insert.
 CC Pfam; PF00503; G-alpha; 1.
 CC PRINTS; PR00318; GPROTEINAI.
 CC PRINTS; PR00441; GPROTEINAI.
 CC ProDom; PD000281; Gprotein_alpha; 1.
 CC ADP-ribosylation; GTP-binding; Lipoprotein; Multigene family;
 CC Myristate; Transducer.
 CC INIT_MET 0 By similarity.
 CC LIPID 1 1 N-myristoyl glycine (By similarity).
 CC FT NP_BIND 40 47 GTP (By similarity).
 CC FT NP_BIND 200 204 GTP (By similarity).
 CC FT NP_BIND 269 272 GTP (By similarity).
 CC FT MOD_RES 178 178 ADP-ribosylarginine (by cholera toxin).
 CC FT MOD_RES 351 351 ADP-ribosylcysteine (by pertussis toxin).
 CC FT MOD_RES 308 323 Missing (in Ref. 1; AAB24072).
 CC CONFLICT 354 AA; 40600 MW; 1A032BDCBF83896D CRC64;
 CC SEQUENCE 354 AA; 40600 MW; 1A032BDCBF83896D CRC64;
 CC
 CC Query Match 100.0%; Score 57; DB 1; Length 354;
 CC Best Local Similarity 100.0%; Pred. No. 0.028;
 CC Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 1 KNNLKDCGLF 10
 CC |||||
 CC Db 345 KNNLKDCGLF 354
 CC
 CC RESULT 25
 CC Q8TAN5 PRELIMINARY; PRT; 354 AA.
 CC ID Q8TAN5
 CC AC Q8TAN5; 21, Created)
 CC DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
 CC DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
 CC DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 CC DE Guanine nucleotide binding protein (G protein), alpha inhibiting
 CC activity polypeptide 1.

RESULT 28	
Q8WSS1	PRELIMINARY; PRT; 354 AA.
ID	Q8WSS1
AC	Q8WSS1
DT	01-MAR-2002 (TrEMBLrel. 20, Created)
DT	01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT	01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE	G protein alpha subunit G1 splicing variant C1G1b.
GN	Names=C1G1;
OS	Ciona intestinalis.
OC	Eukaryota; Metazoa; Chordata; Urochordata; Ascidiacea; Enterogona;
OC	Phlebobranchia; Cionidae; Ciona.
OX	NCBI_TaxID=7719;
RN	[1]
RP	SEQUENCE FROM N.A.
RA	Yoshida R., Kusakabe T., Kamatani M., Iwasa T., Tsuda M.;
RL	Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
DR	EMBL; AB066282; BAB83918.1; -.
DR	HSSP; P10824; 1AS3.
DR	GO; GO:0005525; F:GTP binding; IEA.
DR	GO; GO:0004871; F:signal transducer activity; IEA.
DR	GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR	Pfam; PF00503; G-alpha; 1.
DR	PRINTS; PR00318; GPROTEIN.
DR	PRINTS; PR00441; GPROTEINAI.
DR	SMART; SM00275; G_alpha; 1.
SQ	SEQUENCE 354 AA; 40402 MW; 65526EGF197F9FB1 CRC64;
Query Match 100.0%; Score 57; DB 2; Length 354;	
Best Local Similarity 100.0%; Pred. No. 0.028;	
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 KNNLKDCGLF 10
Db	
	345 KNNLKDCGLF 354
RESULT 29	
Q8WSS2	PRELIMINARY; PRT; 354 AA.
ID	Q8WSS2
AC	Q8WSS2
DT	01-MAR-2002 (TrEMBLrel. 20, Created)
DT	01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT	01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE	G protein alpha subunit G1 splicing variant C1G1a.
GN	Names=C1G1;
OS	Ciona intestinalis.
OC	Eukaryota; Metazoa; Chordata; Urochordata; Ascidiacea; Enterogona;
OC	Phlebobranchia; Cionidae; Ciona.
OX	NCBI_TaxID=7719;
RN	[1]
RP	SEQUENCE FROM N.A.
RA	Yoshida R., Kusakabe T., Kamatani M., Iwasa T., Tsuda M.;
RL	Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
DR	EMBL; AB066281; BAB83917.1; -.
DR	HSSP; P10824; 1AS3
DR	GO; GO:0005525; F:GTP binding; IEA.
DR	GO; GO:0004871; F:signal transducer activity; IEA.
DR	GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR	Pfam; PF00503; G-alpha; 1.
DR	PRINTS; PR00318; GPROTEIN.
DR	PRINTS; PR00441; GPROTEINAI.
DR	ProDom; PD000281; Gprotein_alpha; 1.
DR	SMART; SM00275; G_alpha; 1.
SQ	SEQUENCE 354 AA; 40391 MW; D5EBD748D6AE92F CRC64;
Query Match 100.0%; Score 57; DB 2; Length 354;	
Best Local Similarity 100.0%; Pred. No. 0.028;	
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 KNNLKDCGLF 10
Db	
	345 KNNLKDCGLF 354
RESULT 30	
Q6QM16	PRELIMINARY; PRT; 354 AA.
ID	Q6QM16
AC	Q6QM16
DT	05-JUL-2004 (TrEMBLrel. 27, Created)
DT	05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE	Guanine nucleotide-binding protein G(I) alpha subunit (EC 3.6.5.1).
OS	Lytechinus variegatus (sea urchin).
OC	Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa;
OC	Echinoidea; Euechinoidea; Echinacea; Temnopleuroidea; Toxopneustidae;
OC	Lytechinus.
OX	NCBI_TaxID=7654;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	TISSUE=Ovary;
RX	PubMed=15003628; DOI=10.1016/j.mod.2004.01.005;
RA	Voronina E., Wessel G.M.;
RT	"Regulatory contribution of heterotrimeric G-proteins to oocyte maturation in the sea urchin.";
RL	Mech. Dev. 121:247-259(2004).
DR	EMBL; AY534104; AAS38581.1; -.
DR	HSSP; P10824; 1AS3.
DR	GO; GO:0005525; F:GTP binding; IEA.
DR	GO; GO:0016787; F:hydrolase activity; IEA.
DR	GO; GO:0004871; F:signal transducer activity; IEA.
DR	GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR	InterPro; IPR001019; Gprotein_alpha.
DR	InterPro; IPR001408; Gprotein_alpha1.
DR	InterPro; IPR011025; Transducn_insert.
DR	Pfam; PF00503; G-alpha; 1.
DR	PRINTS; PR00318; GPROTEIN.
DR	PRINTS; PR00441; GPROTEINAI.
DR	ProDom; PD000281; Gprotein_alpha; 1.
DR	SMART; SM00275; G_alpha; 1.
KW	Hydrolase.
SQ	SEQUENCE 354 AA; 40291 MW; F211598F662FB5EB CRC64;
Query Match 100.0%; Score 57; DB 2; Length 354;	
Best Local Similarity 100.0%; Pred. No. 0.028;	
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 KNNLKDCGLF 10
Db	
	345 KNNLKDCGLF 354
RESULT 31	
Q6QM17	PRELIMINARY; PRT; 354 AA.
ID	Q6QM17
AC	Q6QM17
DT	05-JUL-2004 (TrEMBLrel. 27, Created)
DT	05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE	Guanine nucleotide-binding protein G(I) alpha subunit (EC 3.6.5.1).
OS	Strongylocentrotus purpuratus (Purple sea urchin).
OC	Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa;
OC	Echinoidea; Euechinoidea; Echinacea; Echinoida; Strongylocentrotidae;
OC	Strongylocentrotus.
OX	NCBI_TaxID=7668;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	TISSUE=Ovary;
RX	PubMed=15003628; DOI=10.1016/j.mod.2004.01.005;
RA	Voronina E., Wessel G.M.;
RT	"Regulatory contribution of heterotrimeric G-proteins to oocyte maturation in the sea urchin.";
RL	Mech. Dev. 121:247-259(2004).
DR	EMBL; AY534103; AAS38580.1; -.

DR HSP; P10824; 1AS3.
DR GO: GO:0005525; F:GTP binding; IEA.
DR GO: GO:0016787; F:hydrolase activity; IEA.
DR GO: GO:0004871; P:signal transducer activity; IEA.
DR GO: GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro: IPR001010; G-protein_alpha.
DR InterPro: IPR001408; G-protein_alpha.
DR InterPro: IPR0011025; Transducn_insert.
DR Pfam: PF00503; G-alpha; 1.
DR PRINTS; PR00318; G-ALPHA.
DR PRINTS; PR00441; GPROTEINAI.
DR ProDom; PD000281; Gprotein_alpha; 1.
DR SMART; SM00275; G_alpha; 1.
KW Hydrolase.
SQ SEQUENCE 354 AA; 40291 MW; P211598F662FB5EB CRC64;

Query Match 100.0%; Score 57; DB 2; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
|||||
Db 345 KNNLKDCGLF 354

RESULT 32
Q9NL94 ID Q9NL94 PRELIMINARY; PRT; 354 AA.
AC Q9NL94;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE G protein alpha subunit i class.
GN NamesOvGai;
OS Octopus vulgaris (Octopus).
OC Eukaryota; Metazoa; Mollusca; Cephalopoda; Coleoidea; Neocoleoidea;
OC Octopodiformes; Octopoda; Incirrata; Octopodidae; Octopus.
OX NCBI_TaxID=6645;
RN [1]
RP TISSUE=Eye;
RC Iwasa T., Yanai T., Nakagawa M., Kikkawa S., Obata S., Usukura J.,
Teuda M.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB025780; BAA93636.1; -
DR HSP; P10824; 1GDD.
DR GO: GO:0005525; F:GTP binding; IEA.
DR GO: GO:0004871; F:signal transducer activity; IEA.
DR GO: GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro: IPR001019; G-protein_alpha.
DR InterPro: IPR001408; G-protein_alpha.
DR InterPro: IPR0011025; Transducn_insert.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINAI.
DR PRINTS; PR00441; GPROTEINAI.
DR ProDom; PD000281; Gprotein_alpha; 1.
DR SMART; SM00275; G_alpha; 1.
SQ SEQUENCE 354 AA; 40660 MW; C3764529365FEA04 CRC64;

Query Match 100.0%; Score 57; DB 2; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
|||||
Db 345 KNNLKDCGLF 354

RESULT 33
Q7T3D3 ID Q7T3D3 PRELIMINARY; PRT; 354 AA.
AC Q7T3D3;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)

DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Similar to guanine nucleotide binding protein, alpha inhibiting
DE 1.
GN Namesgnail;
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heif F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
Krzywinski M.I., Skalska U., Smallus D.E., Scherch A., Schein J.E.,
Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RA Director MGC Project;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC053164; AAH53164.1; -
DR HSP; P10824; 1AS3.
DR ZFIN; ZDB-GENE-040426-1310; gnail.
DR GO: GO:0004871; F:signal transducer activity; IEA.
DR GO: GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro: IPR001019; G-protein_alpha.
DR InterPro: IPR0011025; Transducn_insert.
DR Pfam; PF00503; G-alpha; 1.
DR ProDom; PD000281; Gprotein_alpha; 1.
DR SMART; SM00275; G_alpha; 1.
SQ SEQUENCE 354 AA; 40329 MW; AF9B7A3F0E0DA01C CRC64;

Query Match 100.0%; Score 57; DB 2; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
|||||
Db 345 KNNLKDCGLF 354

RESULT 34
Q96C71 ID Q96C71 PRELIMINARY; PRT; 355 AA.
AC Q96C71;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Guanine nucleotide binding protein (G protein), alpha inhibiting
DE activity polypeptide 2 (GNAI2 protein).
GN Name=GNAI2;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

OX NCBI_TaxID=9606;
RN
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
RN
RP SEQUENCE FROM N.A.
RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
RL EMBL; BC014627; AAH14627.1; -.
RL EMBL; CR456783; CAG33064.1; -.
RL HSP; P10824; IAS3.
DR GO; GO:0005525; F:GTP binding; IEA.
DR GO; GO:0004871; F:signal transducer activity; IEA.
DR GO; GO:0007186; F:G-protein coupled receptor protein signalin. .; IEA.
DR InterPro; IPR001019; Gprotein_alpha.
DR InterPro; IPR001408; Gprotein_alpha.
DR InterPro; IPR011025; Transducn_insert.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR ProDom; PD000281; Gprotein_alpha; 1.
DR SMART; SM00275; G_alpha; 1.
SQ SEQUENCE 355 AA; 40493 MW; B1C3DBE224D5937C CRC64;

Query Match 100.0%; Score 57; DB 2; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355

RESULT 35
Q6P1C0 PRELIMINARY; PRT; 355 AA.
ID AC Q6P1C0
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Guanine nucleotide binding protein, alpha inhibiting 2.
GN Name=Gnai2;
OS Mus musculus (Mouse);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]

```

```

RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6; TISSUE=Brain;
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6; TISSUE=Brain;
RX Submitted (JAN-2004) to the EMBL/GenBank/DBJ databases.
RL EMBL; BC065159; AAH65159.1; -.
RL HSP; P10824; IAS3.
DR GO; GO:0003924; F:GTPase activity; TAS.
DR GO; GO:0005515; F:protein binding; IPI.
DR GO; GO:0007213; P:acetylcholine receptor signaling, muscarini. .; IMP.
DR GO; GO:0007193; P:G-protein signaling, adenylate cyclase inh. .; IMP.
DR GO; GO:0008016; P:regulation of heart rate; IMP.
DR InterPro; IPR001019; Gprotein_alpha.
DR InterPro; IPR001408; Gprotein_alpha.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR ProDom; PD000281; Gprotein_alpha; 1.
DR SMART; SM00275; G_alpha; 1.
SQ SEQUENCE 355 AA; 40489 MW; 90AC64AFA713493E CRC64;

Query Match 100.0%; Score 57; DB 2; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355

RESULT 36
Q6P3M7 PRELIMINARY; PRT; 355 AA.
ID AC Q6P3M7
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein MGC76300.
GN Name=MGC76300;
OS Xenopus tropicalis (Western clawed frog) (Silurana tropicalis).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;
OC Xenoportinae; Xenopus.
OX NCBI_TaxID=8364;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Embryo;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

```


RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Stapleton M., Soares M.B., Bernaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Vallalon D.K., Wuzny K.C., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skaleka U., Smallus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16999-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Embryo;
 RA Klein S., Gerhard D.S.;
 RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC063931; AA463931.1; -;
 DR HSSP; P10824; IAS3.
 DR GO; GO:0005525; F:GTP binding; IEA.
 DR GO; GO:0004871; F:signal transducer activity; IEA.
 DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . ; IEA.
 DR InterPro; IPR001019; Gprotein_alpha.
 DR InterPro; IPR001408; Gprotein_alpha.
 DR InterPro; IPR011025; Transducn_insert.
 DR Pfam; PF00503; G-alpha; 1.
 DR PRINTS; PR00318; GPROTEINA.
 DR PRINTS; PR00441; GPROTEINA.
 DR ProDom; PD000281; Gprotein_alpha; 1.
 DR SMART; SM00275; G_alpha; 1.
 KW Hypothetical protein.
 SQ SEQUENCE 355 AA; 40434 MW; 444F15DA90FCE6C6 CRC64;
 Query Match 100.0%; Score 57; DB 2; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.028;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 346 KNNLKDCGLF 355
 RESULT 37
 Q6TNT8 PRELIMINARY; PRT; 355 AA.
 ID O6TNT8
 AC O6TNT8
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
 DE Guanine nucleotide binding protein (G protein), alpha inhibiting
 DE activity polypeptide 2 (similar to guanine nucleotide binding protein,
 DE alpha inhibiting 2).
 DN Name=gna12l; Synonyms=GNAI2;
 OS Brachydanio rerio (Zebrafish)
 GC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
 OC Cyprinidae; Danio.
 OC NCBI_TaxID=7955;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Song H.D., Wu X.Y., Sun X.J., Zhou Y., Liu T.X., Deng M., Zhang G.W.,
 RA Sheng Y., Chen Y., Ruan Z., Jiang C.L., Fan H.Y., Zou L.I.,
 RA Kanki J.P., Look A.T., Chen Z.;
 RL Submitted (SEP-2003) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.

RC TISSUE=Brain;
 RX MEDLINE=223388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Stapleton M., Soares M.B., Bernaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Vallalon D.K., Wuzny K.C., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skaleka U., Smallus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RA Director MGC Project;
 RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AV391429; AAQ91241.1; -;
 DR EMBL; BC076100; AAH76100.1; -;
 DR HSSP; P10824; IAS3.
 DR ZFIN; ZDB-GENE-030131-8365; gna12l.
 DR GO; GO:0005525; F:GTP binding; IEA.
 DR GO; GO:0004871; F:signal transducer activity; IEA.
 DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . ; IEA.
 DR InterPro; IPR001019; Gprotein_alpha.
 DR InterPro; IPR001408; Gprotein_alpha.
 DR InterPro; IPR011025; Transducn_insert.
 DR Pfam; PF00503; G-alpha; 1.
 DR PRINTS; PR00318; GPROTEINA.
 DR PRINTS; PR00441; GPROTEINA.
 DR ProDom; PD000281; Gprotein_alpha; 1.
 DR SMART; SM00275; G_alpha; 1.
 SQ SEQUENCE 355 AA; 40836 MW; F14AE52E7DEBA61E CRC64;
 Query Match 100.0%; Score 57; DB 2; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.028;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 346 KNNLKDCGLF 355
 RESULT 38
 Q9W6A4 PRELIMINARY; PRT; 355 AA.
 ID Q9W6A4
 AC Q9W6A4
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Guanine nucleotide-binding protein G12 alpha-subunit.
 DE Squalus acanthias (Spiny dogfish).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
 OC Elasmobranchii; Squala; Hypnosquala; Squaliformes; Squaloidei;
 OC Squalidae; Squalus.
 OC NCBI_TaxID=7797;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Tissue=Rectal gland;
 RA George A.A., Aller S.G., Forrest J.N. Jr.;
 RC "Cloning of Multiple G-protein Alpha Subunits and Characterization of
 RT a Full Length Gi-alpha-2 from the Shark (Squalus acanthias) Rectal
 RT Gland.";

```

RN Bull. Mt. Desert Isl. Biol. Lab. 37:60-63(1998).
RN [2]
RN SEQUENCE FROM N.A.
RC TISSUE=Rectal gland;
RA George A.A., Aller S.G., Forrest J.N. Jr.;
RA Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF109173; RAD26121.2; -.
DR HSSP; P10824; IAS3.
DR GO; GO:0005525; F:GTP binding; IEA.
DR GO; GO:0004871; F:signal transducer activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . ; IEA.
DR InterPro; IPR001019; Gprotein_alpha.
DR InterPro; IPR001408; Gprotein_alpha.
DR InterPro; IPR011025; Transducn_insert.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR ProDom; PD000281; Gprotein_alpha; 1.
DR SMART; SM00275; G_alpha; 1.
SQ SEQUENCE 355 AA; 40285 MW; A3ACD0314581763A CRC64;

Query Match 100.0%; Score 57; DB 2; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 346 KNNLKDCGLF 355

RESULT 39
Q706E0 PRELIMINARY; PRT; 357 AA.
ID Q706E0;
AC Q706E0;
DT 01-MAR-2004 (TREMBlrel. 26, Created)
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)
DE AgCP5651 (Fragment)
GS Name=agCS4259; ORFNames=ENSG00000011071;
ON Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Anopheles.
OX NCBI_TaxID=180454;
RN [1]
RN SEQUENCE FROM N.A.
RC STRAIN=PEST;
RA Anopheles Genome Sequencing Consortium;
RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
CC -1- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAB01008960; EAA11917.1; -.
DR HSSP; P10824; IAS3.
DR GO; GO:0005525; F:GTP binding; IEA.
DR GO; GO:0004871; F:signal transducer activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . ; IEA.
DR InterPro; IPR001019; Gprotein_alpha.
DR InterPro; IPR001408; Gprotein_alpha.
DR InterPro; IPR011025; Transducn_insert.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR ProDom; PD000281; Gprotein_alpha; 1.
FT NON_TER 1
SQ SEQUENCE 357 AA; 40876 MW; A1295839894509A7 CRC64;

Query Match 100.0%; Score 57; DB 2; Length 357;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 348 KNNLKDCGLF 357

Bull. Mt. Desert Isl. Biol. Lab. 37:60-63(1998).
[2]
SEQUENCE FROM N.A.
TISSUE=Rectal gland;
George A.A., Aller S.G., Forrest J.N. Jr.;
Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.
EMBL; AF109173; RAD26121.2; -.
HSSP; P10824; IAS3.
GO; GO:0005525; F:GTP binding; IEA.
GO; GO:0004871; F:signal transducer activity; IEA.
GO; GO:0007186; P:G-protein coupled receptor protein signalin. . ; IEA.
InterPro; IPR001019; Gprotein_alpha.
InterPro; IPR001408; Gprotein_alpha.
InterPro; IPR011025; Transducn_insert.
Pfam; PF00503; G-alpha; 1.
PRINTS; PR00318; GPROTEINA.
ProDom; PD000281; Gprotein_alpha; 1.
SMART; SM00275; G_alpha; 1.
SEQUENCE 355 AA; 40285 MW; A3ACD0314581763A CRC64;

Query Match 100.0%; Score 57; DB 2; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 346 KNNLKDCGLF 355

RESULT 39
Q706E0 PRELIMINARY; PRT; 357 AA.
ID Q706E0;
AC Q706E0;
DT 01-MAR-2004 (TREMBlrel. 26, Created)
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)
DE AgCP5651 (Fragment)
GS Name=agCS4259; ORFNames=ENSG00000011071;
ON Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Anopheles.
OX NCBI_TaxID=180454;
RN [1]
RN SEQUENCE FROM N.A.
RC STRAIN=PEST;
RA Anopheles Genome Sequencing Consortium;
RA Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
CC -1- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAB01008960; EAA11917.1; -.
DR HSSP; P10824; IAS3.
DR GO; GO:0005525; F:GTP binding; IEA.
DR GO; GO:0004871; F:signal transducer activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . ; IEA.
DR InterPro; IPR001019; Gprotein_alpha.
DR InterPro; IPR001408; Gprotein_alpha.
DR InterPro; IPR011025; Transducn_insert.
DR Pfam; PF00503; G-alpha; 1.
DR PRINTS; PR00318; GPROTEINA.
DR ProDom; PD000281; Gprotein_alpha; 1.
FT NON_TER 1
SQ SEQUENCE 357 AA; 40876 MW; A1295839894509A7 CRC64;

Query Match 100.0%; Score 57; DB 2; Length 377;
Best Local Similarity 100.0%; Pred. No. 0.03;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 368 KNNLKDCGLF 377

Query Match 100.0%; Score 57; DB 2; Length 377;
Best Local Similarity 100.0%; Pred. No. 0.03;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 368 KNNLKDCGLF 377

Search completed: March 22, 2005, 06:40:55
Job time : 58 secs

```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 22, 2005, 06:00:26 ; Search time 15 Seconds
(without alignments)
64.145 Million cell updates/sec

Title: US-10-009-809-2

Perfect score: 57 KXNLDKCGLF 10

Sequence: 1 KXNLDKCGLF 10

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR 79:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	57	100.0	354	1 RGHU11	GTP-binding regula
2	57	100.0	354	1 RGHU11	GTP-binding regula
3	57	100.0	354	1 RGHU11	GTP-binding regula
4	57	100.0	354	1 RGHU11	GTP-binding regula
5	57	100.0	354	2 S28157	GTP-binding regula
6	57	100.0	354	2 S24362	GTP-binding regula
7	57	100.0	354	2 I50237	GTP-binding regula
8	57	100.0	354	2 S27013	GTP-binding regula
9	57	100.0	355	1 RGHU12	GTP-binding regula
10	57	100.0	355	1 RGHU12	GTP-binding regula
11	57	100.0	355	1 RGHU12	GTP-binding regula
12	57	100.0	355	2 S28158	GTP-binding regula
13	57	100.0	355	2 I50238	G12 protein alpha
14	57	100.0	355	2 A61031	GTP-binding regula
15	57	100.0	355	2 A48976	GTP-binding regula
16	51	89.5	350	1 RGHU11	GTP-binding regula
17	51	89.5	350	1 RGHU11	GTP-binding regula
18	51	89.5	350	1 RGHU11	GTP-binding regula
19	51	89.5	354	1 RGHU12	GTP-binding regula
20	51	89.5	354	2 S24352	GTP-binding regula
21	51	89.5	354	2 S24352	GTP-binding regula
22	50	87.7	63	2 I48071	GTP-binding protei
23	50	87.7	354	1 RGHU13	GTP-binding regula
24	50	87.7	354	1 RGHU13	GTP-binding regula
25	50	87.7	354	2 S28159	GTP-binding regula
26	50	87.7	354	2 S40508	GTP-binding regula
27	50	87.7	354	2 S40509	G-protein - chicke
28	49	86.0	104	2 B25888	probable GTP-bind
29	41	71.9	355	1 RGHU11	GTP-binding regula

ALIGNMENTS

RESULT 1

RGHU11

GTP-binding regulatory protein Gi alpha-1 chain (adenylate cyclase-inhibiting) - bovine

N;Alternate names: guanine nucleotide binding protein Gi alpha-1 chain; heterotrimeric

C;Species: Bos primigenius taurus (cattle)

C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 09-Jul-2004

C;Accession: A23631; A25888

R;Nukada, T.; Tanabe, T.; Takahashi, H.; Noda, M.; Haga, K.; Haga, T.; Ichiyama, A.; K.

FESS Lett. 137, 305-310, 1986

A;Title: Primary structure of the alpha-subunit of bovine adenylate cyclase-inhibiting

A;Reference number: A23631; MUID:86136587; PMID:2419165

A;Accession: A23631

A;Molecule type: mRNA

A;Residues: 1-354 <NUK>

A;Cross-references: UNIPROT:P04898; GB:X03642; NID:G390; PIDN:CAA27288.1; PID:G391

R;Michel, T.; Winslow, J.W.; Smith, J.A.; Seidman, J.G.; Naeir, E.J.

Proc. Natl. Acad. Sci. U.S.A. 83, 7663-7667, 1986

A;Title: Molecular cloning and characterization of cDNA encoding the GTP-binding protei

A;Reference number: A94131, MUID:87017009; PMID:3094012

A;Accession: A25888

A;Molecule type: mRNA

A;Residues: 106-112; 'S', 114-329, 'N', 331-336, 'E', 338-354 <MIC>

A;Cross-references: GB:M14207; NID:G163129; PIDN:AAA30561.1; PID:G163130

C;Comment: The G proteins are a family of guanine nucleotide-binding proteins that rela

ains. The beta and gamma chains, required for GTPase activity, appear to be common to a

rase; it is specific for each type of G protein.

C;Comment: The Gi alpha chain is specific for G protein that is involved in hormonal re

C;Superfamily: GTP-binding regulatory protein Gs alpha chain

C;Keywords: blocked amino end; GTP binding; heterotrimer; lipoprotein; myristylation; n

F;2-354/Product: GTP-binding regulatory protein Gi alpha-1 chain #status predicted <MAT

F;40-47/Region: nucleotide-binding motif A (P-loop)

F;269-272/Region: GTP-binding NKXD motif

F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted

F;3/Binding site: palmitate (Cys) (covalent) #status predicted

F;178/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted

F;351/Modified site: ADP-ribosylcysteine (Cys) (by pertussis toxin) #status predicted

Query Match 100.0%; Score 57; DB 1; Length 354;

Best Local Similarity 100.0%; Pred. No. 0.0094;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KXNLDKCGLF 10

|||||

Db 345 KXNLDKCGLF 354

RESULT 2

RGHU11

GTP-binding regulatory protein Gi alpha-1 chain (adenylate cyclase-inhibiting) - human

N;Alternate names: guanine nucleotide binding protein Gi alpha-1 chain; heterotrimeric

C;Species: Homo sapiens (man)

C;Date: 31-Dec-1992 #sequence_revision 22-Nov-1996 #text_change 09-Jul-2004

C;Accession: A28318; D28154; T08669
 R;Bray, P.; Carter, A.; Guo, V.; Puckett, C.; Kambholz, J.; Spiegel, A.; Nirenberg, M.
 Proc. Natl. Acad. Sci. U.S.A. 84, 5115-5119, 1987
 A;Title: Human cDNA clones for an alpha subunit of Gi signal-transduction protein.
 A;Reference number: A28318; MUID:87260939; PMID:3110783
 A;Accession: A28318
 A;Molecule type: mRNA
 A;Residues: 6-354 <R>
 A;Cross-references: UNIPROT:P04898; GB:M17219; NID:g183410; PIDN:AAA52581.1; PID:g386747
 R;Itoh, H.; Toyama, R.; Kozasa, T.; Tsukamoto, T.; Matsuo, M.; Kaziro, Y.
 J. Biol. Chem. 263, 6656-6664, 1988
 A;Title: Presence of three distinct molecular species of G-i protein alpha-subunit. Stru
 submitted to the Protein Sequence Database, March 1999
 A;Reference number: A28154; MUID:88198230; PMID:2834384
 A;Accession: D28154
 A;Status: not compared with conceptual translation
 A;Molecule type: DNA
 A;Residues: 1-101 <T>
 A;Cross-references: GB:M20596; GB:M19476; NID:g183189; PIDN:AAA35893.1; PID:g183191
 R;Duesterhoeft, A.; Lauber, J.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
 submitted to the Protein Sequence Database, March 1999
 A;Reference number: Z16467
 A;Accession: T08669
 A;Molecule type: mRNA
 A;Residues: 'WGGCSAATGSAATVPRDSKPTQTRDLGALSRAQKQSLVVRNSRPLLSAPLRTASPTPLRWGRRGPRREAF
 A;Cross-references: EMBL:AL049933
 A;Experimental source: fetal brain; clone DKF2p564K1216
 A;Note: differential sources are due to different assignment of start codons
 C;Comment: The G proteins are a family of guanine nucleotide-binding proteins that relay
 aine. The beta and gamma chains, required for GTPase activity, appear to be common to al
 rase; it is specific for each type of G protein.
 C;Comment: The Gi alpha chain is specific for G protein that is involved in hormonal reg
 C;Genetics:
 A;Gene: GDB:GNAIL
 A;Cross-references: GDB:120003; OMIM:139310
 A;Map position: 7q21-7q21
 A;Note: DKF2p564K1216.1
 C;Superfamily: GTP-binding regulatory protein Gs alpha chain
 C;Keywords: blocked amino end; GTP binding; heterotrimer; lipoprotein; myristylation; nu
 F;2-354/Product: GTP-binding regulatory protein Gi alpha-1 chain #status predicted <MAT>
 F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;269-272/Region: GTP-binding NKXD motif
 F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted
 F;3/Binding site: palmitate (Cys) (covalent) #status predicted
 F;178/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted
 F;351/Modified site: ADP-ribosylcysteine (Cys) (by pertussis toxin) #status predicted
 Query Match 100.0%; Score 57; DB 1; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 345 KNNLKDCGLF 354
 RESULT 3
 RGT11
 N;Alternative names: guanine nucleotide binding protein Gi alpha-1 chain; heterotrimeric G
 C;Species: Rattus norvegicus (Norway rat)
 C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 09-Jul-2004
 C;Accession: C27423
 R;Jones, D.T.; Reed, R.R.
 J. Biol. Chem. 262, 14241-14249, 1987
 A;Title: Molecular cloning of five GTP-binding protein cDNA species from rat olfactory n
 A;Reference number: A92614; MUID:88007678; PMID:2820999
 A;Accession: C27423
 A;Molecule type: mRNA
 A;Residues: 1-354 <JON>
 A;Cross-references: UNIPROT:P10824; GB:M17527; NID:g203167; PIDN:AAA40825.1; PID:g203168
 C;Comment: The G proteins are a family of guanine nucleotide-binding proteins that relay
 aine. The beta and gamma chains, required for GTPase activity, appear to be common to al
 rase; it is specific for each type of G protein.

C;Comment: The Gi alpha chain is specific for G protein that is involved in hormonal reg
 C;Superfamily: GTP-binding regulatory protein Gs alpha chain
 C;Keywords: blocked amino end; GTP binding; heterotrimer; lipoprotein; myristylation; m
 F;2-354/Product: GTP-binding regulatory protein Gi alpha-1 chain #status predicted <MAT>
 F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;269-272/Region: GTP-binding NKXD motif
 F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted
 F;3/Binding site: palmitate (Cys) (covalent) #status predicted
 F;178/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted
 F;351/Modified site: ADP-ribosylcysteine (Cys) (by pertussis toxin) #status predicted
 Query Match 100.0%; Score 57; DB 1; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 345 KNNLKDCGLF 354
 RESULT 4
 RGT11
 N;Alternative names: guanine nucleotide binding protein Gi alpha-1 chain; heterotrimeric
 C;Species: Xenopus laevis (African clawed frog)
 C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 09-Jul-2004
 C;Accession: S11045
 R;Olate, J.; Martinez, S.; Purcell, P.; Jorquera, H.; Codina, J.; Birnbaumer, L.; Allen
 FBS Lett. 268, 27-31, 1990
 A;Title: Molecular cloning and sequence determination of four different cDNA species co
 A;Reference number: S11045; MUID:90346157; PMID:2116977
 A;Accession: S11045
 A;Molecule type: mRNA
 A;Residues: 1-354 <OLA>
 A;Cross-references: UNIPROT:P27044; GB:X56089; NID:964707; PIDN:CAA39569.1; PID:g64708
 C;Comment: The G proteins are a family of guanine nucleotide-binding proteins that relay
 aine. The beta and gamma chains, required for GTPase activity, appear to be common to al
 rase; it is specific for each type of G protein.
 C;Comment: The Gi alpha chain is specific for G protein that is involved in hormonal re
 C;Superfamily: GTP-binding regulatory protein Gs alpha chain
 C;Keywords: blocked amino end; GTP binding; heterotrimer; lipoprotein; myristylation; m
 F;2-354/Product: GTP-binding regulatory protein Gi alpha-1 chain #status predicted <MAT>
 F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;269-272/Region: GTP-binding NKXD motif
 F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted
 F;3/Binding site: palmitate (Cys) (covalent) #status predicted
 F;178/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted
 F;351/Modified site: ADP-ribosylcysteine (Cys) (by pertussis toxin) #status predicted
 Query Match 100.0%; Score 57; DB 1; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 345 KNNLKDCGLF 354
 RESULT 5
 S28157
 N;Alternative names: guanine nucleotide binding protein Gi alpha-1 chain - guinea pig
 C;Species: Cavia porcellus (guinea pig)
 C;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 02-Feb-2001
 C;Accession: S28157
 R;Sakanaka, C.; Izumi, T.; Nakamura, M.; Honda, Z.; Watanabe, T.; Minami, M.; Mutoh, H.
 Biochim. Biophys. Acta 1175, 61-66, 1992
 A;Title: Three types of Galpha protein of the guinea-pig lung: cDNA cloning and analys
 A;Reference number: S28157; MUID:93129640; PMID:1482697
 A;Accession: S28157
 A;Molecule type: mRNA
 A;Residues: 1-354 <SAK>
 C;Superfamily: GTP-binding regulatory protein Gs alpha chain
 C;Keywords: blocked amino end; GTP binding; lipoprotein; myristylation; nucleotide bind

F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;269-272/Region: GTP-binding NKXD motif
 F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted
 F;3/Binding site: palmitate (Cys) (covalent) #status predicted
 F;178/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted

Query Match 100.0%; Score 57; DB 2; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 345 KNNLKDCGLF 354

RESULT 6

GTP-binding regulatory protein alpha chain - starfish (Asterina pectinifera)

C;Species: Asterina pectinifera
 C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
 C;Accession: S24362

R;Chiba, K.; Tadenuma, H.; Matsumoto, M.; Takahashi, K.; Katada, T.; Hoshi, M.

A;Title: The primary structure of the alpha subunit of a starfish guanosine-nucleotide-binding protein

A;Reference number: S24362; MUID:92362619; PMID:1499560

A;Accession: S24362

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-354 <CHI>

A;Cross-references: UNIPROT:P10676; EMBL:X66378; NID:95646; PIDN:CAA47019.1; PID:95647

C;Superfamily: GTP-binding regulatory protein Gs alpha chain

C;Keywords: GTP binding; nucleotide binding; P-loop

F;40-47/Region: nucleotide-binding motif A (P-loop)

F;269-272/Region: GTP-binding NKXD motif

Query Match 100.0%; Score 57; DB 2; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 345 KNNLKDCGLF 354

RESULT 7

IS0237

GTP-binding regulatory protein Gi alpha-1 chain - chicken

N;Alternate names: G11 protein alpha chain

C;Species: Gallus gallus (chicken)

C;Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 09-Jul-2004

C;Accession: IS0237

R;Kilbourne, E.J.; Galper, J.B.

Gene 150, 341-344, 1994

A;Title: Cloning of cDNAs coding for the G alpha i1 and G alpha i2 G-proteins from chick

A;Reference number: IS0237; MUID:95121926; PMID:7821803

A;Accession: IS0237

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-354 <KIL>

A;Cross-references: UNIPROT:P50146; GB:L24548; NID:9666870; PIDN:AAA65066.1; PID:9666871

C;Superfamily: GTP-binding regulatory protein Gs alpha chain

C;Keywords: blocked amino end; GTP binding; lipoprotein; myristylation; nucleotide binding

F;40-47/Region: nucleotide-binding motif A (P-loop)

F;269-272/Region: GTP-binding NKXD motif

F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted

F;3/Binding site: palmitate (Cys) (covalent) #status predicted

F;178/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted

Query Match 100.0%; Score 57; DB 2; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 345 KNNLKDCGLF 354

RESULT 8

S27013

GTP-binding regulatory protein Gi alpha chain - great pond snail

N;Alternate names: guanine nucleotide-binding protein Gi alpha-1 chain

C;Species: Lymnaea stagnalis (great pond snail)

C;Date: 07-Apr-1994 #sequence_revision 07-Apr-1994 #text_change 09-Jul-2004

C;Accession: S27013; S25588

R;Knol, J.C.; Weidemann, W.; Plant, R.J.; Vreugdenhil, E.; van Heerikhuizen, H.

FEBS Lett. 314, 215-219, 1992

A;Title: Molecular cloning of G protein alpha subunits from the central nervous system

A;Reference number: S27013; MUID:93106153; PMID:1468550

A;Accession: S27013

A;Molecule type: mRNA

A;Residues: 1-354 <KNO>

A;Cross-references: UNIPROT:P30682; EMBL:Z15095; NID:99630; PIDN:CAA78807.1; PID:99631

C;Superfamily: GTP-binding regulatory protein Gs alpha chain

C;Keywords: GTP binding; heterotrimer; nucleotide binding; P-loop; signal transduction

F;40-47/Region: nucleotide-binding motif A (P-loop)

F;269-272/Region: GTP-binding NKXD motif

Query Match 100.0%; Score 57; DB 2; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 345 KNNLKDCGLF 354

RESULT 9

RGHUI2

GTP-binding regulatory protein Gi alpha-2 chain (adenylylate cyclase-inhibiting) - human

N;Alternate names: guanine nucleotide binding protein Gi alpha-2 chain; heterotrimeric

C;Species: Homo sapiens (man)

C;Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 09-Jul-2004

C;Accession: S02319; A29025; E28154; S00618; S02320

R;Beals, C.R.; Wilson, C.B.; Perlmutter, R.M.

Proc. Natl. Acad. Sci. U.S.A. 84, 7886-7890, 1987

A;Title: A small multigene family encodes G(i) signal-transduction proteins.

A;Reference number: S02319; MUID:88068503; PMID:3120178

A;Accession: S02319

A;Molecule type: mRNA

A;Residues: 1-355 <BEA>

A;Cross-references: UNIPROT:P04899; EMBL:J03004; NID:9183181; PIDN:AAA52556.1; PID:9183

R;Didsbury, J.R.; Ho, Y.S.; Snyderman, R.

FEBS Lett. 211, 160-164, 1987

A;Title: Human Gi protein alpha-subunit: deduction of amino acid structure from a clone

A;Reference number: A29025; MUID:87105966; PMID:3100330

A;Accession: A29025

A;Molecule type: mRNA

A;Residues: 1-355 <DID>

A;Cross-references: EMBL:X04828; NID:931743; PIDN:CAA28512.1; PID:931744

R;Itoh, H.; Toyama, R.; Kozasa, T.; Tsukamoto, T.; Matsuo, M.; Kaziro, Y.

J. Biol. Chem. 263, 6656-6664, 1988

A;Title: Presence of three distinct molecular species of G-i protein alpha-subunit. Str

A;Reference number: A28154; MUID:88198230; PMID:2834384

A;Accession: B28154

A;Molecule type: mRNA

A;Residues: 1-355 <ITO>

A;Cross-references: GB:J03221

R;Weinstein, I.S.; Spiegel, A.M.; Carter, A.D.

FEBS Lett. 232, 333-340, 1988

A;Title: Cloning and characterization of the human gene for the alpha-subunit of Gi2, a

A;Reference number: S00618; MUID:88242822; PMID:2837412

A;Accession: S00618

A;Molecule type: DNA

A;Residues: 1-39 <WEI>

A;Cross-references: EMBL:X07854; NID:931739; PIDN:CAA30703.1; PID:931740

C;Comment: The G proteins are a family of guanine nucleotide-binding proteins that rela

ains. The beta and gamma chains, required for GTPase activity, appear to be common to all
 C;Comment: The Gi alpha chain is specific for G protein that is involved in hormonal reg
 C;Genetics:
 A;Gene: GDB:GNAI2; GNAI2B
 A;Cross-references: GDB:120516; OMIM:139360
 A;Map position: 3p21.3-3p21.2
 A;Introns: 40/1; 54/2; 101/3; 155/2; 198/2; 241/3; 293/1
 C;Superfamily: GTP-binding regulatory protein Gs alpha chain
 C;Keywords: blocked amino end; GTP binding; heterotrimer; lipoprotein; myristylation; nu
 F;2-355/Product: GTP-binding regulatory protein Gi alpha-2 chain #status predicted <MAT
 F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;270-273/Region: GTP-binding NKXD motif
 F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted
 F;3/Binding site: palmitate (Cys) (covalent) #status predicted
 F;179/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted
 F;352/Modified site: ADP-ribosylcysteine (Cys) (by pertussis toxin) #status predicted
 Query Match 100.0%; Score 57; DB 1; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 346 KNNLKDCGLF 355
 RESULT 10
 RGS12
 GTP-binding regulatory protein Gi alpha-2 chain (adenylate cyclase-inhibiting) - mouse
 N;Alternate names: guanine nucleotide binding protein Gi alpha-2 chain; heterotrimeric G
 C;Species: Mus musculus (house mouse)
 C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 09-Jul-2004
 C;Accession: B25889
 R;Sullivan, K.A.; Liao, Y.C.; Alborzi, A.; Beiderman, B.; Chang, F.H.; Masters, S.B.; Le
 Proc. Natl. Acad. Sci. U.S.A. 83, 6687-6691, 1986
 A;Title: Inhibitory and stimulatory G proteins of adenylate cyclase: cDNA and amino acid
 A;Reference number: A94123; MUID:86313643; PMID:3092218
 A;Accession: B25989
 A;Molecule type: mRNA
 A;Residues: 1-355 <SUL>
 A;Cross-references: UNIPROT:P08752; GB:M13963; NID:G193513; PIDN:AAA37692.1; PID:G309255
 C;Comment: The G proteins are a family of guanine nucleotide-binding proteins that relay
 ains. The beta and gamma chains, required for GTPase activity, appear to be common to al
 C;Comment: The Gi alpha chain is specific for G protein.
 C;Superfamily: The Gi alpha chain is specific for G protein that is involved in hormonal reg
 C;Keywords: blocked amino end; GTP binding; heterotrimer; lipoprotein; myristylation; nu
 F;2-355/Product: GTP-binding regulatory protein Gi alpha-2 chain #status predicted <MAT
 F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;270-273/Region: GTP-binding NKXD motif
 F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted
 F;3/Binding site: palmitate (Cys) (covalent) #status predicted
 F;179/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted
 F;352/Modified site: ADP-ribosylcysteine (Cys) (by pertussis toxin) #status predicted
 Query Match 100.0%; Score 57; DB 1; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 346 KNNLKDCGLF 355
 RESULT 11
 RGR12
 GTP-binding regulatory protein Gi alpha-2 chain (adenylate cyclase-inhibiting) - rat
 N;Alternate names: guanine nucleotide binding protein Gi alpha-2 chain; heterotrimeric G
 C;Species: Rattus norvegicus (Norway rat)
 C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 09-Jul-2004
 C;Accession: D27423; B24882; B35377
 R;Jones, D.T.; Reed, R.R.

J. Biol. Chem. 262, 14241-14249, 1987
 A;Title: Molecular cloning of five GTP-binding protein cDNA species from rat olfactory
 A;Reference number: A92614; MUID:88007678; PMID:2820999
 A;Accession: D27423
 A;Molecule type: mRNA
 A;Residues: 1-355 <JON>
 A;Cross-references: UNIPROT:P04897; GB:M17528; NID:G203165; PIDN:AAA40824.1; PID:G203165
 R;Itoh, H.; Kozasa, T.; Nagata, S.; Nakamura, S.; Katada, T.; Ui, M.; Iwai, S.; Ohnaka,
 Proc. Natl. Acad. Sci. U.S.A. 83, 3776-3780, 1986
 A;Title: Molecular cloning and sequence determination of cDNAs for alpha subunits of the
 A;Reference number: A94707; MUID:86233317; PMID:3086867
 A;Accession: B24882
 A;Molecule type: mRNA
 A;Residues: 1-355 <ITO>
 A;Cross-references: GB:M12672; NID:G204439; PIDN:AAA41260.1; PID:G204440
 R;Binder, M.B.; Ewald, D.A.; Miller, R.J.; Gilman, A.G.
 J. Biol. Chem. 265, 8243-8251, 1990
 A;Title: Purification and characterization of G- α and three types of G- β chains
 A;Reference number: A35377; MUID:90243707; PMID:2159473
 A;Accession: B35377
 A;Molecule type: protein
 A;Residues: 112-126 <LIN>
 C;Comment: The G proteins are a family of guanine nucleotide-binding proteins that relay
 ains. The beta and gamma chains, required for GTPase activity, appear to be common to al
 C;Comment: The Gi alpha chain is specific for G protein.
 C;Superfamily: The Gi alpha chain is specific for G protein that is involved in hormonal reg
 C;Keywords: blocked amino end; GTP binding; heterotrimer; lipoprotein; myristylation; nu
 F;2-355/Product: GTP-binding regulatory protein Gi alpha-2 chain #status predicted <MAT
 F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;270-273/Region: GTP-binding NKXD motif
 F;2/Modified site: myristylated amino end (Gly) (in mature form) #status predicted
 F;3/Binding site: palmitate (Cys) (covalent) #status predicted
 F;179/Modified site: ADP-ribosylarginine (Arg) (by cholera toxin) #status predicted
 F;352/Modified site: ADP-ribosylcysteine (Cys) (by pertussis toxin) #status predicted
 Query Match 100.0%; Score 57; DB 1; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 346 KNNLKDCGLF 355
 RESULT 12
 S2B158
 GTP-binding regulatory protein Gi alpha-2 chain - guinea pig
 C;Species: Cavia porcellus (guinea pig)
 C;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 02-Feb-2001
 C;Accession: S2B158
 R;Sakanaka, C.; Izumi, T.; Nakamura, M.; Honda, Z.; Watanabe, T.; Minami, M.; Mutoh, H.;
 Biochim. Biophys. Acta 1175, 61-66, 1992
 A;Title: Three types of G α protein of the guinea-pig lung: cDNA cloning and analysis
 A;Reference number: S2B157; MUID:93129640; PMID:1482697
 A;Accession: S2B158
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-355 <SAK>
 C;Superfamily: GTP-binding regulatory protein Gs alpha chain
 C;Keywords: GTP binding; nucleotide binding; P-loop
 F;40-47/Region: nucleotide-binding motif A (P-loop)
 F;270-273/Region: GTP-binding NKXD motif
 Query Match 100.0%; Score 57; DB 2; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.0094;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 Db 346 KNNLKDCGLF 355

RESULT 13

I50238
G12 protein alpha-subunit - chicken
C;Species: Gallus gallus (chicken)
C;Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 09-Jul-2004
C;Accession: I50238
R;Kilbourne, B.J.; Galper, J.B.
Gene 150, 341-344, 1994
A;Title: Cloning of cDNAs coding for the G alpha i1 and G alpha i2 G-proteins from chick
A;Reference number: I50237; MUID:95121926; PMID:7821803
A;Accession: I50238
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-355 <ML>
A;Cross-references: UNIPROT:P50147; GB:I24549; NID:G666872; PIDN:AAA65067.1; PID:G666873
C;Superfamily: GTP-binding regulatory protein Gs alpha chain
C;Keywords: GTP binding; nucleotide binding; P-loop
F;40-47/Region: nucleotide-binding motif A (P-loop)
F;270-273/Region: GTP-binding NKXD motif

Query Match 100.0%; Score 57; DB 2; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.0094;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||
Db 346 KNNLKDCGLF 355

RESULT 14

A61031
GTP-binding regulatory protein Gi alpha-2 chain (adenylate cyclase-inhibiting) - dog
C;Species: Canis lupus familiaris (dog)
C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 09-Jul-2004
C;Accession: A61031
R;Holmer, S.R.; Stevens, S.; Homcy, C.J.
Circ. Res. 65, 1136-1140, 1989
A;Title: Tissue- and species-specific expression of inhibitory guanine nucleotide-binding
A;Reference number: A61031; MUID:90003652; PMID:2477170
A;Accession: A61031
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-355 <HOL>
A;Cross-references: UNIPROT:P38400
C;Superfamily: GTP-binding regulatory protein Gs alpha chain
C;Keywords: GTP binding; nucleotide binding; P-loop
F;40-47/Region: nucleotide-binding motif A (P-loop)
F;270-273/Region: GTP-binding NKXD motif

Query Match 100.0%; Score 57; DB 2; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.0094;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||
Db 346 KNNLKDCGLF 355

RESULT 15

A48976
GTP-binding regulatory protein Gi alpha chain - American lobster
C;Species: Homarus americanus (American lobster)
C;Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: A48976; T01964
R;McClintock, T.S.; Byrnes, A.P.; Lerner, M.R.
Brain Res. Mol. Brain Res. 14, 273-276, 1992
A;Title: Molecular cloning of a G-protein alpha i subunit from the lobster olfactory org
A;Reference number: A48976; MUID:93061797; PMID:1279345
A;Accession: A48976
A;Status: preliminary
A;Molecule type: nucleic acid
A;Residues: 1-355 <MCC>
A;Cross-references: UNIPROT:P41776; GB:S47614; NID:G259436; PIDN:AAB24072.1; PID:G259437

A;Experimental source: olfactory organ
A;Note: sequence inconsistent with the nucleotide translation
A;Note: sequence extracted from NCBI backbone (NCBIN:117491, NCBIP:117492)
A;Accession: T01964
A;Status: translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-140, 'P', 142-307, 324-355 <MCW>
A;Cross-references: EMBL:S47614; NID:G259436; PIDN:AAB24072.2; PID:G7330345
C;Superfamily: GTP-binding regulatory protein Gs alpha chain
C;Keywords: GTP binding; nucleotide binding; P-loop
F;41-48/Region: nucleotide-binding motif A (P-loop)
F;270-273/Region: GTP-binding NKXD motif

Query Match 100.0%; Score 57; DB 2; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.0094;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||
Db 346 KNNLKDCGLF 355

Search completed: March 22, 2005, 06:18:33
Job time : 16 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 22, 2005, 06:00:27 ; Search time 22 Seconds
(without alignments)
33.931 Million cell updates/sec

Title: US-10-009-809-2
Perfect score: 57 KNNLKDCCGLF 10
Sequence: 1 KNNLKDCCGLF 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*

1: /cgn2_6/prodata/1/iaa/5A COMB.pcp.*
2: /cgn2_6/prodata/1/iaa/5B COMB.pcp.*
3: /cgn2_6/prodata/1/iaa/6A COMB.pcp.*
4: /cgn2_6/prodata/1/iaa/6B COMB.pcp.*
5: /cgn2_6/prodata/1/iaa/PCTUS COMB.pcp.*
6: /cgn2_6/prodata/1/iaa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	57	100.0	10	1	US-08-019-073-19
2	57	100.0	10	2	US-08-429-964-50
3	57	100.0	10	5	PCT-US93-08062-50
4	57	100.0	10	5	PCT-US94-01768-19
5	57	100.0	10	6	5428134-6
6	57	100.0	10	6	5436320-6
7	57	100.0	10	6	5428134-6
8	57	100.0	10	6	5436320-6
9	57	100.0	13	4	US-09-489-156-16
10	57	100.0	395	4	US-09-949-016-11560
11	57	100.0	709	4	US-09-826-509-589
12	51	89.5	10	6	5428134-1
13	51	89.5	10	6	5428134-10
14	51	89.5	10	6	5436320-1
15	51	89.5	10	6	5436320-7
16	51	89.5	10	6	5428134-1
17	51	89.5	10	6	5428134-10
18	51	89.5	10	6	5436320-1
19	51	89.5	10	6	5436320-7
20	51	89.5	11	1	US-07-868-353A-7
21	51	89.5	11	2	US-08-407-804-7
22	51	89.5	11	3	US-09-124-807-7
23	51	89.5	13	4	US-09-489-156-15
24	51	89.5	40	1	US-07-868-353A-3
25	51	89.5	40	2	US-08-407-804-3
26	51	89.5	40	3	US-09-124-807-3
27	51	89.5	350	1	US-07-868-353A-14

28	51	89.5	350	2	US-08-407-804-23	Sequence 23, Appl
29	51	89.5	350	3	US-09-124-807-23	Sequence 23, Appl
30	51	89.5	354	1	US-07-868-353A-12	Sequence 12, Appl
31	51	89.5	354	1	US-07-868-353A-13	Sequence 13, Appl
32	51	89.5	354	1	US-07-868-353A-15	Sequence 15, Appl
33	51	89.5	354	2	US-08-407-804-21	Sequence 21, Appl
34	51	89.5	354	2	US-08-407-804-22	Sequence 22, Appl
35	51	89.5	354	2	US-08-407-804-24	Sequence 24, Appl
36	51	89.5	354	3	US-09-124-807-21	Sequence 21, Appl
37	51	89.5	354	3	US-09-124-807-22	Sequence 22, Appl
38	51	89.5	354	3	US-09-124-807-24	Sequence 24, Appl
39	51	89.5	357	4	US-09-984-292-7	Sequence 7, Appl
40	50	87.7	11	4	US-09-489-156-39	Sequence 39, Appl
41	50	87.7	13	4	US-09-489-156-18	Sequence 18, Appl
42	50	87.7	295	4	US-09-949-016-10678	Sequence 10678, A
43	50	87.7	354	4	US-09-949-016-6727	Sequence 6727, Ap
44	46	80.7	353	4	US-09-984-292-6	Sequence 6, Appl
45	46	80.7	353	4	US-09-984-292-18	Sequence 18, Appl

ALIGNMENTS

RESULT 1
US-08-019-073-19
; Sequence 19, Application US/08019073
; Patent No. 5559209
; GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: REGULATOR REGIONS OF G
; TITLE OF INVENTION: PROTEINS
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/019, 073
; FILING DATE: 19930218
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/146001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: AMINO ACID
; STRANDEDNESS:
; TOPOLOGY: linear
US-08-019-073-19

Query Match 100.0%; Score 57; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KNNLKDCCGLF 10
|||||

Tue Mar 22 06:57:16 2005

Db 1 KNNLKDCGLF 10

RESULT 2

US-08-429-964-50
; Sequence 50, Application US/08429964
; Patent No. 5962243
; GENERAL INFORMATION:
; APPLICANT: BROWN, MICHAEL S.
; APPLICANT: GOLDSTEIN, JOSEPH L.
; APPLICANT: REISS, YUVAL
; APPLICANT: JAMES, GUY L.
; TITLE OF INVENTION: METHODS FOR THE IDENTIFICATION OF FARNESYL
; TRANSFERASE INHIBITORS
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/429,964
; FILING DATE: 27-APR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021,625
; FILING DATE: 16-FEB-1993
; CLASSIFICATION: 435
; APPLICATION NUMBER: US 07/822,011
; FILING DATE: ABANDONED
; CLASSIFICATION: 435
; APPLICATION NUMBER: PCT/US/91/02650
; FILING DATE: 18-APR-1991
; CLASSIFICATION: 435
; APPLICATION NUMBER: US 07/615,715
; FILING DATE: 20-NOV-1990
; CLASSIFICATION: 435
; APPLICATION NUMBER: US 07/510,706
; FILING DATE: 18-APR-1990 (ABANDONED)
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: PARKER, DAVID L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTSD:432/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (713) 789-2679
; TELEX: 79-0924
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-429-964-50

Query Match 100.0%; Score 57; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||||
Db 1 KNNLKDCGLF 10

RESULT 3

PCT-US93-08062-50
; Sequence 50, Application PC/TUS9308062
; GENERAL INFORMATION:
; APPLICANT:

; SEQUENCE CHARACTERISTICS: BROWN, MICHAEL S.
; SEQUENCE CHARACTERISTICS: GOLDSTEIN, JOSEPH L.
; SEQUENCE CHARACTERISTICS: REISS, YUVAL
; SEQUENCE CHARACTERISTICS: MARSTERS, JR., JAMES C.
; ADDRESSEE: METHODS AND COMPOSITIONS FOR
; THE IDENTIFICATION,
; CHARACTERIZATION AND
; INHIBITION OF
; FARNESYLTRANSFERASE
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK/ASKII
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08062
; FILING DATE: AUGUST 24, 1993
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/935,087
; FILING DATE: 24 AUGUST 1992 (24.08.92)
; NAME: UNKNOWN
; ATTORNEY/AGENT INFORMATION:
; NAME: PARKER, DAVID L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTFD377PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512-320-7200
; TELEFAX: 512-474-7577
; TELEX: NOT APPLICABLE
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acid residues
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear

PCT-US93-08062-50

Query Match 100.0%; Score 57; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||||
Db 1 KNNLKDCGLF 10

RESULT 4

PCT-US94-01768-19
; Sequence 19, Application PC/TUS9401768
; GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: REGULATOR REGIONS OF G PROTEINS
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.

ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 502 or 55SX
OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/01768
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/019,073
FILING DATE: February 18, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Paul T.
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00786/146001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 10
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
PCT-US94-01768-19

Query Match 100.0%; Score 57; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||||

Db 1 KNNLKDCGLF 10
|||||

RESULT 5

5428134-6
Patent No. 5428134
APPLICANT: SPIEGEL, ALLEN M.
TITLE OF INVENTION: ANTIBODY REAGENTS THAT SPECIFICALLY
BIND TO THE CARBOXYL-TERMINAL DECAPTIDE OF SPECIFIC
GTP-BINDING PROTEINS

NUMBER OF SEQUENCES: 11

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/821,849

FILING DATE: 14-JAN-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 564,675

FILING DATE: 08-AUG-1990

APPLICATION NUMBER: 365,919

FILING DATE: 15-JAN-1989

SEQ ID NO:6:

LENGTH: 10

5428134-6

Query Match 100.0%; Score 57; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||||

Db 1 KNNLKDCGLF 10
|||||

RESULT 6

5436320-6
Patent No. 5436320
APPLICANT: SPIEGEL, ALLEN M.
TITLE OF INVENTION: ANTIBODY REAGENTS THAT IDENTIFY THE
CARBOXY-TERMINAL PEPTIDE OF THE GTP-BINDING PROTEIN G

NUMBER OF SEQUENCES: 10
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/820,377
FILING DATE: 14-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 564,675
FILING DATE: 08-AUG-1990
APPLICATION NUMBER: 365,919
FILING DATE: 15-JUN-1989
APPLICATION NUMBER: 100,909
FILING DATE: 25-SEP-1987
SEQ ID NO:6:
LENGTH: 10
5436320-6

Query Match 100.0%; Score 57; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||||

Db 1 KNNLKDCGLF 10
|||||

RESULT 7

5428134-6
Patent No. 5428134
APPLICANT: SPIEGEL, ALLEN M.
TITLE OF INVENTION: ANTIBODY REAGENTS THAT SPECIFICALLY
BIND TO THE CARBOXYL-TERMINAL DECAPTIDE OF SPECIFIC
GTP-BINDING PROTEINS

NUMBER OF SEQUENCES: 11

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/821,849

FILING DATE: 14-JAN-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 564,675

FILING DATE: 08-AUG-1990

APPLICATION NUMBER: 365,919

FILING DATE: 15-JAN-1989

SEQ ID NO:6:

LENGTH: 10

5428134-6

Query Match 100.0%; Score 57; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
|||||

Db 1 KNNLKDCGLF 10
|||||

RESULT 8

5436320-6
Patent No. 5436320
APPLICANT: SPIEGEL, ALLEN M.
TITLE OF INVENTION: ANTIBODY REAGENTS THAT IDENTIFY THE
CARBOXY-TERMINAL PEPTIDE OF THE GTP-BINDING PROTEIN G

NUMBER OF SEQUENCES: 10

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/820,377

FILING DATE: 14-JAN-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 564,675

FILING DATE: 08-AUG-1990

APPLICATION NUMBER: 365,919

FILING DATE: 15-JUN-1989

APPLICATION NUMBER: 100,909

FILING DATE: 25-SEP-1987

SEQ ID NO:6:

LENGTH: 10

5436320-6

Query Match 100.0%; Score 57; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 1 KNNLKDCGLF 10

RESULT 9
US-09-489-156-16
; Sequence 16, Application US/09489156
; Patent No. 6559128
; GENERAL INFORMATION:
; APPLICANT: HAMM, Heidi
; APPLICANT: GILCHRIST, Annette
; TITLE OF INVENTION: INHIBITORS OF G PROTEIN-MEDIATED SIGNALING, METHODS OF MAKING THE
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 0290-29 (NU 99037)
; CURRENT APPLICATION NUMBER: US/09/489,156
; CURRENT FILING DATE: 2000-01-21
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 16
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: G alpha i 1/2 peptide
US-09-489-156-16

Query Match 100.0%; Score 57; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00049;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 4 KNNLKDCGLF 13

RESULT 10
US-09-949-016-11560
; Sequence 11560, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11560
; LENGTH: 395
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-11560

Query Match 100.0%; Score 57; DB 4; Length 395;
Best Local Similarity 100.0%; Pred. No. 0.017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 386 KNNLKDCGLF 395

Query Match 100.0%; Score 57; DB 4; Length 709;
Best Local Similarity 100.0%; Pred. No. 0.032;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 700 KNNLKDCGLF 709

RESULT 12
5428134-1
; Patent No. 5428134
; APPLICANT: Spiegel, Allen M.
; TITLE OF INVENTION: ANTIBODY REAGENTS THAT SPECIFICALLY
; BIND TO THE CARBOXYL-TERMINAL DECAPTIDE OF SPECIFIC
; GTP-BINDING PROTEINS
; NUMBER OF SEQUENCES: 11
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/821,849
; FILING DATE: 14-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 564,675
; FILING DATE: 08-AUG-1990
; APPLICATION NUMBER: 365,919
; FILING DATE: 15-JAN-1989
; SEQ ID NO:1:
; LENGTH: 10
5428134-1

Query Match 89.5%; Score 51; DB 6; Length 10;
Best Local Similarity 90.0%; Pred. No. 0.0045;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 1 KNNLKDCGLF 10

RESULT 13
5428134-10
; Patent No. 5428134
; APPLICANT: Spiegel, Allen M.
; TITLE OF INVENTION: ANTIBODY REAGENTS THAT SPECIFICALLY
; BIND TO THE CARBOXYL-TERMINAL DECAPTIDE OF SPECIFIC
; GTP-BINDING PROTEINS
; NUMBER OF SEQUENCES: 11

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/821,849
; FILING DATE: 14-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 564,675
; FILING DATE: 08-AUG-1990
; APPLICATION NUMBER: 365,919
; FILING DATE: 15-JAN-1989
; SEQ ID NO:10:
; LENGTH: 10
5428134-10

Query Match 89.5%; Score 51; DB 6; Length 10;
Best Local Similarity 90.0%; Pred. No. 0.0045;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 1 KENLKDCGLF 10

RESULT 14
5436320-1
; Patent No. 5436320
; APPLICANT: SPIEGEL, ALLEN M.
; TITLE OF INVENTION: ANTIBODY REAGENTS THAT IDENTIFY THE
; CARBOXY-TERMINAL PEPTIDE OF THE GTP-BINDING PROTEIN G
; NUMBER OF SEQUENCES: 10
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/820,377
; FILING DATE: 14-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 564,675
; FILING DATE: 08-AUG-1990
; APPLICATION NUMBER: 365,919
; FILING DATE: 15-JUN-1989
; APPLICATION NUMBER: 100,909
; FILING DATE: 25-SEP-1987
; SEQ ID NO:1:
; LENGTH: 10
5436320-1

Query Match 89.5%; Score 51; DB 6; Length 10;
Best Local Similarity 90.0%; Pred. No. 0.0045;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 1 KENLKDCGLF 10

RESULT 15
5436320-7
; Patent No. 5436320
; APPLICANT: SPIEGEL, ALLEN M.
; TITLE OF INVENTION: ANTIBODY REAGENTS THAT IDENTIFY THE
; CARBOXY-TERMINAL PEPTIDE OF THE GTP-BINDING PROTEIN G
; NUMBER OF SEQUENCES: 10
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/820,377
; FILING DATE: 14-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 564,675
; FILING DATE: 08-AUG-1990
; APPLICATION NUMBER: 365,919
; FILING DATE: 15-JUN-1989
; APPLICATION NUMBER: 100,909
; FILING DATE: 25-SEP-1987
; SEQ ID NO:7:
; LENGTH: 10
5436320-7

Query Match 89.5%; Score 51; DB 6; Length 10;

Best Local Similarity 90.0%; Pred. No. 0.0045;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
| | | | | | | | | |
Db 1 KENLKDCGLF 10

Search completed: March 22, 2005, 06:21:26
Job time : 23 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 22, 2005, 06:30:50 ; Search time 139 Seconds
(without alignments)

23.780 Million cell updates/sec

Title: US-10-009-809-2

Perfect score: 57

Sequence: 1 KNNLKDCGLF 10

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1401741 seqs, 330541175 residues

Total number of hits satisfying chosen parameters: 1401741

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/2/pubpaa/US09D_PUBCOMB.pep.*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep.*
19: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
20: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	57	100.0	10	16	US-10-465-826-31
2	57	100.0	11	10	US-09-852-910-17
3	57	100.0	11	15	US-10-411-336A-17
4	57	100.0	13	10	US-09-852-910-112
5	57	100.0	13	14	US-10-373-540-16
6	57	100.0	13	15	US-10-411-336A-112
7	57	100.0	339	15	US-10-108-260A-3642
8	57	100.0	339	15	US-10-108-260A-3821
9	57	100.0	353	15	US-10-059-266B-18
10	57	100.0	354	10	US-09-952-680A-19
11	57	100.0	354	15	US-10-352-843-14
12	57	100.0	354	15	US-10-059-266B-4
13	57	100.0	355	9	US-09-947-953-2

14	57	100.0	355	10	US-09-952-680A-20	Sequence 20, Appl
15	57	100.0	355	10	US-09-952-680A-23	Sequence 23, Appl
16	57	100.0	355	15	US-10-116-275-267	Sequence 267, App
17	57	100.0	355	16	US-10-408-765A-427	Sequence 427, App
18	57	100.0	355	16	US-10-408-765A-2392	Sequence 2392, Ap
19	57	100.0	395	17	US-10-491-654-23	Sequence 23, Appl
20	57	100.0	709	10	US-09-826-509-589	Sequence 589, App
21	57	100.0	709	17	US-10-925-095-589	Sequence 589, App
22	53	93.0	10	16	US-10-465-826-4	Sequence 4, Appl
23	53	93.0	26	16	US-10-465-826-10	Sequence 10, Appl
24	53	93.0	26	16	US-10-465-826-19	Sequence 19, Appl
25	51	89.5	10	16	US-10-465-826-2	Sequence 2, Appl
26	51	89.5	11	10	US-09-789-996-7	Sequence 7, Appl
27	51	89.5	11	10	US-09-852-910-15	Sequence 15, Appl
28	51	89.5	11	15	US-10-411-336A-15	Sequence 15, Appl
29	51	89.5	13	14	US-10-373-540-15	Sequence 15, Appl
30	51	89.5	26	16	US-10-465-826-25	Sequence 25, Appl
31	51	89.5	40	10	US-09-789-996-3	Sequence 3, Appl
32	51	89.5	157	10	US-09-952-680A-33	Sequence 33, Appl
33	51	89.5	350	10	US-09-789-996-23	Sequence 23, Appl
34	51	89.5	350	10	US-09-952-680A-24	Sequence 24, Appl
35	51	89.5	350	15	US-10-352-843-15	Sequence 15, Appl
36	51	89.5	350	15	US-10-380-393B-1	Sequence 1, Appl
37	51	89.5	350	15	US-10-059-266B-8	Sequence 8, Appl
38	51	89.5	350	16	US-10-408-765A-428	Sequence 428, App
39	51	89.5	354	10	US-09-789-996-21	Sequence 21, Appl
40	51	89.5	354	10	US-09-789-996-22	Sequence 22, Appl
41	51	89.5	354	10	US-09-789-996-24	Sequence 24, Appl
42	51	89.5	354	10	US-09-952-680A-25	Sequence 25, Appl
43	51	89.5	357	9	US-09-984-292-7	Sequence 7, Appl
44	51	89.5	357	9	US-09-989-497-7	Sequence 7, Appl
45	50	87.7	10	16	US-10-465-826-1	Sequence 1, Appl

ALIGNMENTS

RESULT 1
US-10-465-826-31
Sequence 31, Application US/10465826
Publication No. US20040137006A1
GENERAL INFORMATION:
APPLICANT: ALLERGENE LTD.
APPLICANT: Eisenberg, Ronit
APPLICANT: Raz, Tamari
TITLE OF INVENTION: ANTI-ALLERGIC COMPLEX MOLECULES
FILE REFERENCE: ALL/002 US
CURRENT APPLICATION NUMBER: US/10/465,826
PRIOR FILING DATE: 2003-06-20
PRIOR APPLICATION NUMBER: PCT/IL01/01186
PRIOR FILING DATE: 2001-12-20
NUMBER OF SEQ ID NOS: 32
SOFTWARE: PatentIn version 3.1
SEQ ID NO 31
LENGTH: 10
TYPE: PRT
ORGANISM: Homo sapiens
US-10-465-826-31

Query Match 100.0%; Score 57; DB 16; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0012;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 1 KNNLKDCGLF 10

RESULT 2

US-09-852-910-17
Sequence 17, Application US/09852910
Publication No. US20030096297A1
GENERAL INFORMATION:

```
; APPLICANT: Hamm, Heidi
; APPLICANT: Gilchrist, Annette
; TITLE OF INVENTION: Method For Identifying Inhibitors of G Protein Coupled Receptor S
; FILE REFERENCE: 2661-101
; CURRENT APPLICATION NUMBER: US/09/852,910
; CURRENT FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: US 60/275,472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-852-910-17

Query Match      100.0%; Score 57; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0014;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
        |||||
Db      2 KNNLKDCGLF 11

RESULT 3
US-10-411-336A-17
; Sequence 17, Application US/10411336A
; Publication No. US20040018558A1
; GENERAL INFORMATION:
; APPLICANT: GILCHRIST, ANNETTE
; APPLICANT: HAMM, HEIDI
; TITLE OF INVENTION: METHOD FOR IDENTIFYING MODULATORS OF G PROTEIN COUPLED RECEPTOR
; TITLE OF INVENTION: SIGNALING
; FILE REFERENCE: 2661-102
; CURRENT APPLICATION NUMBER: US/10/411,336A
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: US 09/852910
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: US 60/275472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 273
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-336A-17

Query Match      100.0%; Score 57; DB 15; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0014;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
        |||||
Db      2 KNNLKDCGLF 11

RESULT 4
US-09-852-910-112
; Sequence 112, Application US/09852910
; Publication No. US20030096297A1
; GENERAL INFORMATION:
; APPLICANT: Hamm, Heidi
; APPLICANT: Gilchrist, Annette
; TITLE OF INVENTION: Method For Identifying Inhibitors of G Protein Coupled Receptor S
; FILE REFERENCE: 2661-101
; CURRENT APPLICATION NUMBER: US/09/852,910
; CURRENT FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: US 60/275,472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 112
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; NAME/KEY: misc feature
; LOCATION: (1)-(13)
; OTHER INFORMATION: G alpha i minigene peptide
US-09-852-910-112

Query Match      100.0%; Score 57; DB 10; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0016;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
        |||||
Db      4 KNNLKDCGLF 13

RESULT 5
US-10-373-540-16
; Sequence 16, Application US/10373540
; Publication No. US20030162258A1
; GENERAL INFORMATION:
; APPLICANT: HAMM, Heidi
; APPLICANT: GILCHRIST, ANNETTE
; TITLE OF INVENTION: INHIBITORS OF G PROTEIN-MEDIATED SIGNALING, METHODS OF MAKING TH
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 0290-29 (NU 99037)
; CURRENT APPLICATION NUMBER: US/10/373,540
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US/09/489,156
; PRIOR FILING DATE: PRIOR FILING DATE: 2000-01-21
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: G alpha i 1/2 peptide
US-10-373-540-16

Query Match      100.0%; Score 57; DB 14; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0016;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
        |||||
Db      4 KNNLKDCGLF 13

RESULT 6
US-10-411-336A-112
; Sequence 112, Application US/10411336A
; Publication No. US20040018558A1
; GENERAL INFORMATION:
; APPLICANT: GILCHRIST, ANNETTE
; APPLICANT: HAMM, HEIDI
; TITLE OF INVENTION: METHOD FOR IDENTIFYING MODULATORS OF G PROTEIN COUPLED RECEPTOR
; TITLE OF INVENTION: SIGNALING
; FILE REFERENCE: 2661-102
; CURRENT APPLICATION NUMBER: US/10/411,336A
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: US 09/852910
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: US 60/275472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 273
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 112
; LENGTH: 13
; TYPE: PRT
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: G alpha i minigene peptide
US-10-411-336A-112

Query Match      100.0%; Score 57; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0016;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
Db      4 KNNLKDCGLF 13
|||||

RESULT 7
US-10-108-260A-3642
; Sequence 3642, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1el full length cDNA
; FILE REFERENCE: HI-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3642
; LENGTH: 339
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-3642

Query Match      100.0%; Score 57; DB 15; Length 339;
Best Local Similarity 100.0%; Pred. No. 0.044;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
Db      330 KNNLKDCGLF 339
|||||

RESULT 8
US-10-108-260A-3821
; Sequence 3821, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1el full length cDNA
; FILE REFERENCE: HI-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3821
; LENGTH: 339
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-3821

Query Match      100.0%; Score 57; DB 15; Length 339;
Best Local Similarity 100.0%; Pred. No. 0.044;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
Db      330 KNNLKDCGLF 339
|||||

RESULT 9
US-10-059-266B-18
; Sequence 18, Application US/10059266B
; Publication No. US20040072157A1
; GENERAL INFORMATION:
; APPLICANT: Graber, Stephen G.
; TITLE OF INVENTION: Soluble Chimeric G Protein Alpha Subunits
; FILE REFERENCE: 033524-001
; CURRENT APPLICATION NUMBER: US/10/059,266B
; CURRENT FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 60/265,068
; PRIOR FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 353
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gq1131N25C alpha subunit
US-10-059-266B-18

Query Match      100.0%; Score 57; DB 15; Length 353;
Best Local Similarity 100.0%; Pred. No. 0.045;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
Db      344 KNNLKDCGLF 353
|||||

RESULT 10
US-09-952-680A-19
; Sequence 19, Application US/09952680A
; Publication No. US20030087239A1
; GENERAL INFORMATION:
; APPLICANT: Stanton, Marty
; APPLICANT: Epstein, David
; APPLICANT: Hameguchi, No. US20030087239Aluko
; TITLE OF INVENTION: Target Activated Biosensor and Methods of Using Same
; FILE REFERENCE: 23239-501
; CURRENT APPLICATION NUMBER: US/09/952,680A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: 60/232,454
; PRIOR FILING DATE: 2000-09-13
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 354
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-952-680A-19

Query Match      100.0%; Score 57; DB 10; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.045;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
Db      345 KNNLKDCGLF 354
|||||

RESULT 11
US-10-352-843-14
; Sequence 14, Application US/10352843
; Publication No. US20040014135A1
; GENERAL INFORMATION:
; APPLICANT: Moore, Lisa
; APPLICANT: Kindt, Rachel
; APPLICANT: Kopczyński, Jenny
; APPLICANT: Doberstein, Stephen
; APPLICANT: Cockett, Mark
; APPLICANT: Ramanathan, Chandra
; APPLICANT: Lodge, Nicholas
; APPLICANT: Fitzgerald, Kevin
; APPLICANT: Stouch, Terry
; TITLE OF INVENTION: TREATING URINARY INCONTINENCE
```

1.

RESULT 16
US-10-116-275-267
; Sequence 267, Application US/10116275
; Publication No. US20030211476A1
; GENERAL INFORMATION:
; APPLICANT: Elan Pharmaceutical Technology
; APPLICANT: O'Mahony, Daniel J.
; APPLICANT: Brayden, David
; APPLICANT: Byrne, Daragh
; APPLICANT: Lambkin, Imelda
; APPLICANT: Higgins, Lisa
; TITLE OF INVENTION: Genetic Analysis of Peyer's Patches and M Cells and Methods and
; FILE REFERENCE: E1067/20087
; CURRENT APPLICATION NUMBER: US/10/116,275
; CURRENT FILING DATE: 2002-10-04
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 267
; LENGTH: 355
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-116-275-267

Query Match 100.0%; Score 57; DB 15; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355

RESULT 17
US-10-408-765A-427
; Sequence 427, Application US/10408765A
; Publication No. US20040101874A1
; GENERAL INFORMATION:
; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Zhang, Bing
; APPLICANT: Gibson, Bradford W.
; APPLICANT: Taylor, Steven W.
; APPLICANT: Glenn, Gary M.
; APPLICANT: Warnock, Dale E.
; TITLE OF INVENTION: TARGETS FOR THERAPEUTIC INTERVENTION
; FILE REFERENCE: 660088.465
; CURRENT APPLICATION NUMBER: US/10/408,765A
; CURRENT FILING DATE: 2003-04-04
; NUMBER OF SEQ ID NOS: 3077
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 427
; LENGTH: 355
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-408-765A-427

Query Match 100.0%; Score 57; DB 16; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355

RESULT 18
US-10-408-765A-2392
; Sequence 2392, Application US/10408765A
; Publication No. US20040101874A1
; GENERAL INFORMATION:

; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Fahy, Eoin D.
; APPLICANT: Zhang, Bing
; APPLICANT: Gibson, Bradford W.
; APPLICANT: Taylor, Steven W.
; APPLICANT: Glenn, Gary M.
; APPLICANT: Warnock, Dale E.
; TITLE OF INVENTION: TARGETS FOR THERAPEUTIC INTERVENTION
; FILE REFERENCE: 660088.465
; CURRENT APPLICATION NUMBER: US/10/408,765A
; CURRENT FILING DATE: 2003-04-04
; NUMBER OF SEQ ID NOS: 3077
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2392
; LENGTH: 355
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-408-765A-2392

Query Match 100.0%; Score 57; DB 16; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355

RESULT 19
US-10-491-654-23
; Sequence 23, Application US/10491654
; Publication No. US20050014689A1
; GENERAL INFORMATION:
; APPLICANT: SUGARU, Ei-ji
; APPLICANT: TSUCHIDA, Atsushi
; APPLICANT: YAMANAKA, Mitsugu
; APPLICANT: TAIJI, Mutsuo
; TITLE OF INVENTION: REMEDIES FOR LIFE STYLE-RELATED DISEASES OR CIBOPHOBIA
; TITLE OF INVENTION: AND METHOD OF SCREENING THE SAME
; FILE REFERENCE: 228328
; CURRENT APPLICATION NUMBER: US/10/491,654
; CURRENT FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: PCT/JP02/10250
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: JP 2001-306872
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin Ver. 3.1
; SEQ ID NO 23
; LENGTH: 695
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Insert cDNA sequence contained in pc901HISG-alpha-12.
US-10-491-654-23

Query Match 100.0%; Score 57; DB 17; Length 695;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 696 KNNLKDCGLF 695

RESULT 20
US-09-826-509-589
; Sequence 589, Application US/09826509
; Publication No. US20030204073A1
; GENERAL INFORMATION:
; APPLICANT: Lehmann-Bruinsma, Karin
; APPLICANT: Liaw, Chen W.

APPLICANT: Lin, I-Lin
TITLE OF INVENTION: No. US20030204073A1-Endogenous, Constitutively Activated Known G
FILE REFERENCE: AREN-207
CURRENT APPLICATION NUMBER: US/09/826,509
CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 60/195,747
PRIOR FILING DATE: 2000-04-07
PRIOR APPLICATION NUMBER: 09/170,496
PRIOR FILING DATE: 1998-10-13
NUMBER OF SEQ ID NOS: 589
SOFTWARE: PatentIn Version 2.1
SEQ ID NO 589
LENGTH: 709
TYPE: PRT
ORGANISM: Homo sapiens
US-09-826-509-589

Query Match 100.0%; Score 57; DB 10; Length 709;
Best Local Similarity 100.0%; Pred. No. 0.092;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDGLF 10
DB 700 KNNLKDGLF 709

RESULT 21
US-10-925-095-589
Sequence 589, Application US/10925095
Publication No. US2005019840A1
GENERAL INFORMATION:
APPLICANT: Lehmann-Bruinsma, Karin
APPLICANT: Liaw, Chen W.
APPLICANT: Lin, I-Lin
TITLE OF INVENTION: Non-Endogenous, Constitutively Activated Known G
FILE REFERENCE: AREN-207
CURRENT APPLICATION NUMBER: US/10/925,095
CURRENT FILING DATE: 2004-08-24
PRIOR APPLICATION NUMBER: US/09/826,509
PRIOR FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 60/195,747
PRIOR FILING DATE: 2000-04-07
PRIOR APPLICATION NUMBER: 09/170,496
PRIOR FILING DATE: 1998-10-13
NUMBER OF SEQ ID NOS: 589
SOFTWARE: PatentIn Version 2.1
SEQ ID NO 589
LENGTH: 709
TYPE: PRT
ORGANISM: Homo sapiens
US-10-925-095-589

Query Match 100.0%; Score 57; DB 17; Length 709;
Best Local Similarity 100.0%; Pred. No. 0.092;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDGLF 10
DB 700 KNNLKDGLF 709

Search completed: March 22, 2005, 06:44:06
Job time : 139 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 22, 2005, 06:31:49 ; Search time 164 Seconds
(without alignments)
23.583 Million cell updates/sec

Title: US-10-009-809-2
Perfect score: 57
Sequence: 1 KNNLKDCGLF 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues 50
Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 500 summaries

Database : A_Geneseq_16Dec04:.*
1: Geneseq1980s:.*
2: Geneseq1990s:.*
3: Geneseq2000s:.*
4: Geneseq2001s:.*
5: Geneseq2002s:.*
6: Geneseq2003as:.*
7: Geneseq2003bs:.*
8: Geneseq2004s:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	57	100.0	10	2 AAR61259	Aar61259 Control p
2	57	100.0	10	2 AAR49785	Aar49785 Farnesylt
3	57	100.0	10	2 AAW04476	Aaw04476 Weak inh
4	57	100.0	10	5 AAE26151	Aae26151 Galphai2
5	57	100.0	11	6 ABJ36652	Abj36652 G protein
6	57	100.0	13	6 ABJ36771	Abj36771 G protein
7	57	100.0	13	7 ABW00010	Abw00010 Human G a
8	57	100.0	13	7 ADF45264	Adf45264 G alpha c
9	57	100.0	23	4 AAO08372	Aao08372 Human pol
10	57	100.0	26	4 AAY72144	Aay72144 Modified
11	57	100.0	27	4 AAY72145	Aay72145 Anti-alle
12	57	100.0	288	6 ABR41313	Abr41313 Human DIT
13	57	100.0	339	7 ADM05136	Adm05136 Human pro
14	57	100.0	339	7 ADM04957	Adm04957 Human pro
15	57	100.0	353	7 ADE57521	Ades7521 Human Pro
16	57	100.0	353	7 ADE57515	Ades7515 Rat Prote
17	57	100.0	353	7 ADE57517	Ades7517 Human Pro
18	57	100.0	353	7 ADE57519	Ades7519 Rat Prote
19	57	100.0	353	8 ADM06152	Adm06152 Rat Gil-H
20	57	100.0	354	3 AAY85290	Aay85290 Human G-a
21	57	100.0	354	4 AAB99064	Aab99064 Human G-p
22	57	100.0	354	5 ABB09273	Abb09273 G protein
23	57	100.0	354	7 ABR82632	Abr82632 C. elegan
24	57	100.0	354	7 ADC09608	Adc09608 Human G-p
25	57	100.0	354	7 ADE59387	Ades9387 Human Pro

26	57	100.0	354	7 ADE59391	Ades9391 Human Pro
27	57	100.0	354	7 ADE59385	Ades9385 Rat Prote
28	57	100.0	354	7 ADE59389	Ades9389 Rat Prote
29	57	100.0	354	7 ADD46017	Add46017 Human Pro
30	57	100.0	354	8 ADN06138	Adn06138 Rat Gil a
31	57	100.0	354	8 ADQ08808	Adq08808 Clona inc
32	57	100.0	355	3 AAY85149	Aay85149 Human G-a
33	57	100.0	355	4 AAB99065	Aab99065 Human G-p
34	57	100.0	355	5 ABB09274	Abb09274 G protein
35	57	100.0	355	5 ABB09277	Abb09277 G protein
36	57	100.0	355	5 AAU79335	Aau79335 Human inh
37	57	100.0	355	7 ADC09612	Adc09612 Human G-p
38	57	100.0	355	7 ADC09609	Adc09609 Human G-p
39	57	100.0	355	7 ADJ68621	Adj68621 Human hea
40	57	100.0	355	7 ADJ70586	Adj70586 Human hea
41	57	100.0	355	7 ADP70781	Adp70781 Minicell
42	57	100.0	355	8 ADM67196	Adm67196 Human adi
43	57	100.0	355	8 ABM80456	Abm80456 Tumour-as
44	57	100.0	362	8 ADG36979	Adg36979 Human GPC
45	57	100.0	695	6 ABR56305	Abr56305 pc901HISG
46	57	100.0	709	4 ABB56396	Abb56396 TSHR-Gs-a
47	57	100.0	709	6 ABR55447	Abr55447 Amino aci
48	57	100.0	725	4 AAB99036	Aab99036 Human som
49	57	100.0	784	7 ADG37260	Adg37260 Fusion co
50	57	100.0	987	7 ADC51269	Adc51269 Chimeric

ALIGNMENTS

RESULT 1
AAR61259
ID AAR61259 standard; peptide; 10 AA.
AC AAR61259;
XX
XX
DT 25-MAR-2003 (revised)
DT 13-APR-1995 (first entry)
XX
DE Control peptide corresponding to Gi2 alpha Lys346-Phe355.
XX
XX Anticouplone; G-protein; Regulator region; Immunosuppressant.
XX
OS Synthetic.
XX
PN WO9419002-Al.
XX
PD 01-SEP-1994.
XX
XX 17-FEB-1994; 94WO-US001768.
PR 18-FEB-1993; 93US-00019073.
XX
PA (GEHO) GEN HOSPITAL CORP.
XX
PI Nishimoto I;
XX
DR WPI; 1994-293996/36.
XX
PT Anticouplone sequences of G proteins - inhibit activation of G protein by G-coupled receptor, used to treat neuromuscular and autoimmune diseases, cancer, diabetes, hypertension, AIDS etc.
XX
PS Disclosure; Page 8; 52pp; English.
XX
CC Control peptide, showed no effect on peptide (AAR61267) induced Gi2 activation. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 10 AA;

Query Match 100.0%; Score 57; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0013;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      1 KNNLKDCGLF 10
DB      1 KNNLKDCGLF 10

RESULT 2
AAR49785
ID AAR49785 standard; peptide; 10 AA.
XX
AC AAR49785;
XX
XX 25-MAR-2003 (revised)
DT 08-AUG-1994 (first entry)
XX
DE Farnesyltransferase-inhibitor.
XX
XX Farnesyltransferase-inhibitor; farnesyltransferase; FT; p21ras;
KW ras protein; farnesylation; cancer therapy.
XX
XX Synthetic.
XX
XX WO9404561-A1.
PN
XX
XX 03-MAR-1994.
PD
XX
XX 24-AUG-1993; 93WO-US008062.
PF
XX
XX 24-AUG-1992; 92US-00935087.
PR
XX
XX (TEXA ) UNIV TEXAS SYSTEM.
PA (GETH ) GENENTECH INC.
XX
XX Brown MS, Goldstein JL, Reiss Y, Marsters JC;
PI WPI; 1994-083105/10.
DR
XX
XX New farnesyl-transferase inhibitors - used for inhibiting attachment of a
PT farnesyl moiety to a p21ras protein in malignant cells.
XX
XX Disclosure; Page 49; 183pp; English.
PS
XX
XX Peptides given in AAR49741-75, AAR49777-78 and AAR49785-88, which include
CC a family of tetrapeptides based on the recognition site (AAR49776) of
CC farnesyltransferase (FT), are potential anticancer agents that inhibit
CC FT, thereby preventing expression of p21ras. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
XX Sequence 10 AA;
SQ

Query Match 100.0%; Score 57; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0013;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
DB      1 KNNLKDCGLF 10

RESULT 3
AAW04476
ID AAW04476 standard; peptide; 10 AA.
XX
XX AAW04476;
AC
XX
XX 05-AUG-1997 (first entry)
DT
XX
XX Weak inhibitor of farnesyl transferase.
DE
XX
XX Farnesyl transferase; inhibitor; cancer; tumour; neoplasia; prenyl;
KW ras protein; K-ras B; malignant; detection; identification.
XX
XX Synthetic.
OS

```

```

XX WO9634113-A2.
PN
XX 31-OCT-1996.
PD
XX
XX 29-APR-1996; 96WO-US005969.
PF
XX
XX 27-APR-1995; 95US-00429964.
PR
XX (TEXA ) UNIV TEXAS SYSTEM.
PA
XX Brown MS, Goldstein JL, James GL;
PI WPI; 1996-497642/49.
XX
XX Assay for farnesyl transferase activity - by determining ability to
PT transfer farnesyl moiety to K-Ras B protein, partic. useful for
PT identifying inhibitors.
XX
XX Disclosure; Page 179; 257pp; English.
PS
XX
XX AAW04476-W04478 are weak peptide inhibitors of farnesyl transferase (FT)
CC activity. FT peptide inhibitors block the attachment of prenyl groups to
CC ras proteins in malignant cells of patients suffering from cancer or a
CC precancerous state and as such are used to treat cancer. The peptides
CC were identified by determining the ability of candidate substances to
CC inhibit a FT enzyme, by inhibiting the transfer of a farnesyl moiety to a
CC K-Ras B protein
XX
XX Sequence 10 AA;
SQ

Query Match 100.0%; Score 57; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0013;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KNNLKDCGLF 10
DB      1 KNNLKDCGLF 10

RESULT 4
AAE26151
ID AAE26151 standard; peptide; 10 AA.
XX
XX AAE26151;
AC
XX 14-NOV-2002 (first entry)
DT
XX
XX Galphai2 peptide, peptide b.
DE
XX
XX Antiallergic agent; nasal allergy; eye; skin; acute urticaria; psoriasis;
KW psychogenic; allergic asthma; interstitial cystitis; bowel disease;
KW multiple sclerosis; dermatological; antiinflammatory; neuroprotective;
KW migraine.
XX
XX Unidentified.
OS
XX WO200250097-A2.
XX
XX 27-JUN-2002.
PD
XX
XX 20-DEC-2001; 2001WO-IL001186.
PF
XX
XX 21-DEC-2000; 2000IL-00140473.
PR
XX (ALLE-) ALLERGENE LTD.
XX
XX Eisenberg R, Raz T;
PI
XX WPI; 2002-636474/68.
XX
XX New antiallergic agent having first cell penetrating segment joined to
PT antiallergic decapeptide providing antiallergic effect within mast cells,
PT

```

PT through linker which provides bend or turn at junction between segments.

PS Example 7; Page 51; Sipp; English.

XX
XX
CC The invention relates to an anti-allergic agent, comprising a complex molecule having at least a first segment competent for importation of the molecule into mast cells, joined to a second segment through a linker, where the second segment is the anti-allergic decapeptide derived from Galphai 3, providing anti-allergic effect within mast cells, and linker provides a bend or turn at or near junction between the two segments. The invention is useful for treating allergic conditions such as nasal allergy, allergic reactions in an eye of the subject, allergic reactions in the skin of the subject, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis, bowel diseases, migraines or multiple sclerosis. The invention is also useful for preventing late phase inflammatory responses induced by protein kinase activation, CC preferably mitogen activated protein kinase activation, where the anti-allergic agent is peptide 2, peptide 2-Succ and peptide 2-Cyc. The invention provides specific direct and targeted treatment of allergies and related inflammatory conditions. The present sequence is Galphai2 peptide

XX Sequence 10 AA;

Query Match 100.0%; Score 57; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0013;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 KNNLKDCGLF 10
Db 1 KNNLKDCGLF 10
|||||

RESULT 5

ABJ36692
ID ABJ36692 standard; peptide; 11 AA.

XX AC ABJ36692;

XX 01-MAY-2003 (first entry)

DE G protein coupled receptor related peptide SEQ ID No 17.

XX Nootropic; cardiant; antiarteriosclerotic; hypotensive; cytostatic;
KW antibacterial; analgesic; antiallergic; antiasthmatic; antiinflammatory;
KW osteopathic; neuroprotective; anxiolytic; anorectic; lead compound;
KW G protein coupled receptor signaling inhibitor; GPCR; library;
KW high throughput screening assay; stroke; myocardial infarction;
KW restenosis; atherosclerosis; hypotension; cancer; infection; asthma;
KW septic shock; pain; allergic disorder; inflammatory bowel disease;
KW osteoporosis; obesity; psychotic; neurological disorder; anxiety;
KW schizophrenia; Alzheimer's disease.

XX Homo sapiens.

OS WO200272778-A2.

XX 19-SEP-2002.

XX 14-MAR-2002; 2002WO-US007561.

XX 14-MAR-2001; 2001US-0275472P.

PR 11-MAY-2001; 2001US-00852910.

XX (CUEB-) CUE BIOTECH.

XX Gilchrist A, Hamm HE;

XX WPI; 2003-247841/24.

XX Identifying G protein coupled receptor (GPCR) signaling inhibitors,
PT useful in screening drugs for treating stroke, cancers or pain, by
PT identifying compounds that block GPCR mediated signaling with high

PT affinity and specificity.

XX Claim 94; Page 24; 94pp; English.

XX
XX
CC The invention relates to a novel method for identifying a G protein coupled receptor (GPCR) signaling inhibitor. The novel method comprises selecting or identifying a member of a library of peptides and/or candidate compounds, having binding to a GPCR of higher affinity than that of the native peptide. The peptide library is based on a native GPCR binding peptide. The method is useful for identifying inhibitors of a G protein coupled receptor (GPCR) signaling. The method is particularly useful for identifying drugs that antagonise the binding between a GPCR and its extracellular ligand(s). The method is especially useful in modern high throughput screening assays for identifying potent lead compounds. The compounds, peptides or inhibitors identified by the method are useful for preventing, ameliorating or treating diseases in which GPCR signaling is a causative factor or in which a specific class of G protein is relevant, e.g. stroke, myocardial infarction, restenosis, atherosclerosis, hypotension, cancers, infections, septic shock, pain, allergic disorders, asthma, inflammatory bowel disease, osteoporosis, obesity, or psychotic and neurological disorders (e.g. anxiety, schizophrenia or Alzheimer's disease). This sequence represents a peptide relating to the G protein coupled receptors of the invention

XX Sequence 11 AA;

Query Match 100.0%; Score 57; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0014;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 KNNLKDCGLF 10

Db 2 KNNLKDCGLF 11
|||||

RESULT 6

ABJ36771

ID ABJ36771 standard; peptide; 13 AA.

XX AC ABJ36771;

XX 01-MAY-2003 (first entry)

DE G protein coupled receptor related peptide SEQ ID No 112.

XX Nootropic; cardiant; antiarteriosclerotic; hypotensive; cytostatic;
KW antibacterial; analgesic; antiallergic; antiasthmatic; antiinflammatory;
KW osteopathic; neuroprotective; anxiolytic; anorectic; lead compound;
KW G protein coupled receptor signaling inhibitor; GPCR; library;
KW high throughput screening assay; stroke; myocardial infarction;
KW restenosis; atherosclerosis; hypotension; cancer; infection; asthma;
KW septic shock; pain; allergic disorder; inflammatory bowel disease;
KW osteoporosis; obesity; psychotic; neurological disorder; anxiety;
KW schizophrenia; Alzheimer's disease.

XX Unidentified.

XX WO200272778-A2.

XX 19-SEP-2002.

XX 14-MAR-2002; 2002WO-US007561.

XX 14-MAR-2001; 2001US-0275472P.

PR 11-MAY-2001; 2001US-00852910.

XX (CUEB-) CUE BIOTECH.

XX Gilchrist A, Hamm HE;

XX WPI; 2003-247841/24.

XX Identifying G protein coupled receptor (GPCR) signaling inhibitors,

PT useful in screening drugs for treating stroke, cancers or pain, by
 PT identifying compounds that block GPCR mediated signaling with high
 PT affinity and specificity.

XX Disclosure; Page 44; 94pp; English.

XX The invention relates to a novel method for identifying a G protein
 CC coupled receptor (GPCR) signaling inhibitor. The novel method comprises
 CC selecting or identifying a member of a library of peptides and/or than
 CC candidate compounds, having binding to a GPCR of higher affinity than
 CC that of the native peptide. The peptide library is based on a native GPCR
 CC binding peptide. The method is useful for identifying inhibitors of a G
 CC protein coupled receptor (GPCR) signaling. The method is particularly
 CC useful for identifying drugs that antagonise the binding between a GPCR
 CC and its extracellular ligand(s). The method is especially useful in
 CC modern high throughput screening assays for identifying potent lead
 CC compounds. The compounds, peptides or inhibitors identified by the method
 CC are useful for preventing, ameliorating or treating diseases in which
 CC GPCR signaling is a causative factor or in which a specific class of G
 CC protein is relevant, e.g. stroke, myocardial infarction, restenosis,
 CC atherosclerosis, hypotension, cancers, infections, septic shock, pain,
 CC allergic disorders, asthma, inflammatory bowel disease, osteoporosis,
 CC obesity, or psychotic and neurological disorders (e.g. anxiety,
 CC schizophrenia or Alzheimer's disease). This sequence represents a peptide
 CC relating to the G protein coupled receptors of the invention

XX Sequence 13 AA;

Query Match 100.0%; Score 57; DB 6; Length 13;
 Best Local Similarity 100.0%; Pred. No. 0.0017;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 DB 4 KNNLKDCGLF 13

RESULT 7

ABW00010
 ID ABW00010 standard; peptide; 13 AA.

AC AEW00010;

XX 15-JAN-2004 (first entry)

DE Human G alpha carboxy terminal peptide, Galphai1/2.

XX G protein alpha; Galpha; myocardial infarction; atherosclerosis; therapy;
 KW hypotension; hypertension; angina pectoris; stroke; Parkinson's disease;
 KW Alzheimer's disease; rheumatoid arthritis; Grave's disease; diabetes;
 KW obesity; cancer; infection; ulcer; human.

OS Homo sapiens.

XX US6559128-B1.

PN 06-MAY-2003.

XX 21-JAN-2000; 2000US-00489156.

XX 21-JAN-2000; 2000US-00489156.

PA (NOUN) UNIV NORTHWESTERN.

XX Hamm HE, Gilchrist A;

XX WPI; 2003-719631/68.

DR N-PSDB; AAD60735.

XX New carboxy terminal G protein alpha (G alpha) peptides which block G
 PT protein signaling, useful for treating pathological disorders such as
 PT stroke, myocardial infarction, atherosclerosis, hypotension, and
 PT hypertension.

XX Claim 2; Fig 2B; 43pp; English.

XX The present invention relates to new carboxy terminal G protein alpha
 CC (Galpha) peptides which block G protein signalling. The invention is
 CC useful for treating pathological diseases such as stroke, myocardial
 CC infarction, atherosclerosis, hypotension, hypertension, angina pectoris,
 CC cancers, bacterial infections, fungal infections, viral infections,
 CC rheumatoid arthritis, Grave's disease, diabetes, obesity, ulcer,
 CC Parkinson's disease, Alzheimer's disease. The invention is also useful
 CC for preventing conception in a mammal. The present sequence is human G
 CC alpha carboxy terminal peptide

XX Sequence 13 AA;

Query Match 100.0%; Score 57; DB 7; Length 13;
 Best Local Similarity 100.0%; Pred. No. 0.0017;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 DB 4 KNNLKDCGLF 13

RESULT 8

ADP45264
 ID ADP45264 standard; peptide; 13 AA.

XX ADF45264;

XX 12-FEB-2004 (first entry)

XX G alpha carboxy terminal peptide #2.

XX minigene; modified carboxy terminal alpha peptide; G-protein;
 KW G-protein coupled receptor; GPCR; G-protein-mediated signaling event;
 KW stroke; myocardial infarction; restenosis; atherosclerosis; hypotension;
 KW hypertension; angina pectoris; cancer; bacterial infection;
 KW fungal infection; protozoan infection; viral infection; septic shock;
 KW pain; chronic allergic disorder; asthma; inflammatory bowel disease;
 KW osteoporosis; rheumatoid arthritis; Grave's disease; diabetes;
 KW vascular sclerosis; chronic rejection; urinary retention; infertility;
 KW ulcer; obesity; benign prostatic hypertrophy; anxiety; epilepsy;
 KW schizophrenia; manic depression; Parkinson's disease;
 KW Alzheimer's disease; delirium; dementia; drug addiction; anorexia;
 KW bulimia.

XX Synthetic.

XX US2003162258-A1.

XX 28-AUG-2003.

XX 24-FEB-2003; 2003US-00373540.

XX 21-JAN-2000; 2000US-00489156.

XX (NOUN) UNIV NORTHWESTERN.

XX Hamm HE, Gilchrist A;

XX WPI; 2003-897929/82.

DR N-PSDB; ADF45298.

XX New nucleic acid molecule comprising a minigene that encodes a modified
 PT carboxy terminal Galpha peptide, useful for blocking G-protein-mediated
 PT signaling events or for treating disorders such as stroke, cancer or
 PT atherosclerosis.

XX Claim 10; SEQ ID NO 16; 47pp; English.

XX The invention relates to an isolated nucleic acid comprising a minigene,
 CC where the minigene encodes a modified carboxy terminal alpha peptide that

CC blocks the site of interaction between a G-protein and a G-protein
 CC coupled receptor (GPCR) in a cell. The composition and methods are useful
 CC in blocking G-protein-mediated signaling events. These may also be used
 CC for identifying unknown interactions between G-proteins and GPCRs, and
 CC for treating pathological disorders associated with G-protein-mediated
 CC signaling events, such as stroke, myocardial infarction, restenosis,
 CC atherosclerosis, hypotension, hypertension, angina pectoris, cancers,
 CC bacterial infections, fungal infections, protozoan infections, viral
 CC inflammatory bowel disease, osteoporosis, rheumatoid arthritis, asthma,
 CC disease, diabetes, disorders associated with solid organ transplant,
 CC vascular sclerosis, chronic rejection, urinary retention, infertility,
 CC ulcers, obesity, benign prostatic hypertrophy, anxiety, epilepsy,
 CC schizophrenia, manic depression, Parkinson's disease, Alzheimer's
 CC disease, delirium, dementia, drug addiction, anorexia or bulimia. The
 CC present sequence is used in the exemplification of the invention.

XX Sequence 13 AA;

Query Match 100.0%; Score 57; DB 7; Length 13;
 Best Local Similarity 100.0%; Pred. No. 0.0017;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
 Db 4 KNNLKDCGLF 13

RESULT 9
 AAO08372
 ID AAO08372 standard; protein; 23 AA.

AC AAO08372;
 XX 06-NOV-2001 (first entry)

DE Human polypeptide SEQ ID NO 22264.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorders; arthritis; inflammation.

XX Homo sapiens.

XX WO200164835-A2.

XX 07-SEP-2001.

XX 26-FEB-2001; 2001WO-US004927.

XX 28-FEB-2000; 2000US-00515126.

XX 18-MAY-2000; 2000US-00577409.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Drmanac RT;

XX WPI; 2001-514838/56.

XX N-PSDB; AA188303.

XX Isolated nucleic acids and polypeptides, useful for preventing diagnosing
 PT and treating e.g. leukemia, inflammation and immune disorders.

XX Claim 20; SEQ ID NO 22264; 1399pp + Sequence Listing; English.

XX The invention relates to human polynucleotides (AA179941-AA193841) and
 CC the encoded proteins (AA00010-AA013910) that exhibit activity relating to
 CC cytokine, cell proliferation or cell differentiation or which may induce
 CC production of other cytokines in other cell populations. The
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
 CC peptide therapy. The polypeptides have various cytokine-like activities,
 CC e.g. stem cell growth factor activity, haematopoiesis regulating

CC activity, tissue growth factor activity, immunomodulatory activity and
 CC activin/inhibin activity and may be useful in the diagnosis and/or
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
 CC inflammation. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 23 AA;

Query Match 100.0%; Score 57; DB 4; Length 23;
 Best Local Similarity 100.0%; Pred. No. 0.0031;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KNNLKDCGLF 10
 Db 14 KNNLKDCGLF 23

RESULT 10

AAAY72144

ID AAY72144 standard; peptide; 26 AA.

XX AAY72144;

XX 24-APR-2001 (first entry)

XX Modified anti-allergic peptide 5m.

XX Anti-allergic peptide; therapeutic; migraine; psoriasis; asthma;
 KW multiple sclerosis; nasal allergy; mast cell degranulation; histamine;
 KW allergy; eye; skin; acute urticaria; interstitial cystitis; vasotropic;
 KW psychogenic; bowel disease; dermatological; antiinflammatory; G alphas;
 KW neuroprotective; antipsoriatic; Kaposi fibroblast growth factor;
 KW fusion peptide.

XX Synthetic.

XX Key Location/Qualifiers

FT Peptide 1..16

FT /label= Signal peptide

FT /note= "Signal sequence of Kaposi fibroblast growth

FT factor; this region is referred in claim 48"

FT Peptide 17..26

FT /label= G alphas peptide

FT /note= "Corresponds to C-terminal sequence of G alphas"

FT Misc-difference 18

FT /note= "Wild type Glu substituted with Asn"

XX WO200078346-A1.

XX 28-DEC-2000.

XX 14-JUN-2000; 2000WO-IL000346.

XX 17-JUN-1999; 99IL-00130526.

XX (ALLE-) ALLERGENE LTD.

XX Eisenberg R, Raz T;

XX WPI; 2001-080758/09.

XX Novel anti-allergic agents for treating allergic conditions such as
 PT allergic reactions in eye, skin, nasal allergy, asthma, migraines, has
 PT peptides for cell penetration and reducing mast cell degranulation.

XX Example 2; Page 20; 63pp; English.

XX The present sequence is modified anti-allergic peptide 5m consisting of a
 CC signal sequence of Kaposi fibroblast growth factor, linked to the C-
 CC terminal G alphas sequence. The last 10 amino acids of this peptide are
 CC homologous to the C-terminal G alphas2 sequence. The invention relates to
 CC therapeutic complex molecules which are useful as anti-allergic agents.

CC These anti-allergic agents are useful for treating allergic conditions
CC such as nasal allergy, allergic reaction in the eye or skin, acute
CC urticaria, psoriasis, psychogenic or allergic asthma, interstitial
CC cystitis, bowel diseases, migraines and multiple sclerosis. The
CC therapeutic complex is highly specific, direct and provides targeted
CC treatment of allergies and related inflammatory conditions. It comprises
CC molecules having at least a first segment i.e., a signal peptide which is
CC competent for the importation of the complex into the mast cells, and a
CC second segment which is having the anti-allergic effect is able to block
CC or significantly reduce the G protein-mediated contribution to mast cell
CC degranulation and in turn the release of histamine. The invention also
CC discloses methods for preventing and treating allergies
SQ Sequence 26 AA;
Query Match 100.0%; Score 57; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KNNLKDCGLF 10
| | | | | | | |
DB 17 KNNLKDCGLF 26
RESULT 11
AAV72145
ID AAV72145 standard; peptide; 27 AA.
AC AAV72145;
XX
XX 24-APR-2001 (first entry)
XX
XX Anti-allergic peptide 12.
XX
XX Anti-allergic peptide; therapeutic; migraine; psoriasis; asthma;
XX multiple sclerosis; nasal allergy; mast cell degranulation; histamine;
XX allergic; eye; skin; acute urticaria; interstitial cystitis; vasotropic;
XX psychogenic; bowel disease; dermatological; antiinflammatory; G alphas;
XX neuroprotective; antipsoriatic; Kaposi fibroblast growth factor;
XX fusion peptide.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT Peptide 2. 17
FT /label= Signal_peptide
FT /note= "Signal sequence of Kaposi fibroblast growth
FT factor; this region is referred in claim 48"
FT 18. 27
FT /label= G_alphas_peptide
FT /note= "Corresponds to C-terminal sequence of G alphas"
FT Misc-difference 19
FT /note= "Wild type Glu substituted with Asn"
XX
XX WO200078346-A1.
XX
XX 28-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-IL000346.
XX
XX 17-JUN-1999; 99IL-00130526.
XX
XX (ALLE-) ALLERGENE LTD.
XX
XX Eisenberg R, Raz T;
XX
XX WPI; 2001-080758/09.
XX
XX Novel anti-allergic agents for treating allergic conditions such as
XX allergic reactions in eye, skin, nasal allergy, asthma, migraines, has
XX peptides for cell penetration and reducing mast cell degranulation.
XX Example 2; Page 20; 63pp; English.

XX The present sequence is anti-allergic peptide 12 consisting of a signal
CC sequence of Kaposi fibroblast growth factor, linked to the C-terminal G
CC alphas sequence. This peptide is obtained by adding a lysine residue to
CC the N-terminus of anti-allergic peptide 5 (AAV72142), for improving the
CC peptide solubility. The invention relates to therapeutic complex
CC molecules which are useful as anti-allergic agents. These anti-allergic
CC agents are useful for treating allergic conditions such as nasal allergy,
CC allergic reaction in the eye or skin, acute urticaria, psoriasis,
CC psychogenic or allergic asthma, interstitial cystitis, bowel diseases,
CC migraines and multiple sclerosis. The therapeutic complex is highly
CC specific, direct and provides targeted treatment of allergies and
CC related inflammatory conditions. It comprises molecules having at least a
CC first segment i.e., a signal peptide which is competent for the
CC importation of the complex into the mast cells, and a second segment
CC which is having the anti-allergic effect is able to block or
CC significantly reduce the G protein-mediated contribution to mast cell
CC degranulation and in turn the release of histamine. The invention also
CC discloses methods for preventing and treating allergies
XX Sequence 27 AA;
Query Match 100.0%; Score 57; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.0037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KNNLKDCGLF 10
| | | | | | | |
DB 18 KNNLKDCGLF 27
RESULT 12
ABR41313
ID ABR41313 standard; protein; 288 AA.
XX
XX ABR41313;
XX
XX 02-JUN-2003 (first entry)
XX
XX Human DITP intracellular signalling protein.
XX
XX Human; dithp; diagnostic and therapeutic polynucleotide; diagnosis;
XX cancer; cell proliferative disorder; autoimmune disorder;
XX inflammatory disorder; infection; hormonal disorder; metabolic disorder;
XX neurological disorder; gastrointestinal disorder; transport disorder;
XX connective tissue disorder; drug screening; proteome analysis;
XX gene therapy; antisense therapy; genotyping; transgenic animal; knock in;
XX disease model; toxicological testing; transcript imaging;
XX intracellular signalling.
XX
XX Homo sapiens.
XX
XX WO200297031-A2.
XX
XX 05-DEC-2002.
XX
XX 27-MAR-2002; 2002WO-US010056.
XX
XX 28-MAR-2001; 2001US-0279619P.
XX 29-MAR-2001; 2001US-0280067P.
XX 29-MAR-2001; 2001US-0280068P.
XX 16-MAY-2001; 2001US-0291280P.
XX 17-MAY-2001; 2001US-0291829P.
XX 19-MAY-2001; 2001US-0291849P.
XX 19-JUN-2001; 2001US-0299428P.
XX 20-JUN-2001; 2001US-0299776P.
XX 20-JUN-2001; 2001US-0300001P.
XX
XX (INCY-) INCYTE GENOMICS INC.
XX
XX Daffo A, Jones AL, Tran AB, Dahl CR, Gietzen D, Chinn J;
XX Daffour GE, Hillman JL, Yu JY, Tuason O, Yap PE, Amshay SR;
XX Daughtery SC, Dam TC, Liu TF, Nguyen DA, Kleefeld Y, Gerstin EH;

XX Claim 1; SEQ ID NO 3642; 305pp; English.

XX The invention relates to a novel human polynucleotide and the encoded

XX polypeptide. A polynucleotide of the invention may have a use in gene

XX therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful

XX as a primer for synthesizing the polynucleotide or as a probe for

XX detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are

XX useful in gene therapy, for developing a diagnostic marker or medicines

XX for regulating their expression and activity, or as a target of gene

XX therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides

XX are useful as pharmaceutical agents. The present sequence represents a

XX protein sequence of the invention.

XX Sequence 339 AA;

Query Match 100.0%; Score 57; DB 7; Length 339;

Best Local Similarity 100.0%; Pred. No. 0.058;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 330 KNNLKDCGLF 339

RESULT 15

AD57521

ID ADE57521 standard; protein; 353 AA.

XX ADE57521;

XX 29-JAN-2004 (first entry)

DE Human Protein P04898, SEQ ID NO 3393.

XX Human; pain; neuronal tissue; gene therapy;

KW spinal segmental nerve injury; chronic constriction injury; CCI;

KW spared nerve injury; SNI; Chung.

XX Homo sapiens.

XX WO2003016475-A2.

XX 27-FEB-2003.

XX 14-AUG-2002; 2002WO-US025765.

XX 14-AUG-2001; 2001US-0312147P.

PR 01-NOV-2001; 2001US-0346382P.

PR 26-NOV-2001; 2001US-0333347P.

XX (GEHO) GEN HOSPITAL CORP.

PA (FARB) BAYER AG.

XX Woolf C, D'urso D, Befort K, Costigan M;

XX WPI; 2003-268312/26.

DR GENBANK; P04898.

XX New composition comprising two or more isolated polypeptides, useful for

PT preparing a medicament for treating pain in an animal.

XX Claim 1; Page; 1017pp; English.

XX The invention discloses a composition comprising two or more isolated rat

XX or human polynucleotides or a polynucleotide which represents a fragment,

XX derivative or allelic variation of the nucleic acid sequence. Also

XX claimed are a vector comprising the novel polynucleotide, a host cell

XX comprising the vector, a method for identifying a nucleotide sequence

XX which is differentially regulated in an animal subjected to pain and a

XX kit to perform the method, an array, a method for identifying an agent

XX that increases or decreases the expression of the polynucleotide sequence

XX that is differentially expressed in neuronal tissue of a first animal

CC subjected to pain, a method for identifying a compound which regulates

CC the expression of a polynucleotide sequence which is differentially

CC expressed in an animal subjected to pain, a method for identifying a

CC compound that regulates the activity of one or more of the

CC polynucleotides, a method for producing a pharmaceutical composition, a

CC method for identifying a compound or small molecule that regulates the

CC activity in an animal of one or more of the polypeptides given in the

CC specification, a method for identifying a compound useful in treating

CC pain and a pharmaceutical composition comprising the one or more

CC polypeptides or their antibodies. The polynucleotide or the compound that

CC modulates its activity is useful for preparing a medicament for treating

CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction

CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene

CC therapy). The sequence presented is a human protein (shown in table 2 of

CC the specification) which is differentially expressed during pain. Note:

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic form directly from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 353 AA;

Query Match 100.0%; Score 57; DB 7; Length 353;

Best Local Similarity 100.0%; Pred. No. 0.06;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 344 KNNLKDCGLF 353

RESULT 16

AD57515

ID ADE57515 standard; protein; 353 AA.

XX ADE57515;

XX 29-JAN-2004 (first entry)

DE Rat Protein P10824, SEQ ID NO 3377.

XX Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;

KW chronic constriction injury; CCI; spared nerve injury; SNI; Chung.

XX Rattus norvegicus.

XX WO2003016475-A2.

XX 27-FEB-2003.

XX 14-AUG-2002; 2002WO-US025765.

XX 14-AUG-2001; 2001US-0312147P.

PR 01-NOV-2001; 2001US-0346382P.

PR 26-NOV-2001; 2001US-0333347P.

XX (GEHO) GEN HOSPITAL CORP.

PA (FARB) BAYER AG.

XX Woolf C, D'urso D, Befort K, Costigan M;

XX WPI; 2003-268312/26.

DR GENBANK; P10824.

XX New composition comprising two or more isolated polypeptides, useful for

PT preparing a medicament for treating pain in an animal.

XX Claim 1; Page; 1017pp; English.

XX The invention discloses a composition comprising two or more isolated rat

XX or human polynucleotides or a polynucleotide which represents a fragment,

XX derivative or allelic variation of the nucleic acid sequence. Also

XX claimed are a vector comprising the novel polynucleotide, a host cell

XX comprising the vector, a method for identifying a nucleotide sequence

XX which is differentially regulated in an animal subjected to pain and a

XX kit to perform the method, an array, a method for identifying an agent

XX that increases or decreases the expression of the polynucleotide sequence

XX that is differentially expressed in neuronal tissue of a first animal

CC which is differentially regulated in an animal subjected to pain and a
 CC kit to perform the method, an array, a method for identifying an agent
 CC that increases or decreases the expression of the polynucleotide sequence
 CC that is differentially expressed in neuronal tissue of a first animal
 CC subjected to pain, a method for identifying a compound which regulates
 CC the expression of a polynucleotide sequence which is differentially
 CC expressed in an animal subjected to pain, a method for identifying a
 CC compound that regulates the activity of one or more of the
 CC polynucleotides, a method for producing a pharmaceutical composition, a
 CC method for identifying a compound or small molecule that regulates the
 CC activity in an animal of one or more of the polypeptides given in the
 CC specification, a method for identifying a compound useful in treating
 CC pain and a pharmaceutical composition comprising the one or more
 CC polypeptides or their antibodies. The polynucleotide or the compound that
 CC modulates its activity is useful for preparing a medicament for treating
 CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
 CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
 CC therapy). The sequence presented is a rat protein (shown in Table 2 of
 CC the specification) which is differentially expressed during pain. Note:
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic form directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 353 AA;

Query Match 100.0%; Score 57; DB 7; Length 353;
 Best Local Similarity 100.0%; Pred. No. 0.06; 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0;

QY 1 KNNLKDCGLF 10
 DB 344 KNNLKDCGLF 353
 |||||

RESULT 17

ADE57517
 ID ADE57517 standard; protein; 353 AA.

XX AC

XX AC ADE57517;

XX DT 29-JAN-2004 (first entry)

XX DE Human Protein P04898, SEQ ID NO 3379.

XX KW Human; pain; neuronal tissue; gene therapy;

XX KW spinal segmental nerve injury; chronic constriction injury; CCI;

XX KW spared nerve injury; SNI; Chung.

XX OS Homo sapiens.

XX PN WO2003016475-A2.

XX PD 27-FEB-2003.

XX PF 14-AUG-2002; 2002WO-US025765.

XX PR 14-AUG-2001; 2001US-0312147P.

XX PR 01-NOV-2001; 2001US-0346382P.

XX PR 26-NOV-2001; 2001US-0333347P.

XX XX (GEHO) GEN HOSPITAL CORP.

XX PA (FARB) BAYER AG.

XX XX Woolf C, D'urso D, Befort K, Costigan M;

XX XX WPI; 2003-268312/26.

XX DR GENBANK; P04898.

XX XX New composition comprising two or more isolated polypeptides, useful for

XX PT preparing a medicament for treating pain in an animal.

XX PS Claim 1; Page; 1017pp; English.

XX XX

CC The invention discloses a composition comprising two or more isolated rat
 CC or human polynucleotides or a polynucleotide which represents a fragment,
 CC derivative or allelic variation of the nucleic acid sequence. Also
 CC claimed are a vector comprising the novel polynucleotide, a host cell
 CC comprising the vector, a method for identifying a nucleotide sequence
 CC which is differentially regulated in an animal subjected to pain and a
 CC kit to perform the method, an array, a method for identifying an agent
 CC that increases or decreases the expression of the polynucleotide sequence
 CC that is differentially expressed in neuronal tissue of a first animal
 CC subjected to pain, a method for identifying a compound which regulates
 CC the expression of a polynucleotide sequence which is differentially
 CC expressed in an animal subjected to pain, a method for identifying a
 CC compound that regulates the activity of one or more of the
 CC polynucleotides, a method for producing a pharmaceutical composition, a
 CC method for identifying a compound or small molecule that regulates the
 CC activity in an animal of one or more of the polypeptides given in the
 CC specification, a method for identifying a compound useful in treating
 CC pain and a pharmaceutical composition comprising the one or more
 CC polypeptides or their antibodies. The polynucleotide or the compound that
 CC modulates its activity is useful for preparing a medicament for treating
 CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
 CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
 CC therapy). The sequence presented is a human protein (shown in Table 2 of
 CC the specification) which is differentially expressed during pain. Note:
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic form directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 353 AA;

Query Match 100.0%; Score 57; DB 7; Length 353;
 Best Local Similarity 100.0%; Pred. No. 0.06; 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0;

QY 1 KNNLKDCGLF 10
 DB 344 KNNLKDCGLF 353
 |||||

RESULT 18

ADE57519
 ID ADE57519 standard; protein; 353 AA.

XX AC ADE57519;

XX XX 29-JAN-2004 (first entry)

XX DE Rat Protein P10824, SEQ ID NO 3381.

XX KW Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;

XX KW chronic constriction injury; CCI; spared nerve injury; SNI; Chung.

XX OS Rattus norvegicus.

XX PN WO2003016475-A2.

XX PD 27-FEB-2003.

XX PF 14-AUG-2002; 2002WO-US025765.

XX XX 14-AUG-2001; 2001US-0312147P.

XX PR 01-NOV-2001; 2001US-0346382P.

XX PR 26-NOV-2001; 2001US-0333347P.

XX XX (GEHO) GEN HOSPITAL CORP.

XX PA (FARB) BAYER AG.

XX XX Woolf C, D'urso D, Befort K, Costigan M;

XX XX WPI; 2003-268312/26.

XX DR GENBANK; P10824.

XX PT New composition comprising two or more isolated polypeptides, useful for

PT preparing a medicament for treating pain in an animal.
XX
PS Claim 1; Page; 1017pp; English.
XX
CC The invention discloses a composition comprising two or more isolated rat
CC or human polynucleotides or a polynucleotide which represents a fragment,
CC derivative or allelic variation of the nucleic acid sequence. Also
CC claimed are a vector comprising the novel polynucleotide, a host cell
CC comprising the vector, a method for identifying a nucleotide sequence
CC which is differentially regulated in an animal subjected to pain and a
CC kit to perform the method, an array, a method for identifying an agent
CC that increases or decreases the expression of the polynucleotide sequence
CC that is differentially expressed in neuronal tissue of a first animal
CC subjected to pain, a method for identifying a compound which regularly
CC the expression of a polynucleotide sequence which is differentially
CC expressed in an animal subjected to pain, a method for identifying a
CC compound that regulates the activity of one or more of the
CC polynucleotides, a method for producing a pharmaceutical composition, a
CC method for identifying a compound or small molecule that regulates the
CC activity in an animal of one or more of the polypeptides given in the
CC specification, a method for identifying a compound useful in treating
CC pain and a pharmaceutical composition comprising the one or more
CC polypeptides or their antibodies. The polynucleotide or the compound that
CC modulates its activity is useful for preparing a medicament for treating
CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
CC therapy). The sequence presented is a rat protein (shown in Table 2 of
CC the specification) which is differentially expressed during pain. Note:
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic form directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 353 AA;

Query Match 100.0%; Score 57; DB 7; Length 353;
Best Local Similarity 100.0%; Pred. No. 0.06;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 344 KNNLKDCGLF 353

RESULT 19
ADN06152
ID ADN06152 standard; protein; 353 AA.
XX
AC ADN06152;
XX
DT 01-JUL-2004 (first entry)
XX
DE Rat Gil-Human Gq chimeric alpha subunit (Gilq31N25C).
XX
KW G protein; alpha subunit; physiological response; neurotransmitter;
KW sensory stimuli; rat; Gil alpha subunit; human; Gq.
XX
OS Rattus sp.
OS Homo sapiens.
OS Chimeric.
XX
PN US2004072157-A1.
XX
PD 15-APR-2004.
XX
PF 31-JAN-2002; 2002US-00059266.
XX
PR 31-JAN-2001; 2001US-0265068P.
XX
PA (GRAB/) GRABER S G.
XX
PI Graber SG;
XX
DR WPI; 2004-328563/30.

DR N-PSDB; ADN06151.
XX
PT New chimeric approximately subunit of G proteins that affect receptor
PT coupling of the G proteins, useful in mediating an array of physiological
PT responses initiated by hormones, neurotransmitters and sensory stimuli.
XX
PS Claim 19; SEQ ID NO 18; 68pp; English.
XX
CC The invention relates to chimeric alpha subunit of G proteins. The
CC chimeric alpha subunit of G proteins is useful in mediating an array of
CC physiological responses initiated by hormones, neurotransmitters, sensory
CC stimuli and other signalling molecules. The present sequence is rat Gil-
CC human Gq chimeric alpha subunit protein.
XX
SQ Sequence 353 AA;

Query Match 100.0%; Score 57; DB 8; Length 353;
Best Local Similarity 100.0%; Pred. No. 0.06;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 344 KNNLKDCGLF 353

RESULT 20
AAV85290
ID AAV85290 standard; protein; 354 AA.
XX
AC AAV85290;
XX
DT 14-JUL-2000 (first entry)
XX
DE Human G-alpha-11 amino acid sequence.
XX
KW G-alpha-11; G protein; adenylyl cyclase hormonal inhibition; tumour;
KW plasma membrane regulation; antisense composition; treatment; prevent;
KW delay; infection; inflammation; tumour formation; research; diagnose.
XX
OS Homo sapiens.
XX
PN US6046321-A.
XX
PD 04-APR-2000.
XX
PF 09-APR-1999; 99US-00289377.
XX
PR 09-APR-1999; 99US-00289377.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowseert LM;
XX
DR WPI; 2000-292434/25.
DR N-PSDB; AAA10854.
XX
PT New antisense compounds targeting nucleic acids encoding human G-alpha-11
PT useful for modulating G-alpha-11 expression and for treating diseases
PT associated with G-alpha-11 expression.
XX
PS Disclosure; Col 41-44; 31pp; English.
XX
CC This sequence represents the human G-alpha-11 amino acid sequence. Human
CC G-alpha-11 is a member of the Gi subfamily of G proteins which is
CC involved in hormonal inhibition of adenylyl cyclase and in the regulation
CC of plasma membrane enzymes. The expression of G-alpha-11 is altered in
CC some tumours. The invention relates to antisense oligonucleotides
CC represented in AAA10814-A10853 which inhibit the expression of G-alpha-
CC 11. The antisense oligonucleotides can be used in the treatment of
CC diseases or conditions associated with the expression of G-alpha-11 by
CC modulating the expression of G-alpha-11 in cells or tissues. The
CC antisense compositions may also be used prophylactically, e.g. to prevent
CC or delay infection, inflammation, or tumour formation. Furthermore, the

CC antisense oligonucleotides may also be useful in research and
 CC diagnostics, e.g. in detecting nucleic acids encoding G-alpha-11 by
 CC conjugation of an enzyme to the oligonucleotide, or radiolabelling the
 CC oligonucleotide. Kits using such detection means for detecting the level
 CC of G-alpha-11 in the sample may also be prepared. Antisense
 CC oligonucleotides, which are able to inhibit specific gene expression, are
 CC often used to elucidate the function of particular genes. These antisense
 CC compounds are also used to distinguish between functions of various
 CC members of a biological pathway
 XX
 SQ Sequence 354 AA;

Query Match 100.0%; Score 57; DB 3; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.06;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||
 Db 345 KNNLKDCGLF 354

RESULT 21

AAB99064
 ID AAB99064 standard; protein; 354 AA.

XX AAB99064;

XX 23-AUG-2001 (first entry)

XX Human G-protein alpha subunit 11.

XX G-protein coupled receptor; GPCR; GnRH receptor; disease treatment;
 KW gonadotrophin releasing; hormone receptor; hormone dependent cancer;
 KW human; catfish; goldfish; cow; sheep; horse; fruitfly; pig; rat; mouse;
 KW gene therapy.

XX Homo sapiens.

XX WO200136446-A2.

XX 25-MAY-2001.

XX 17-NOV-2000; 2000WO-GB004385.

XX 17-NOV-1999; 99GB-00027215.

XX (UYBR-) UNIV BRISTOL.

XX Mcardle CA;

XX WPI; 2001-355607/37.

XX Use of a vector encoding G-protein coupled receptors for manufacturing
 PT medicaments for treating cancer, diseases of cardiovascular system,
 PT nervous system, digestive system, immune system, or muscle diseases.

XX Disclosure; Fig 19; 78pp; English.

XX The present invention describes a prodrug comprising a vector encoding a
 CC G-protein coupled receptor (GPCR). This can be used in the treatment of
 CC diseases, including hormone-dependent cancers, cardiovascular, nervous
 CC system, digestive system, immune system, respiratory, skeletal,
 CC endocrine, sensory and muscle diseases and disorders. The present
 CC sequence is a protein described in the exemplification of the invention

XX Sequence 354 AA;

Query Match 100.0%; Score 57; DB 4; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.06;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||

Db 345 KNNLKDCGLF 354

RESULT 22

ABB09273

ID ABB09273 standard; protein; 354 AA.

XX ABB09273;

XX 10-JUL-2002 (first entry)

XX G protein-coupled receptor (GPCR) I1 SEQ ID NO:19.

XX Target activated nucleic acid biosensor; signalling moiety; GPCR;
 KW nucleic acid sensor; detection; engineering; drug optimisation;
 KW G protein-coupled receptor.

XX Homo sapiens.

XX WO200222882-A2.

XX 21-MAR-2002.

XX 13-SEP-2001; 2001WO-US028835.

XX 13-SEP-2000; 2000US-0232454P.

XX (ARCH-) ARCHEMIX CORP.

XX Stanton M, Epstein D, Hamaguchi N;

XX WPI; 2002-393977/42.

XX Nucleic acid sensor for detecting target molecule, comprises target
 PT molecule activation site and optical signalling unit that changes its
 PT optical properties upon allosteric modulation sensor after recognition of
 PT target.

XX Example 12; Page 89; 144pp; English.

XX The present invention describes a nucleic acid sensor molecule (I)
 CC comprising a target molecule activation site comprising a structure that
 CC recognises a target molecule and an optical signalling unit including at
 CC least one nucleotide coupled to a signalling moiety that changes its
 CC optical properties upon allosteric modulation of (I) following
 CC recognition of the target molecule. (I) is useful for detecting a target
 CC molecule associated with a pathological condition or genetic alteration.
 CC (I) is useful for identifying a drug compound, by identifying a nucleic
 CC acid biosensor-based molecule profile of target molecules associated with
 CC a disease trait in a patient, administering a candidate compound to the
 CC patient, and monitoring changes in the profile. Alternatively, the method
 CC involves identifying a number of pathway target molecules, administering
 CC a candidate compound to a patient having a disease trait, and monitoring
 CC changes in the structure, level or activity of two or more of the pathway
 CC target molecules using (I). The profile of target molecules or the
 CC changes in the structure is compared to the profile of a reference
 CC healthy or diseased population. (I) is useful in multiple assays, for the
 CC detection of target molecule. (I) is also useful in diagnostic
 CC applications and drug optimisation. The present sequence represents a G
 CC protein-coupled receptor, which is used in an example from the present
 CC invention

XX Sequence 354 AA;

Query Match 100.0%; Score 57; DB 5; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.06;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||

Db 345 KNNLKDCGLF 354

Query Match 100.0%; Score 57; DB 7; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.06;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 345 KNNLKDCGLF 354

RESULT 27
ADE59385
ID ADE59385 standard; protein; 354 AA.
XX ADE59385;
XX
DT 29-JAN-2004 (first entry)
XX
DE Rat Protein P04897, SEQ ID NO 5279.
XX
KW Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;
KW chronic constriction injury; CCI; spared nerve injury; SNI; Chung.
XX
OS Rattus norvegicus.
XX
FN WO2003016475-A2.
XX
PD 27-FEB-2003.
XX
PF 14-AUG-2002; 2002WO-US025765.
XX
PR 14-AUG-2001; 2001US-0312147P.
PR 01-NOV-2001; 2001US-0346382P.
PR 26-NOV-2001; 2001US-0333347P.
XX
PA (GEO) GEN HOSPITAL CORP.
PA (FARB) BAYER AG.
XX
FI Woolf C, D'urso D, Befort K, Costigan M;
XX WPI; 2003-268312/26.
DR GENBANK; P04897.
XX
PT New composition comprising two or more isolated polypeptides, useful for
PT preparing a medicament for treating pain in an animal.
XX
PS Claim 1; Page; 1017pp; English.

The invention discloses a composition comprising two or more isolated rat
or human polynucleotides or a polynucleotide which represents a fragment,
derivative or allelic variation of the nucleic acid sequence. Also
claimed are a vector comprising the novel polynucleotide, a host cell
comprising the vector, a method for identifying a nucleotide sequence
which is differentially regulated in an animal subjected to pain and a
kit to perform the method, an array, a method for identifying an agent
that increases or decreases the expression of the polynucleotide sequence
that is differentially expressed in neuronal tissue of a first animal
subjected to pain, a method for identifying a compound which regulates
the expression of a polynucleotide sequence which is differentially
expressed in an animal subjected to pain, a method for identifying a
compound that regulates the activity of one or more of the
polynucleotides, a method for producing a pharmaceutical composition, a
method for identifying a compound or small molecule that regulates the
activity in an animal of one or more of the polypeptides given in the
specification, a method for identifying a compound useful in treating
pain and a pharmaceutical composition comprising the one or more
polypeptides or their antibodies. The polynucleotide or the compound that
modulates its activity is useful for preparing a medicament for treating
pain (e.g. spinal segmental nerve injury (SNI)) in an animal (e.g. gene
injury (CCI) and spared nerve injury (SNI)). The sequence presented is a rat protein (shown in Table 2 of
the specification) which is differentially expressed during pain. Note:
The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic form directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 354 AA;
Query Match 100.0%; Score 57; DB 7; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.06;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
DB 345 KNNLKDCGLF 354

RESULT 28
ADE59389
ID ADE59389 standard; protein; 354 AA.
XX ADE59389;
XX
DT 29-JAN-2004 (first entry)
XX
DE Rat Protein P04897, SEQ ID NO 5283.
XX
KW Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;
KW chronic constriction injury; CCI; spared nerve injury; SNI; Chung.
XX
OS Rattus norvegicus.
XX
FN WO2003016475-A2.
XX
PD 27-FEB-2003.
XX
PF 14-AUG-2002; 2002WO-US025765.
XX
PR 14-AUG-2001; 2001US-0312147P.
PR 01-NOV-2001; 2001US-0346382P.
PR 26-NOV-2001; 2001US-0333347P.
XX
PA (GEO) GEN HOSPITAL CORP.
PA (FARB) BAYER AG.
XX
FI Woolf C, D'urso D, Befort K, Costigan M;
XX WPI; 2003-268312/26.
DR GENBANK; P04897.
XX
PT New composition comprising two or more isolated polypeptides, useful for
PT preparing a medicament for treating pain in an animal.
XX
PS Claim 1; Page; 1017pp; English.

The invention discloses a composition comprising two or more isolated rat
or human polynucleotides or a polynucleotide which represents a fragment,
derivative or allelic variation of the nucleic acid sequence. Also
claimed are a vector comprising the novel polynucleotide, a host cell
comprising the vector, a method for identifying a nucleotide sequence
which is differentially regulated in an animal subjected to pain and a
kit to perform the method, an array, a method for identifying an agent
that increases or decreases the expression of the polynucleotide sequence
that is differentially expressed in neuronal tissue of a first animal
subjected to pain, a method for identifying a compound which regulates
the expression of a polynucleotide sequence which is differentially
expressed in an animal subjected to pain, a method for identifying a
compound that regulates the activity of one or more of the
polynucleotides, a method for producing a pharmaceutical composition, a
method for identifying a compound or small molecule that regulates the
activity in an animal of one or more of the polypeptides given in the
specification, a method for identifying a compound useful in treating
pain and a pharmaceutical composition comprising the one or more
polypeptides or their antibodies. The polynucleotide or the compound that
modulates its activity is useful for preparing a medicament for treating
pain (e.g. spinal segmental nerve injury (SNI)) in an animal (e.g. gene
injury (CCI) and spared nerve injury (SNI)). The sequence presented is a rat protein (shown in Table 2 of
the specification) which is differentially expressed during pain. Note:
The sequence data for this patent did not form part of the printed

CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
 CC therapy). The sequence presented is a rat protein (shown in Table 2 of
 CC the specification) which is differentially expressed during pain. Note:
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic form directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

CC Sequence 354 AA;

Query Match 100.0%; Score 57; DB 7; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.06;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 DB 345 KNNLKDCGLF 354
 |||||

RESULT 29
 ADD46017
 ID ADD46017 standard; protein; 354 AA.

AC ADD46017;

DT 29-JAN-2004 (first entry)

DE Human Protein P04899, SEQ ID NO 11689.

KW Human; pain; neuronal tissue; gene therapy;

KW spinal segmental nerve injury; chronic constriction injury; CCI;

KW spared nerve injury; SNI; Chung.

OS Homo sapiens.

PN WO2003016475-A2.

XX 27-FEB-2003.

PF 14-AUG-2002; 2002WO-US025765.

PR 14-AUG-2001; 2001US-0312147P.

PR 01-NOV-2001; 2001US-0346382P.

PR 26-NOV-2001; 2001US-0333347P.

XX (GEHO) GEN HOSPITAL CORP.

PA (FARB) BAYER AG.

PI Woolf C, D'urso D, Befort K, Costigan M;

XX WPI; 2003-268312/26.

DR GENBANK; P04899.

PT New composition comprising two or more isolated polypeptides, useful for
 PT preparing a medicament for treating pain in an animal.

PS Claim 1; Page; 1017pp; English.

XX The invention discloses a composition comprising two or more isolated rat
 CC or human polynucleotides or a polynucleotide which represents a fragment,
 CC derivative or allelic variation of the nucleic acid sequence. Also
 CC claimed are a vector comprising the novel polynucleotide, a host cell
 CC comprising the vector, a method for identifying a nucleotide sequence
 CC which is differentially regulated in an animal subjected to pain and a
 CC kit to perform the method, an array, a method for identifying an agent
 CC that increases or decreases the expression of the polynucleotide sequence
 CC that is differentially expressed in neuronal tissue of a first animal
 CC subjected to pain, a method for identifying a compound which regulates
 CC the expression of a polynucleotide sequence which is differentially
 CC expressed in an animal subjected to pain, a method for identifying a
 CC compound that regulates the activity of one or more of the
 CC polynucleotides, a method for producing a pharmaceutical composition, a
 CC method for identifying a compound or small molecule that regulates the
 CC activity in an animal of one or more of the polypeptides given in the

CC specification, a method for identifying a compound useful in treating
 CC pain and a pharmaceutical composition comprising the one or more
 CC polypeptides or their antibodies. The polynucleotide or the compound that
 CC modulates its activity is useful for preparing a medicament for treating
 CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
 CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
 CC therapy). The sequence presented is a human protein (shown in Table 2 of
 CC the specification) which is differentially expressed during pain. Note:
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic form directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

CC Sequence 354 AA;

Query Match 100.0%; Score 57; DB 7; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.06;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 DB 345 KNNLKDCGLF 354
 |||||

RESULT 30

ADN06138

ID ADN06138 standard; protein; 354 AA.

XX AC ADN06138;

DT 01-JUL-2004 (first entry)

DE Rat GII alpha subunit protein.

KW G protein; alpha subunit; physiological response; neurotransmitter;
 KW sensory stimuli; rat; GII alpha subunit.

OS Rattus sp.

PN US2004072157-A1.

PD 15-APR-2004.

PF 31-JAN-2002; 2002US-00059266.

PR 31-JAN-2001; 2001US-0265068P.

XX (GRAB/) GRABER S G.

PI Graber SG;

XX WPI; 2004-328563/30.

DR N-PSDB; ADN06137.

PT New chimeric approximatela subunit of G proteins that affect receptor
 PT coupling of the G proteins, useful in mediating an array of physiological
 PT responses initiated by hormones, neurotransmitters and sensory stimuli.

PS Disclosure; SEQ ID NO 4; 68pp; English.

XX The invention relates to chimeric alpha subunit of G proteins. The
 CC chimeric alpha subunit of G proteins is useful in mediating an array of
 CC physiological responses initiated by hormones, neurotransmitters, sensory
 CC stimuli and other signalling molecules. The present sequence is rat GII
 CC alpha subunit protein.

CC Sequence 354 AA;

Query Match 100.0%; Score 57; DB 8; Length 354;
 Best Local Similarity 100.0%; Pred. No. 0.06;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||


```

Db      345 KNNLKDCGLF 354
RESULT 31
ADQ08808
ID ADQ08808 standard; protein; 354 AA.
XX
AC ADQ08808;
XX
DT 26-AUG-2004 (first entry)
XX
DE Ciona intestinalis nervous system associated protein SeqID210.
XX
KW gene cluster; nervous system; sea-squirt tailbud; embryo; larva;
KW nervous system disease.
XX
OS Ciona intestinalis.
XX
PN JP2004057127-A.
XX
PD 26-FEB-2004.
XX
PF 31-JUL-2002; 2002JP-00222532.
XX
PR 31-JUL-2002; 2002JP-00222532.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI; 2004-208712/20.
DR N-PSDB; ADQ08807.
XX
PT Novel genes derived from Ciona intestinalis (sea squirt), expressed in
PT nervous system in the tailbud embryo or larva, useful for studying the
PT development of nervous system.
XX
PS Claim 4; SEQ ID NO 210; 897pp; Japanese.
XX
CC This invention relates to a novel gene cluster, where the encoded
CC proteins are expressed in the nervous system of sea-squirt tailbud embryo
CC or larva. The invention is useful for studying the development of the
CC nervous system of the sea-squirt and for research purposes. The genes may
CC be used for determining the disease-development mechanisms in the nervous
CC system. In addition, novel gene clusters expressed in nervous system of
CC sea-squirt tailbud embryo or larva allows development of diagnostics and
CC therapeutics related to nervous system diseases. The present sequence is
CC that of a protein encoded by a C intestinalis gene of the invention.
XX
SQ Sequence 354 AA;
Query Match 100.0%; Score 57; DB 8; Length 354;
Best Local Similarity 100.0%; Pred. No. 0.06; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0;
QY 1 KNNLKDCGLF 10
Db 345 KNNLKDCGLF 354
RESULT 32
AAY85149
ID AAY85149 standard; protein; 355 AA.
XX
AC AAY85149;
XX
DT 23-JUN-2000 (first entry)
XX
DE Human G-alpha-i2 amino acid sequence.
XX
DE G-alpha-i2; antisense inhibitor; infection; inflammation; prevent;
KW tumour formation; treatment; inhibit.
XX
OS Homo sapiens.
XX
PF 17-NOV-2000; 2000WO-GB004385.
XX

FH Key Location/Qualifiers
FT Misc-difference 343
FT /label= unknown
FT /note= "Encoded by GNC"
XX
PN US6040179-A.
XX
PD 21-MAR-2000.
XX
PF 25-JUN-1999; 99US-00339993.
XX
PR 25-JUN-1999; 99US-00339993.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowser LM;
XX
DR WPI; 2000-270140/23.
DR N-PSDB; AAA09737.
XX
PT Novel antisense oligonucleotide containing compounds, useful for
PT inhibiting the expression of G-alpha-i2 in human cells and tissues and
PT treating infection, inflammation and cancer.
XX
PS Example 13; Col 43-46; 31pp; English.
XX
CC This sequence represents the human G-alpha-i2 amino acid sequence. G-
CC alpha-i2 is a member of the G1 subfamily of G proteins, which is involved
CC in hormonal inhibition of adenylyl cyclase and in the regulation of
CC plasma membrane enzymes. The expression of G-alpha-i2 has been shown to
CC be altered in some tumours. Mice lacking the G-alpha-i2 gene display
CC growth retardation and develop adenocarcinoma of the colon and a form of
CC lethal diffuse colitis similar to ulcerative colitis in humans. The
CC invention relates to antisense inhibitory oligonucleotide sequences,
CC which target the human G-alpha-i2 nucleotide sequence. The antisense
CC molecules are useful for inhibiting the expression of G-alpha-i2 in human
CC cells or tissues, and for treating and preventing various disorders such
CC as infection, inflammation and tumour formation. The antisense
CC oligonucleotides are also useful for research and diagnostic purposes
XX
SQ Sequence 355 AA;
Query Match 100.0%; Score 57; DB 3; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.061;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355
RESULT 33
AAB99065
ID AAB99065 standard; protein; 355 AA.
XX
AC AAB99065;
XX
DT 23-AUG-2001 (first entry)
XX
DE Human G-protein alpha subunit i2.
XX
KW G-protein coupled receptor; GPCR; GnRH receptor; disease treatment;
KW gonadotrophin releasing; hormone receptor; hormone dependent cancer;
KW human; catfish; goldfish; cow; sheep; horse; fruitfly; pig; rat; mouse;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN WO200136446-A2.
XX
PD 25-MAY-2001.
XX
PF 17-NOV-2000; 2000WO-GB004385.
XX

```


XX PR 17-NOV-1999; 99GB-00027215.
 XX (UYBR-) UNIV BRISTOL.
 XX PA
 XX PI Mcardle CA;
 XX DR WPI; 2001-355607/37.
 XX PT Use of a vector encoding G-protein coupled receptors for manufacturing
 XX PT medicaments for treating cancer, diseases of cardiovascular system,
 XX PT nervous system, digestive system, immune system, or muscle diseases.
 XX PS Disclosure; Fig 19; 78pp; English.
 XX CC The present invention describes a prodrug comprising a vector encoding a
 CC G-protein coupled receptor (GPCR). This can be used in the treatment of
 CC diseases, including hormone-dependent cancers, cardiovascular, nervous
 CC system, digestive system, immune system, respiratory, skeletal,
 CC endocrine, sensory and muscle diseases and disorders. The present
 CC sequence is a protein described in the exemplification of the invention
 XX SQ Sequence 355 AA;
 Query Match 100.0%; Score 57; DB 4; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.061;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 DB 346 KNNLKDCGLF 355
 RESULT 34
 ABB09274
 ID ABB09274 standard; protein; 355 AA.
 XX AC ABB09274;
 XX DT 10-JUL-2002 (first entry)
 XX DE G protein-coupled receptor (GPCR) I2 SEQ ID NO:20.
 XX KW Target activated nucleic acid biosensor; signalling moiety; GPCR;
 KW nucleic acid sensor; detection; engineering; drug optimisation;
 KW G protein-coupled receptor.
 XX OS Homo sapiens.
 XX PN WO200222882-A2.
 XX PD 21-MAR-2002.
 XX PF 13-SEP-2001; 2001WO-US028835.
 XX PR 13-SEP-2000; 2000US-0232454P.
 XX PA (ARCH-) ARCHEMIX CORP.
 XX PI Stanton M, Epstein D, Hamaguchi N;
 XX DR WPI; 2002-393977/42.
 XX PT Nucleic acid sensor for detecting target molecule, comprises target
 PT molecule activation site and optical signalling unit that changes its
 PT optical properties upon allosteric modulation sensor after recognition of
 PT target.
 XX PS Example 12; Page 89; 144pp; English.
 XX CC The present invention describes a nucleic acid sensor molecule (I)
 CC comprising a target molecule activation site comprising a structure that
 CC recognises a target molecule and an optical signalling unit including at
 CC least one nucleotide coupled to a signalling moiety that changes its
 CC optical properties upon allosteric modulation of (I) following
 CC recognition of the target molecule. (I) is useful for detecting a target

CC least one nucleotide coupled to a signalling moiety that changes its
 CC optical properties upon allosteric modulation of (I) following
 CC recognition of the target molecule. (I) is useful for detecting a target
 CC molecule associated with a pathological condition or genetic alteration.
 CC (I) is useful for identifying a drug compound, by identifying a nucleic
 CC acid biosensor-based molecule profile of target molecules associated with
 CC a disease trait in a patient, administering a candidate compound to the
 CC patient, and monitoring changes in the profile. Alternately, the method
 CC involves identifying a number of pathway target molecules, administering
 CC a candidate compound to a patient having a disease trait, and monitoring
 CC changes in the structure, level or activity of two or more of the pathway
 CC target molecules using (I). The profile of target molecules or the
 CC changes in the structure is compared to the profile of a reference
 CC healthy or diseased population. (I) is also useful in multiple assays, for the
 CC detection of target molecule. (I) is also useful in diagnostic
 CC applications and drug optimisation. The present sequence represents a G
 CC protein-coupled receptor, which is used in an example from the present
 CC invention
 XX SQ Sequence 355 AA;
 Query Match 100.0%; Score 57; DB 5; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.061;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 DB 346 KNNLKDCGLF 355

RESULT 35
 ABB09277
 ID ABB09277 standard; protein; 355 AA.
 XX AC ABB09277;
 XX DT 10-JUL-2002 (first entry)
 XX DE G protein-coupled receptor (GPCR) g02 SEQ ID NO:23.
 XX KW Target activated nucleic acid biosensor; signalling moiety; GPCR;
 KW nucleic acid sensor; detection; engineering; drug optimisation;
 KW G protein-coupled receptor.
 XX OS Homo sapiens.
 XX PN WO200222882-A2.
 XX PD 21-MAR-2002.
 XX PF 13-SEP-2001; 2001WO-US028835.
 XX PR 13-SEP-2000; 2000US-0232454P.
 XX PA (ARCH-) ARCHEMIX CORP.
 XX PI Stanton M, Epstein D, Hamaguchi N;
 XX DR WPI; 2002-393977/42.
 XX PT Nucleic acid sensor for detecting target molecule, comprises target
 PT molecule activation site and optical signalling unit that changes its
 PT optical properties upon allosteric modulation sensor after recognition of
 PT target.
 XX PS Example 12; Page 89; 144pp; English.
 XX CC The present invention describes a nucleic acid sensor molecule (I)
 CC comprising a target molecule activation site comprising a structure that
 CC recognises a target molecule and an optical signalling unit including at
 CC least one nucleotide coupled to a signalling moiety that changes its
 CC optical properties upon allosteric modulation of (I) following
 CC recognition of the target molecule. (I) is useful for detecting a target

CC molecule associated with a pathological condition or genetic alteration.
 CC (I) is useful for identifying a drug compound, by identifying a nucleic
 CC acid biosensor-based molecule profile of target molecules associated with
 CC a disease trait in a patient, administering a candidate compound to the
 CC patient, and monitoring changes in the profile. Alternately, the method
 CC involves identifying a number of pathway target molecules, administering
 CC a candidate compound to a patient having a disease trait, and monitoring
 CC changes in the structure, level or activity of two or more of the pathway
 CC target molecules using (I). The profile of target molecules or the
 CC changes in the structure is compared to the profile of a reference
 CC healthy or diseased population. (I) is useful in multiple assays, for the
 CC detection of target molecule. (I) is also useful in diagnostic
 CC applications and drug optimisation. The present sequence represents a G
 CC protein-coupled receptor, which is used in an example from the present
 CC invention

SQ Sequence 355 AA;
 Query Match 100.0%; Score 57; DB 5; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.061;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||
 Db 346 KNNLKDCGLF 355

RESULT 36
 AAU79335
 ID AAU79335 standard; protein; 355 AA.

AC AAU79335;

DT 02-JUL-2002 (First entry)

DE Human inhibitory G protein alpha i2.

XX Human; inhibitory G protein alpha i2; antiarrhythmic; cardiant;
 KW gene therapy; cardiac arrhythmia; ventricular arrhythmia; syncope;
 KW atrial arrhythmia; sinus bradycardia; sinus tachycardia;
 KW atrial tachycardia; atrial fibrillation; atrial flutter;
 KW atrioventricular nodal block; atrioventricular node reentry tachycardia;
 KW atrioventricular reciprocating tachycardia; ventricular tachycardia;
 KW ventricular fibrillation; sick sinus syndrome; Stokes-Adams attack;
 KW chronic fatigue syndrome; cardiomyopathy.

XX Homo sapiens.

XX WO200219966-A2.

XX 14-MAR-2002.

XX 06-SEP-2001; 2001WO-US027623.

XX 06-SEP-2000; 2000US-0230311P.

PR 05-JUN-2001; 2001US-0295989P.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Donahue JK, Marban E;

XX WPI; 2002-329822/36.

DR N-PSDB; ABK48300, ABK48301, ABK48302, ABK48303, ABK48304, ABK48305,

DR ABK48306, ABK48307, ABK48308.

XX Preventing or treating cardiac arrhythmia, e.g. atrial fibrillation,
 PT comprises administering at least one polynucleotide capable of modulating
 PT electrical property in standard cardiac electrophysiological assay.

XX Disclosure; Fig 9A; 63pp; English.

XX The invention describes a method of preventing or treating cardiac
 CC arrhythmia comprising administering to a mammal at least one

CC polynucleotide capable of modulating an electrical property in a standard
 CC cardiac electrophysiological assay, and expressing the polynucleotide to
 CC prevent or treat the cardiac arrhythmia. The method is useful for
 CC treating or preventing a wide range of ventricular or atrial arrhythmia,
 CC including, sinus bradycardia (indications of which include sick sinus
 CC syndrome, Stokes-Adams attacks, syncope, chronic fatigue syndrome and
 CC cardiomyopathies), sinus tachycardia, atrial tachycardia, atrial
 CC fibrillation, atrial flutter, atrioventricular nodal block,
 CC atrioventricular node reentry tachycardia, atrioventricular reciprocating
 CC tachycardia, ventricular tachycardia or ventricular fibrillation. The new
 CC method of treating cardiac arrhythmia: is genetically and spatially
 CC controllable, i.e. they provide for administration of at least one pre-
 CC defined polynucleotide to an identified heart tissue or focal area; may
 CC be employed to supply the heart with one or a combination of different
 CC therapeutic proteins; provides treated cells and tissue that usually
 CC remain responsive to endogenous nerves and hormones; provides targeted
 CC delivery to isolated regions of the heart (using highly localised gene
 CC therapy); has readily detected therapeutic effects and incorporates a
 CC method to rescue gene transfer-induced changes by conventional
 CC electrophysiological methods. This is the amino acid sequence of the
 CC human inhibitory G protein sub-unit G alpha i2, the polynucleotide
 CC encoding which is used in the treatment of heart arrhythmia

XX SQ Sequence 355 AA;

Query Match 100.0%; Score 57; DB 5; Length 355;

Best Local Similarity 100.0%; Pred. No. 0.061;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
 |||||
 Db 346 KNNLKDCGLF 355

RESULT 37

ADC09612

ID ADC09612 standard; protein; 355 AA.

XX ADC09612;

XX 18-DEC-2003 (first entry)

DE Human G-protein coupled receptor-related protein, SEQ ID 23.

XX Nucleic acid sensor molecule; ligase; cis-hammerhead; protein kinase;
 KW human; G-protein coupled receptor.

XX Homo sapiens.

XX WO2003014375-A2.

XX 20-FEB-2003.

XX 09-AUG-2002; 2002WO-US025319.

XX 09-AUG-2001; 2001US-0311378P.

PR 21-AUG-2001; 2001US-0313932P.

PR 13-SEP-2001; 2001US-00952680.

PR 13-NOV-2001; 2001US-0338188P.

PR 18-JAN-2002; 2002US-0349959P.

PR 13-MAR-2002; 2002US-0364486P.

PR 25-MAR-2002; 2002US-0367991P.

PR 04-APR-2002; 2002US-0369887P.

PR 01-MAY-2002; 2002US-0376744P.

PR 31-MAY-2002; 2002US-0385097P.

XX (ARCH-) ARCHEMIX CORP.

XX Stanton M, Epstein D, Hamaguchi N, Kurz M, Keefe T, Wilson C;

PI Grate D, Marshall KA, Mccauley T, Kurz J;

XX WPI; 2003-300534/29.

DR XX

PT Nucleic acid sensor molecule, for identifying/detecting protein kinase in
 PT a sample, comprises a target modulation domain which recognizes a target
 PT molecule, a linker domain, a catalytic domain, and an optical signal
 PT generator.

XX Example 5; SEQ ID NO 23; 423pp; English.

XX The present invention relates to nucleic acid sensor molecules (I), which
 CC comprise a target modulation domain that recognizes a target molecule
 CC (TM), a linker domain, a catalytic domain, and an optical signal
 CC generating unit. The catalytic domain comprises a ligase or cis-
 CC hammerhead. (I) are useful for identifying or detecting TM in a sample,
 CC preferably a protein kinase in a sample. Target molecules include
 CC proteins, post-translationally modified forms of proteins, peptides,
 CC nucleic acids, oligosaccharides, nucleotides, metabolites, drugs, toxins,
 CC biohazards, ions, carbohydrates, polysaccharides, hormones, receptors,
 CC antigens, antibodies, viruses, metabolites, co-factors, drugs, dyes,
 CC nutrients, growth factors, cAMP, cGMP, protein kinase,
 CC phosphorylated protein kinase, extracellular signal regulated kinase
 CC (ERK), a component or product of mitogen activated protein (MAP) kinase
 CC pathway, a MAP kinase pathway associated protein, an extracellular
 CC component of MAP kinase pathway, a component of ERK1/2 MAP, JNK MAP or
 CC p38 MAP kinase pathway, an endogenous form of MAP kinase (MEK), MAP
 CC kinase kinase, or MAP kinase (MEKK), or RAF kinase, Ras protein,
 CC phosphatase, GTP binding protein, G-protein coupled receptor (GPCR),
 CC cytochrome, growth factor, cellular metabolite, small molecule or lysozyme.
 CC (I) are also useful for identifying a modulator of protein kinase
 CC activity. In an example from the invention, nucleic acid sensor molecules
 CC which signal human G-protein coupled receptors e.g. the present sequence,
 CC were obtained.

XX Sequence 355 AA;

Query Match 100.0%; Score 57; DB 7; Length 355;

Best Local Similarity 100.0%; Pred. No. 0.061;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

|||||

Db 346 KNNLKDCGLF 355

RESULT 38

ADC09609

ID ADC09609 standard; protein; 355 AA.

AC ADC09609;

XX 18-DEC-2003 (first entry)

XX Human G-protein coupled receptor-related protein, SEQ ID 20.

XX Nucleic acid sensor molecule; ligase; cis-hammerhead; protein kinase;
 KW human; G-protein coupled receptor.

XX Homo sapiens.

XX WO2003014375-A2.

XX 20-FEB-2003.

XX 09-AUG-2002; 2002WO-05025319.

XX 09-AUG-2001; 2001US-0311378P.

PR 21-AUG-2001; 2001US-0313932P.

PR 13-SEP-2001; 2001US-00952680.

PR 13-NOV-2001; 2001US-0338186P.

PR 18-JAN-2002; 2002US-0349959P.

PR 13-MAR-2002; 2002US-0364486P.

PR 25-MAR-2002; 2002US-0367991P.

PR 04-APR-2002; 2002US-0369987P.

PR 01-MAY-2002; 2002US-0376744P.

PR 31-MAY-2002; 2002US-0385097P.

XX PA

XX (ARCH-) ARCHEMIX CORP.

XX Stanton M, Epstein D, Hamaguchi N, Kurz M, Keefe T, Wilson C;

PI Grate D, Marshall KA, Mccauley T, Kurz J;

XX WPI; 2003-300534/29.

XX Nucleic acid sensor molecule, for identifying/detecting protein kinase in
 PT a sample, comprises a target modulation domain which recognizes a target
 PT molecule, a linker domain, a catalytic domain, and an optical signal
 PT generator.

XX Example 5; SEQ ID NO 20; 423pp; English.

XX The present invention relates to nucleic acid sensor molecules (I), which
 CC comprise a target modulation domain that recognizes a target molecule
 CC (TM), a linker domain, a catalytic domain, and an optical signal
 CC generating unit. The catalytic domain comprises a ligase or cis-
 CC hammerhead. (I) are useful for identifying or detecting TM in a sample,
 CC preferably a protein kinase in a sample. Target molecules include
 CC proteins, post-translationally modified forms of proteins, peptides,
 CC nucleic acids, oligosaccharides, nucleotides, metabolites, drugs, toxins,
 CC biohazards, ions, carbohydrates, polysaccharides, hormones, receptors,
 CC antigens, antibodies, viruses, metabolites, co-factors, drugs, dyes,
 CC nutrients, growth factors, cAMP, cGMP, protein kinase,
 CC phosphorylated protein kinase, extracellular signal regulated kinase
 CC (ERK), a component or product of mitogen activated protein (MAP) kinase
 CC pathway, a MAP kinase pathway associated protein, an extracellular
 CC component of MAP kinase pathway, a component of ERK1/2 MAP, JNK MAP or
 CC p38 MAP kinase pathway, an endogenous form of MAP kinase (MEK), MAP
 CC kinase kinase, or MAP kinase (MEKK), or RAF kinase, Ras protein,
 CC phosphatase, GTP binding protein, G-protein coupled receptor (GPCR),
 CC cytochrome, growth factor, cellular metabolite, small molecule or lysozyme.
 CC (I) are also useful for identifying a modulator of protein kinase
 CC activity. In an example from the invention, nucleic acid sensor molecules
 CC which signal human G-protein coupled receptors e.g. the present sequence,
 CC were obtained.

XX Sequence 355 AA;

Query Match 100.0%; Score 57; DB 7; Length 355;

Best Local Similarity 100.0%; Pred. No. 0.061;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

|||||

Db 346 KNNLKDCGLF 355

RESULT 39

ADJ68621

ID ADJ68621 standard; protein; 355 AA.

AC ADJ68621;

XX 06-MAY-2004 (first entry)

XX Human heat mitochondrial protein as a therapeutic target SeqID427.

XX mitochondrial; human; screening assay; diabetes mellitus;

KW Huntington's disease; osteoarthritis;

KW Leber's hereditary optic neuropathy; LHON;

KW mitochondrial encephalopathy lactic acidosis and stroke; MELAS;

KW myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;

KW neuroprotective; nootropic; antidiabetic; anticonvulsant; antiarthritic;

XX osteopathic; ophthalmological; cytostatic.

OS Homo sapiens.

XX WO2003087768-A2.

XX 23-OCT-2003.

XX 04-APR-2003; 2003WO-US010870.
 XX
 PR 12-APR-2002; 2002US-0372843P.
 PR 17-JUN-2002; 2002US-0389987P.
 PR 20-SEP-2002; 2002US-0412418P.
 XX
 PA (MITO-) MITOKOR.
 PA (BUCK-) BUCK INST AGE RES.
 XX
 PI Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;
 PI Warnock DE;
 XX
 DR WPI; 2003-845369/78.
 XX
 XX Identifying a mitochondrial target for drug screening assays and for
 PT treating diseases associated with altered mitochondrial function,
 PT comprises detecting a modified polypeptide in a sample and correlating
 PT with the disease.
 XX
 XX Claim 1; SEQ ID NO 427; 180pp; English.
 XX
 CC This invention relates to novel mitochondrial targets that can be used
 CC for therapeutic intervention in treating a disease associated with
 CC altered mitochondrial function. Specifically, it refers to a method for
 CC identifying proteins of the human heart mitochondrial proteome that are
 CC useful for drug screening assays, as well as therapeutic targets. The
 CC present invention describes a method for identifying such proteins that
 CC can be used in the treatment of various diseases associated with altered
 CC mitochondrial function including diabetes mellitus, Huntington's disease,
 CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial
 CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy
 CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these
 CC compositions have neuroprotective, nontropic, antidiabetic,
 CC anticonvulsant, antiarthritic, osteopathic, ophthalmological and
 CC cytostatic activities. This polypeptide sequence is a human heart
 CC mitochondrial protein of the invention.
 XX
 SQ Sequence 355 AA;
 Query Match 100.0%; Score 57; DB 7; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.061; 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 |||||
 Db 346 KNNLKDCGLF 355
 RESULT 40
 ADJ70586
 ID ADJ70586 standard; protein; 355 AA.
 XX
 AC ADJ70586;
 XX
 DT 06-MAY-2004 (first entry)
 DE Human heart mitochondrial protein as a therapeutic target SeqID2392.
 XX
 KW mitochondrial; human; screening assay; diabetes mellitus;
 KW Huntington's disease; osteoarthritis;
 KW Leber's hereditary optic neuropathy; LHON;
 KW mitochondrial encephalopathy lactic acidosis and stroke; MELAS;
 KW myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;
 KW neuroprotective; nontropic; antidiabetic;
 KW osteopathic; ophthalmological; cytostatic.
 XX
 OS Homo sapiens.
 XX
 PN WO2003087768-A2.
 XX
 PD 23-OCT-2003.
 XX

PF 04-APR-2003; 2003WO-US010870.
 XX
 PR 12-APR-2002; 2002US-0372843P.
 PR 17-JUN-2002; 2002US-0389987P.
 PR 20-SEP-2002; 2002US-0412418P.
 XX
 PA (MITO-) MITOKOR.
 PA (BUCK-) BUCK INST AGE RES.
 XX
 PI Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;
 PI Warnock DE;
 XX
 DR WPI; 2003-845369/78.
 XX
 XX Identifying a mitochondrial target for drug screening assays and for
 PT treating diseases associated with altered mitochondrial function,
 PT comprises detecting a modified polypeptide in a sample and correlating
 PT with the disease.
 XX
 XX Claim 1; SEQ ID NO 2392; 180pp; English.
 XX
 CC This invention relates to novel mitochondrial targets that can be used
 CC for therapeutic intervention in treating a disease associated with
 CC altered mitochondrial function. Specifically, it refers to a method for
 CC identifying proteins of the human heart mitochondrial proteome that are
 CC useful for drug screening assays, as well as therapeutic targets. The
 CC present invention describes a method for identifying such proteins that
 CC can be used in the treatment of various diseases associated with altered
 CC mitochondrial function including diabetes mellitus, Huntington's disease,
 CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial
 CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy
 CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these
 CC compositions have neuroprotective, nontropic, antidiabetic,
 CC anticonvulsant, antiarthritic, osteopathic, ophthalmological and
 CC cytostatic activities. This polypeptide sequence is a human heart
 CC mitochondrial protein of the invention.
 XX
 SQ Sequence 355 AA;
 Query Match 100.0%; Score 57; DB 7; Length 355;
 Best Local Similarity 100.0%; Pred. No. 0.061; 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 |||||
 Db 346 KNNLKDCGLF 355
 RESULT 41
 ADP70781
 ID ADP70781 standard; protein; 355 AA.
 XX
 AC ADP70781;
 XX
 DT 12-AUG-2004 (first entry)
 DE Minicell related human G i protein.
 XX
 KW minicell; eukaryotic; archaeobacterial; organellar membrane protein;
 KW fusion; transmembrane; membrane-anchoring domain; vaccination;
 KW drug discovery; proteomics.
 XX
 OS Homo sapiens.
 OS Unidentified.
 XX
 PN WO2003072014-A2.
 XX
 PD 04-SEP-2003.
 XX
 PF 28-MAY-2002; 2002WO-US016877.
 XX
 XX 25-FEB-2002; 2002US-0359843P.
 PR 24-MAY-2002; 2002US-00154951.

XX (MPEX-) MPEX BIOSCIENCE INC.
XX Sabadini RA, Surber M, Berkley N, Segall A, Klepper R;
PI Giacalone M, Gerhart W;
XX WPI; 2003-833248/77.
DR N-PSDB; ADP70682.
XX
XX New minicells containing specific membrane proteins, useful e.g. for
PT delivering therapeutic or diagnostic agents, in drug screening and for
PT protein production.
XX
XX Disclosure; Page 532-535; 669pp; English.
XX
XX The invention relates to a novel minicell that includes a eukaryotic,
CC archaeobacterial or organellar membrane protein. The invention further
CC comprises: a minicell that includes; a membrane protein fusion consisting
CC of a polypeptide with at least one transmembrane or membrane-anchoring
CC domain and a second polypeptide not derived from eubacterial protein and
CC being neither a His tag nor a glutathione-S-transferase polypeptide; or a
CC membrane conjugate, comprising membrane protein chemically linked to a
CC compound or a biologically active compound; displays a synthetic linkage
CC group, (non-)covalently attached to a membrane component; is sterically
CC stabilised with half-life in vivo longer than the wild type; includes an
CC expression cassette comprising an open reading frame that encodes the
CC membrane protein; includes at least one nucleic acid and displays a
CC eukaryotic and eubacterial expression sequences, independently linked to
CC an open reading frame; includes two nucleic acids, one with eukaryotic
CC and the other with eubacterial expression sequences, linked to different
CC open reading frames; contains a crystal of the membrane protein; or
CC displays a binding group and can selectively absorb and/or internalise an
CC undesirable compound; producing the minicells; a poroplast comprising a
CC vesicle, bordered by a eubacterial inner membrane, that is accessible to
CC a compound present in solution with the poroplast, surrounded by a
CC eubacterial cell wall; producing (cellular) poroplasts; a solid support
CC carrying a minicell; a device comprising: a microchip, associated with a
CC biosensor and comprising, or contacting, a minicell that displays the
CC binding group; or microchips, associated with a biosensor and comprising
CC sets of minicells, in a known pattern, that display different targets; a
CC library of minicells that express different exogenous proteins, different
CC fusion proteins or a constant protein and a variable protein; a parent
CC cell that produces minicells; and using minicells. These processes are
CC used for a wide range of diagnostic and (gene) therapeutic procedures
CC (including vaccination). also for drug discovery, functional proteomics
CC and research. This sequence represents a protein derived from a DNA
CC sequence used in the construction of a minicell of the invention.
XX
SQ Sequence 355 AA;
Query Match 100.0%; Score 57; DB 7; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.061; 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355
RESULT 42
ADM67196
ID ADM67196 standard; protein; 355 AA.
XX
XX ADM67196;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX Human adipocyte specific G-protein alpha inhibiting 1 protein SeqID 550.
DE
XX human; adipocyte specific; adipose tissue; anti-obesity;
KW high mobility group I-C protein; HMGI-C; obesity; leptin; ob; diabetes;
KW adipogenesis; hypertension; cardiovascular disease; anorectic;

KW antidiabetic; hypotensive; G-protein alpha inhibiting 1.
XX
XX Homo sapiens.
XX
XX WO2004011618-A2.
XX
XX 05-FEB-2004.
XX
XX 29-JUL-2003; 2003WO-US023684.
XX
XX 29-JUL-2002; 2002US-0398785P.
XX
XX 12-JUN-2003; 2003US-0478206P.
XX
XX (HMGE-) HMGNE INC.
XX
XX Chada K, Chouinard R, Ashar H, Sayed AMD;
XX
XX WPI; 2004-143846/14.
XX
XX N-PSDB; ADM66917.
XX
XX Identifying adipocyte specific genes, useful for treating obesity or
PT diabetes, and for identifying drug targets, by differential gene
PT expression analysis between adipose tissue or stromal vascular tissue of
PT mice of different genotypes.
XX
XX Disclosure; SEQ ID NO 550; 91pp; English.
XX
XX This invention relates to a novel method for identifying genes that are
CC over-expressed in adipose tissue and as such it provides targets for anti
CC -obesity pharmaceutical compositions. Specifically, it refers to a high
CC mobility group I-C protein (HMGI-C) that is associated with obesity and
CC is epistatic to leptin, furthermore, it refers to the ob gene where an
CC autosomal recessive trait is linked to obesity and diabetes. The present
CC invention describes performing differential gene expression analysis
CC between the white adipose tissue (WAT) or stromal vascular tissue (SVT)
CC of any two different mice selected from a group consisting of wild-type,
CC HMGI-C -/-, ob/ob, or HMGI-C -/- ob/ob genotype mice. Accordingly, using
CC this method novel nucleotides and the encoded proteins thereof were
CC identified that are adipocyte specific, and as such can be used for
CC preventing adipogenesis, diagnosing and treating diabetes, obesity,
CC hypertension and cardiovascular disease, as well as screening for
CC compounds that can modulate or prevent adipogenesis and treat diabetes or
CC obesity. These compositions exhibit anorectic, antidiabetic and
CC hypotensive activities. This polypeptide sequence is a human homologue of
CC a murine adipocyte specific protein sequence of the invention.
XX
SQ Sequence 355 AA;
Query Match 100.0%; Score 57; DB 8; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.061; 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355
RESULT 43
ADM80456
ID ADM80456 standard; protein; 355 AA.
XX
XX ADM80456;
AC
XX
XX 18-NOV-2004 (first entry)
DT
XX
XX Tumour-associated antigenic target (TAT) polypeptide PRO71103, SEQ:1148.
DE
XX Tumour-associated antigenic target; TAT; human; overexpression; cancer;
KW tumour; diagnosis; cell proliferative disorder; breast cancer;
KW colorectal cancer; lung cancer; ovarian cancer; liver cancer;
KW central nervous system cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; melanoma; leukaemia; hybridisation probe;
KW chromosome identification; chromosome mapping; gene mapping;

```

KW gene therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN WO2004030615-A2.
XX
PD 15-APR-2004.
XX
PF 29-SEP-2003; 2003WO-US028547.
XX
PR 02-OCT-2002; 2002US-0414971P.
XX
PA (GETH ) GENENTECH INC.
XX
PI Wu TD, Zhang Z, Zhou Y;
XX
XX WPI; 2004-347921/32.
DR N-PSDB; ACN37935.
XX
XX New tumor-associated antigenic target polypeptides and nucleic acids,
PT useful in preparing a medicament for treating or detecting a
PT proliferative disorder, e.g. breast, lung, colorectal, ovarian or
PT prostate cancer or tumor.
XX
PS Claim 12; SEQ ID NO 1148; 7273pp; English.
XX
XX The invention relates to human tumour-associated antigenic target (TAT)
CC polypeptides, and their related nucleic acids. The TAT polypeptides are
CC overexpressed in cancer tissues compared to normal tissues, and may thus
CC serve as effective targets for the diagnosis and treatment of cancer in
CC mammals. The invention also relates to nucleic acid and polypeptide
CC sequences at least 80% identical to the TAT nucleic acids and
CC polypeptides; expression vectors and host cells comprising a TAT nucleic
CC acid; an antibody specific for a TAT polypeptide; a peptide or organic
CC molecule which binds to a TAT polypeptide; fusion proteins comprising a
CC TAT polypeptide; and methods and compositions for the treatment or
CC diagnosis of cancer in mammals. TAT polypeptides, nucleic acids,
CC antibodies, antagonists, binding molecules and compositions are useful
CC for diagnosing or treating a cell proliferative disorder associated with
CC increased TAT expression, particularly cancers such as breast cancer,
CC colorectal cancer, lung cancer, ovarian cancer, liver cancer, bladder
CC cancer, pancreatic cancer, cervical cancer, cancers of the central
CC nervous system, melanoma and leukaemia. TAT nucleic acids may further be
CC used as hybridisation probes, in chromosome and gene mapping, in
CC chromosome identification and in gene therapy. The present sequence
CC represents a TAT polypeptide of the invention
XX
SQ Sequence 355 AA;
Query Match 100.0%; Score 57; DB 8; Length 355;
Best Local Similarity 100.0%; Pred. No. 0.061;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 346 KNNLKDCGLF 355
|||||
RESULT 44
ADG36979
ID ADG36979 standard; protein; 362 AA.
XX
XX ADG36979;
AC
XX 26-FEB-2004 (first entry)
XX
XX Human GPCR Gi2 alpha-Hisx6 fusion protein.
DE
XX Human; GPCR; G protein-coupled receptor; C-PLACE 1003238; G16 alpha;
KW Gi2 alpha; uropathic; gynaecological; GDP/GTP exchange reaction;
KW urinary tract disease; placental disease; tonsil disease;
KW Hisx6 fusion protein.
XX

KW Synthetic.
OS Homo sapiens.
XX
PN JP2003232790-A.
XX
PD 22-AUG-2003.
XX
PF 12-FEB-2002; 2002JP-00034569.
XX
PR 12-FEB-2002; 2002JP-00034569.
XX
PA (SUMU ) SUMITOMO SEIYAKU KK.
XX
XX WPI; 2004-014845/02.
DR N-PSDB; ADG36978.
XX
XX Ligand screening system comprising a component which is a lipid bilayer
PT membrane that contains C-PLACE1003238 and a region concerned in binding
PT of G-protein.
XX
XX Example 1; SEQ ID NO 17; 28pp; Japanese.
PS
XX The invention relates to a screening system of a ligand with respect to C
CC -PLACE1003238 (a GPCR), where a ligand-receptor interaction promotes
CC activity of GDP or GTP exchange reaction of G-protein subunits comprises,
CC a component which is a lipid bilayer membrane that contains a polypeptide
CC having a region which is concerned in binding with guanine nucleotide in
CC G protein-coupling receptor (GPCR) of the G-protein alpha (G16 alpha or
CC Gi2 alpha) subunit that belongs to the Gi family. Also included are
CC screening a ligand (involving comparing the effect of effector when
CC interacting with ligand in presence or absence of the test material),
CC producing a prophylactic and therapeutic agent of diseases of the urinary
CC tract, placenta or tonsil (involving mixing the effector and a carrier),
CC identifying a marker substance of the disease in the urinary tract,
CC placenta or tonsil (involving comparing the presence of ligand identified
CC in the biological sample derived tonsils obtained from patients and
CC normal humans), diagnosing disease in urinary tract, placenta or tonsil
CC and an antibody recognising the peptide which consists of amino acids 12-
CC 36 of C-PLACE1003238. The screening system is useful for screening for
CC the ligand which is useful in treating and preventing the disease in the
CC tissue of urinary organ, placenta or tonsil. The present sequence is a
CC Human GPCR Gi2 alpha-Hisx6 fusion protein used in the screening method of
CC the-invention.
XX
SQ Sequence 362 AA;
Query Match 100.0%; Score 57; DB 8; Length 362;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 353 KNNLKDCGLF 362
|||||
RESULT 45
ABR56305
ID ABR56305 standard; protein; 695 AA.
XX
XX ABR56305;
AC
XX 20-NOV-2003 (first entry)
XX
XX pc90LHISGalphai2 protein.
DE
XX Human; anorectic; antidiabetic; antilipemic; hypothalamus;
KW G-protein coupled receptor 901; obesity; diabetes; hyperlipaemia;
KW cibophobia; anorexia nervosa.
XX
XX Unidentified.
OS
XX WO2003030936-A1.
PN
XX

```

PD 17-APR-2003.
 XX
 PF 02-OCT-2002; 2002WO-JP010250.
 XX
 PR 02-OCT-2001; 2001JP-00306872.
 XX
 XX (SUMU) SUMITOMO PHARM CO LTD.
 XX
 PI Suguru E, Tsuchida A, Yamanaka M, Taiji M;
 XX
 DR WPI; 2003-354886/33.
 DR N-PSDB; ACC70860.
 XX
 XX Inhibitors of expression or activity of G-protein coupled receptor 901
 PT for treatment of lifestyle-related diseases and cibophobia.
 XX
 PS Disclosure; Page 79-81; 91pp; Japanese.
 XX
 CC The present invention relates to novel remedies for the treatment of
 CC diseases containing as an active component an inhibitor of the expression
 CC or activity of hypothalamus-expressed G-protein coupled receptor 901 and
 CC for treatment of cibophobia containing as an active component a
 CC potentiator of the expression or activity of G-protein coupled receptor
 CC 901. The diseases which can be treated include obesity, diabetes and
 CC hyperlipaemia, and cibophobia (anorexia nervosa). The present sequence
 CC was used to illustrate the invention
 XX
 SQ Sequence 695 AA;
 Query Match 100.0%; Score 57; DB 6; Length 695;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 DB 696 KNNLKDCGLF 695
 RESULT 46
 ABB56396
 ID ABB56396 standard; protein; 709 AA.
 XX
 AC ABB56396;
 XX
 DT 18-FEB-2002 (first entry)
 XX
 DE TSHR-Gs-alpha fusion protein, SEQ ID NO: 589.
 XX
 KW Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;
 KW constitutively activated GPCR; TSHR-Gs-alpha; TSHR-Gi-alpha; fusion;
 KW TSHR; thyroid stimulating hormone receptor; agonist; disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200177172-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 05-APR-2001; 2001WO-US011098.
 XX
 PR 07-APR-2000; 2000US-0195747P.
 XX
 XX (AREN-) ARENA PHARM INC.
 XX
 PI Lehmann-Bruinsma K, Liaw CW, Lin I;
 XX
 DR WPI; 2001-648759/74.
 DR N-PSDB; ABI90836.
 XX
 PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
 PT disease treatment, comprises contacting candidate compounds with versions
 PT of GPCRs.

XX
 PS Example 6; Page 392-394; 394pp; English.
 XX
 CC The invention relates to G protein-coupled receptors (GPCRs) for which
 CC the endogenous ligand has been identified. Non-endogenous constitutively
 CC activated versions of known GPCRs are used in the invention for the
 CC direct identification of candidate compounds as receptor agonists,
 CC inverse agonists or partial agonists. Such agonists are useful as
 CC therapeutic agents for diseases or disorders associated with GPCRs. The
 CC present sequence is a GPCR fusion protein containing thyroid stimulating
 CC hormone receptor (TSHR)
 XX
 SQ Sequence 709 AA;
 Query Match 100.0%; Score 57; DB 4; Length 709;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 DB 700 KNNLKDCGLF 709
 RESULT 47
 ABR55447
 ID ABR55447 standard; protein; 709 AA.
 XX
 AC ABR55447;
 XX
 DT 29-JUL-2003 (first entry)
 XX
 DE Amino acid sequence of an endogenous MCH receptor-G protein Gi fusion.
 XX
 KW G-protein receptor; SLC-1; melanin concentrating hormone receptor;
 KW MCH receptor; obesity; obesity related disorder; anxiety; depression;
 KW diabetes; syndrome X; impaired glucose tolerance; dyslipidemia;
 KW hypertension; coronary heart disease; cardiovascular disorder;
 KW atherosclerosis; insulin resistance; psoriasis;
 KW polycystic ovarian syndrome; renal disease; diabetic nephropathy;
 KW glomerulonephritis; glomerular sclerosis; nephrotic syndrome;
 KW hypertensive nephrosclerosis; microalbuminuria; eating disorder;
 KW movement disorder; Parkinson's disease; Huntington's chorea; steroid;
 KW pituitary hormone disorder; epinephrine release disorder;
 KW anxiety disorder; gastrointestinal disorder; cardiovascular disorder;
 KW electrolyte balance disorder; respiratory disorder; asthma;
 KW reproductive disorder; immune disorder; endocrine disorder;
 KW musculoskeletal disorder; neuroendocrine disorder; cognitive disorder;
 KW memory disorder; motor coordination disorder;
 KW sensory integration disorder; motor integration disorder;
 KW dopaminergic function disorder; sensory transmission disorder;
 KW olfaction disorder; sympathetic innervation disorder; affective disorder;
 KW stress-related disorder; fluid-balance disorder; seizure disorder; pain;
 KW psychotic behaviour; morphine tolerance; opiate addiction; migraine.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT Protein 1..353
 FT Protein /note= "MCH receptor"
 FT Protein 356..711
 FT Protein /note= "G protein Gi"
 XX
 PN WO2003028641-A2.
 XX
 PD 10-APR-2003.
 XX
 PF 30-SEP-2002; 2002WO-US031059.
 XX
 PR 01-OCT-2001; 2001US-0326463P.
 PR 02-OCT-2001; 2001US-0326758P.
 XX
 XX (TAIS) TAISHO PHARM CO LTD.
 PA

XX Sekiguchi Y, Kanuma K, Omodera K, Tran T, Kramer BA, Beeley NRA;
 XX WPI; 2003-441069/41.
 DR N-PSDB; ACC70137.
 XX
 XX Method of modulating G-protein receptor, SLC-1 for treating e.g. obesity,
 PT depression or anxiety, comprises contacting a melanin concentrating
 PT hormone (MCH) receptor antagonist with the SLC-1 receptor.
 XX
 XX Example 3582; Page 1169-1171; 1171pp; English.
 XX
 CC The specification describes a method of modulating the G-protein
 CC receptor, SLC-1. The method comprises contacting SLC-1 with a melanin
 CC concentrating hormone (MCH) receptor antagonist. This antagonist is of a
 CC formula given in the specification. Antagonists of the invention are used
 CC for treatment of obesity, obesity related disorder, anxiety, or
 CC depression in mammals. They are also used for treating type II diabetes,
 CC syndrome X, impaired glucose tolerance; dyslipidemia, hypertension,
 CC coronary heart disease and other cardiovascular disorders including
 CC atherosclerosis, insulin resistance associated with obesity and
 CC psoriasis, for treating diabetic complications and other diseases e.g.
 CC polycystic ovarian syndrome (PCOS), renal disease e.g. diabetic
 CC nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic
 CC syndrome, hypertensive nephrosclerosis, end-stage renal diseases and
 CC microalbuminuria as well as eating disorder, movement disorder e.g.
 CC Parkinson's disease, Huntington's chorea, a steroid or pituitary hormone
 CC disorder, an epinephrine release disorder, anxiety disorder,
 CC gastrointestinal disorder, a cardiovascular disorder, an electrolyte
 CC balance disorder, a respiratory disorder, asthma, reproductive function
 CC disorder, immune disorder, endocrine disorder, musculoskeletal disorder,
 CC a neuroendocrine disorder, a cognitive disorder, memory disorder, sensory
 CC modulation and transmission disorder, motor coordination disorder,
 CC sensory integration disorder, a motor integration disorder, dopaminergic
 CC function disorder, sensory transmission disorder, olfaction disorder,
 CC sympathetic innervation disorder, affective disorder, stress-related
 CC disorder, fluid-balance disorder, seizure disorder, pain, psychotic
 CC behaviour, morphine tolerance, opiate addiction or migraine. The present
 CC sequence is a fusion of endogenous human MCH receptor and G protein Gi,
 CC which is used in the course of the invention
 XX
 XX Sequence 709 AA;
 XX
 Query Match 100.0%; Score 57; DB 6; Length 709;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 DB 700 KNNLKDCGLF 709
 |||||
 RESULT 48
 AAB99036
 ID AAB99036 standard; protein; 725 AA.
 XX
 AC AAB99036;
 XX
 XX 24-AUG-2001 (first entry)
 DT
 XX Human somatostatin receptor 2/Galphai1 fusion protein.
 DE
 XX G-protein coupled receptor; GPCR; GnRH receptor; disease treatment;
 KW gonadotropin releasing; hormone receptor; hormone dependent cancer;
 KW human; catfish; goldfish; cow; sheep; horse; fruitfly; pig; mouse;
 KW gene therapy.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200136446-A2.
 XX
 XX 25-MAY-2001.
 PD

XX 17-NOV-2000; 2000WO-GB004385.
 PF
 XX 17-NOV-1999; 99GB-00027215.
 PR
 XX (UYBR-) UNIV BRISTOL.
 PA
 XX Mcardle CA;
 PI
 XX WPI; 2001-355607/37.
 DR
 XX Use of a vector encoding G-protein coupled receptors for manufacturing
 PT medicaments for treating cancer, diseases of cardiovascular system,
 PT nervous system, digestive system, immune system, or muscle diseases.
 PT
 XX Disclosure; Page 30-31; 78pp; English.
 PS
 XX The present invention describes a prodrug comprising a vector encoding a
 CC G-protein coupled receptor (GPCR). This can be used in the treatment of
 CC diseases, including hormone-dependent cancers, cardiovascular, nervous
 CC system, digestive system, immune system, respiratory, skeletal,
 CC endocrine, sensory and muscle diseases and disorders. The present
 CC sequence is a protein described in the exemplification of the invention
 XX
 XX Sequence 725 AA;
 XX
 Query Match 100.0%; Score 57; DB 4; Length 725;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KNNLKDCGLF 10
 DB 716 KNNLKDCGLF 725
 |||||
 RESULT 49
 ADG37260
 ID ADG37260 standard; protein; 784 AA.
 XX
 AC ADG37260;
 XX
 XX 26-FEB-2004 (first entry)
 DT
 XX Fusion construct pcSHT1AHISGalphai2.
 DE
 XX screening; human; G protein coupled receptor; GPCR;
 KW lipid bilayer membrane; fusion protein; G-alpha 16; G-alpha i2;
 KW G-alpha S2; orphan GPCR;
 KW G protein conjugation seven-transmembrane-type receptor.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX JP2003210192-A.
 XX
 XX 29-JUL-2003.
 PD
 XX 18-JAN-2002; 2002JP-00010871.
 PF
 XX 18-JAN-2002; 2002JP-00010871.
 XX
 XX (SUMU) SUMITOMO SEIYAKU KK.
 PA
 XX WPI; 2003-819838/77.
 DR N-PSDB; ADG37257.
 DR
 XX Screening ligands for G protein coupled receptor comprises lipid bilayer
 PT membrane containing embedded fusion protein comprising target G protein
 PT coupled receptor and G alpha protein.
 XX
 XX Example 2; SEQ ID NO 20; 29pp; Japanese.
 PS
 XX This invention describes a novel system of screening for ligands of the
 CC

CC human G protein coupled receptor (GPCR). The method comprises a lipid
CC bilayer membrane in which a fusion protein comprising target GPCR and G-
CC alpha 16 or G-alpha i2 or G-alpha S2 is embedded. The invention also
CC discloses a second screening system where an orphan GPCR (G protein
CC conjugation seven-transmembrane-type receptor) is used to screen compound
CC having agonist and/or antagonist activity for the GPCR and to screen low
CC molecular non-peptide ligands. The screening is rapid and favourable.
XX
XX SQ Sequence 784 AA;

Query Match 100.0%; Score 57; DB 7; Length 784;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10
Db 775 KNNLKDCGLF 784

RESULT 50
ADC51269
ID ADC51269 standard; protein; 987 AA.
AC ADC51269;
XX
DT 18-DEC-2003 (first entry)
XX
DE Chimeric ECFP, EGFP, G alpha i2, rap1 GAP11 protein.
XX
KW G protein activation; ECFP; enhanced cyan fluorescent protein; EYFP;
KW enhanced yellow fluorescent protein; G alpha i2; rap1 GAP11; rat; human.
XX

OS Chimeric.
OS Synthetic.
OS Rattus sp.
OS Homo sapiens.

XX JP2003024078-A.

PN 28-JAN-2003.

XX 18-JUL-2001; 2001JP-00218756.

XX 18-JUL-2001; 2001JP-00218756.

XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

XX WPI; 2003-486383/46.
XX N-PSDB; ADC51268.

XX Novel fusion polypeptide for measuring G protein activation, comprises G
PT protein alpha subunit trimer, its target protein, a fluorescent acceptor
PT protein and a fluorescent donor protein, linked to each other.

XX Disclosure; SEQ ID NO 12; 20pp; Japanese.

XX The invention relates to a fusion polypeptide for measuring G protein
CC activation, comprising all or a part of an amino acid sequence of G
CC protein alpha subunit trimer (Ia), a target protein (Ib) of G protein
CC alpha subunit trimer, a fluorescent acceptor protein (Ic) and a
CC fluorescent donor protein (Id), or their variant amino acid sequences,
CC linked to each other. The fusion polypeptide is useful for measuring the
CC activation of G protein trimer, in vitro or in vivo. In vivo measurement
CC of G protein trimer activation is possible using the fusion polypeptide.
CC The present sequence is used in the exemplification of the invention.

XX Sequence 987 AA;

Query Match 100.0%; Score 57; DB 7; Length 987;
Best Local Similarity 100.0%; Pred. No. 0.18;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KNNLKDCGLF 10

Db 733 KNNLKDCGLF 742

Search completed: March 22, 2005, 06:46:58
Job time : 165 secs

This Page Blank (uspto)